var title_f35_48_36608="Leukoplakia - palate";
var content_f35_48_36608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukoplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white plaque is present on the hard palate and gingiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36608=[""].join("\n");
var outline_f35_48_36608=null;
var title_f35_48_36609="Prenatal ultrasound image of duodenal atresia";
var content_f35_48_36609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of duodenal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 221px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADdAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uoor7H1e18PeGvgr4Hu9K8EeGdW8Vaza6fa2kd3psUnnzSRKzu5wCeM5JYcsCTQB8cU9FDNgsqj1OcV9YeOYPCniH9ly98Vab4W0DTNWZLdJms7COJ4JhdRpIFIG5QeeM52t3r5Oz7cUASeSucefF/49/hUbLjoysPUUh6e9JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQApHGaWNC7hQQCfU4ptLQBcXT5WPytER67uKjmtDHn97E5HZST/AEqFWZRxxjuKmQu0D5KqDzz1NAFatXSNEuNUUmCSBMHH7xiM/kDWX3r0/wCGMsUsv/Hkht1GMs3G7ufegDlj4K1IKWMlttH8W5sf+g0638F3s8nlre6er/3Wdx/7LXt40mO5jaKK7QRk722jhB6ZrKvtIngt2WCICO5YiKXy8s3vQB5XJ4A1VGYGazIXkkO2B/47VY+Dr/eFW4s3z1Ku2B9flr1CFJdJhWO6aZyW2gSrgCsXUywvZFtVkYt85DDg/TFAHIXPgXUYEZmu9PYKOdsjH8Pu1Y074darfoHju9ORCM7pJXAH/jtdHBABtl+0pG55ZH7fhTLnVlijVhO4QnpnAIFAHDeJvDd14elRLue1m39DA5YfqBWHWt4j1U6rqJm2Ksa/Koz1HrWVQAlFFFABXb+Evhtq/ijTUvbC50+KJ92BPI4bhivZD3FcURhQcjntX0V8BtM0/Vk8CWWq2dtfWk2oXPmW9zEssb4t7sjKsCDggH6gUAcJJ8EvEiLk3ukEe00n/wAbpf8AhSPiby9/2rSsf9dZP/iK9X1HXdKs9f1uP/hBvA/2DTfEA0oo/hsqvkFsea95nyY2HHykZPYV1/i3TdJ8NfEi/tNF0yx021l0mykaKzt1hQv512CxCgDOABn2FAHzunwU8SMuftekj2Msn/xFKPgn4jO7/TdI46/vpP8A43XvsOoRm4VZMBWOKuakq26F1OVYZzQB89J8DfEzoGF5o+Ccf66T/wCN09vgT4nUgG90YZ/6bSf/ABuvoGyvVaBdvapIJ3mZ5W6CgD58HwH8UE/8fmj/APf6T/43S/8AChfFPa90Y/SaT/43X0xb3UDQBcjfim2DN9pbzB8pPGaAPmiT4D+KEj3te6N9POkz/wCi6WP4C+KZBkXujDvzNJ/8br6ccK1yQ33RVWWVhdhIx8p4oA+b4/gF4pfpf6Jn0M8v/wAbqxB+zx4tmLBb/QxtGTmeX/43X02LVI4kkdsZpo1CG281nlUKeOtAHzWn7OXi54941HQMen2iXP8A6Kp1v+zf4wn3bdQ0FQOpaeX/AONV9PWN1b3WxYZVx14NbNu0cIMZP3qAPlCL9mPxpNC8kGo+H5dv8K3EuT9MxVwXin4ZeIfDFz5OqxwIf7ysxX/0GvvnT0NnueJtytzioPEvhzTfGWky297GomKkB8cqaAPz6tfCF7cx747myA9C7Z/9Bpw8Gakz7VktSfZm/wDia9g8f/DTVvB82+FXltSSQy+lY+nYaNGxhx1zQB5ZfeGr+y/1/lj6E/4VQ+wSbtpZAfqf8K9p1uyXUUjVACy9a4HXNN+x3TkD2xQBhaT4en1OURxXVpExOP3rMP5Ka7mP4I+I5Y0eO+0dlYZBE0n/AMbrlrAmG5jCna2cmvbPhv4xWSRrK7fIAwp96APPG+B/iUHi90g/SaT/AON1LF8CfFEi7heaOB7zSf8Axuvoy2QMOP4uRVzaRH5fagD5nPwJ8Tj/AJfdG/7/AEn/AMbotPgV4mui3lX2jfL1Jmk/+N19MLFut3Ud+BSadYmAFFPuxoA+c1/Z78WMm4X+h4/67y//ABuuY8efC/WvBOkQ6jqt1p0sMs4twttI7MGKs2TuQDGFPevs20CvG2w5xxXjP7UkXl/D/T89Tqif+ipaAPlyiiigBa+sdI8ZfCDVdE8BSeMNeknu/D+kxWp0yawlltfNMKo5dfJIcgqMENj5Qea+UI1DEgsFGOppDkN8360AfS3xA8V/DCy+EvjLQfAmv3E82s3kV7Fp72sqRQv58TOsWYlCLtToSfugCvmuMfPgru9s4pVCuQBlXJ9eKkuoJbSXy5gFbGeMEGgBkplAw+7b23c0xSQrDI/EUFjtxgDPPFMoAKKKKACiiigAooooAKKKKACiipIIZJ5VihjaSRjhVUZJoAjorr7D4e6/cvia1+ygDLGbIwPXjNaE/wALdbKB9PaG+jPAMR5J+nWgDgaVsZ+XOPetTV/D2q6RcyW+oWM0UsfLAjNZNADmYtjP6DFJRSUALXX/AA2u4YNXeO4baki8ZbAz9O9cfU1pcPa3Mc8WN8bblz0zQB9KaRoSlvtd1C/lDlUBKKfc962r67stpmu1lWZVxBGvypGB3rwjSfiLq63UX2kwzAHgOxUfzrS1bx9LeFjdJapIOyEvQB1es6vJdRl5mSWIfdSV8/jik0bU7TTraW5mto5b+XiJOgQeprz+x8UWK3y3F8ZriQdCy/Kn0ArL1/xCLqd/seTv+9K45+ijoBQB0+ozQy3rzO8buxLSEsAo9sCuH1jU5bq5cLKfJHChRtFUJJ5JFCuxKjoOlRUAFFFFABVmwnjt7lZZYRMq/wABOAarUUATXU3nzvIEWMMchVHAr334E6jBox8GarffaPsNreXLTNBbyTsgaC5QHbGrNjc6jgd6+fK+gfgy4Twlalzhf3mP+/jUAek6jD8NbuXWorzxD4uOm6zqH9pX2mnSZ1hml3BgCfsnmBcgcBx0qDxt4j03xD46u7/RmuHsxpdpbh5rSW3+dZblmUCRVJwHTkDHNYSys91I8hzHuwKlv0jWQFDyRQA6QmSOEg4KnNa324TWTI5yQMCsa3jeQqoqSMhZGiHLA80Ab2lxLFEfM6kcVNBI4Z4tvDGsuGdmlTccAVqy3KhFZRyKAJltmS6Ug5Fb8qgRxY4Peufg1OG2XzblgMjjNcZ4t+I8duzQ2x57EUAek6jeW1jA0s0qgdOtc/ceKLKKQeXIrEDNeCa74yv9QjMTytjOetZMOtXCqxLsTjHWgD2DxB8Q5S5jjfao4FcFrvjPUZUISVtufWuYQXep5aJWLVVnFzajy7qMjnAyKAO68OePL2zdQZWJr0vw/wDEj7RIi3Ugrwm0099nm881YS1uosOoYc5oA+s9F8XRXUwUSKVA9a6aG9dmWW3bqc8V8Z6f4ovtOlba7cGvXvAHxOil8u0vG2yHjmgD6DmmstZT7HqESsrDHPrXgXxV+Hs/hu7e90xGks5CTgD7teswTrcRi5hcE4yCK27G9t9XsZLXUFWSMjHNAHyHp2qrHP5cvDHjFaGoaDHqsTSjlgM10/xc+Gs2kakdW0sF7MnLBe1cv4e1dYHCzn5HIWgDznUtOkhupCinMftVPQdQks73zixDBq9g8c6NFaW63sC5jkGWrx7VLRvP82JSIyaAPoz4e+J49WgjQsPMRcY9a7Rpi4P86+WvBniB9C1JG3YBPIzX0lo+oR6jo0NxCQWcZPtQBr27Ex471dkJSxZY/wDWPxmqkYCwoR1PWrkLjymc4JXgUAO0U+UywM2XPJryv9q8r/wgWnheg1SP/wBFS16dpUTJcSTytgnpXl/7VO0/DvTGU5zqiZ/79S0AfK1FFFAE9rbvcyFIwSwGeKniLQuYphuUcZAyVqC1meB2aIkMVxkdqmF3dK5PmkE9cjrQBFOiCZsMNvqBj9KixlsA7j2rQhuoJDi6ThupXOaZ9lVt08JcRKeB3oAoMMHBGDSVdggW9lkxMsbAZBlb71Vmd9vls3yqenagCOiipIEEkqqzrGD/ABHoKAGk5AGBx6Cm05hhiMg4PUd6bQAUUU+KN5ZUjjUs7nAA7mgBtOjjeWRUiVndjgKoySa7nR/hzfzyI2qyC0hOCdvzNj+Qr1rwb4Y0/QLxrnQbJ5nVMLNKu9ifUHtQB5Vofwy1SV45NcVtPhJB2P8AfZT39q9m07SPDPhq1jt9J0mKeRFBe9mAZlPqSKr+KfEoVCl/CJ7uQbFWThlPtiqNtJdX1gtu29AwwysuxSPc96AOzsvEtjLkQaZc6rn5GYSDyyfpWVa+DL6a8urvzp9NknfKQ2zZWMVyltBLaXUiWSsWQ5ZYm+Uexrb03W9XmMyRXU9pIBwivlQPbNAHU3vhLTdGt4Bq2rW0k5+aSVjuJHoc964zxH4C8DeIZVj0u++x3bH/AFhcbGJ9c1pw6Zpl/p9xe6vq9wC2Q4J+81cTeeHrCKBpLb7SjSP8rPnA+lAHOeMfhW2gXawW+qQ3krjKpHgn8ea8+1PS73TZCl5bvGQcZIyPzr2Qrq1pDiOETJGMiRcFj7HNFvqt5qOmy2j6Mk10+R5suAi/hQB4bTlUtnGOPeu/1vwFcIhlj8qKUDLIGytcFPDJBK0cqlXU4INADKKKczb8AKBj0FADKKKKACiiigAooooAKKKKACve/hREZvBFsq/e/ef+jGrwSvoD4Nn/AIpO0x2En/oxqAOgcFCsX9080qxNKZZC3C1bktnCPKwzk1WmjktIOvEhoAvWU6+V8uN4FUYxInmTnO4tiizQpcgg8EdK0IApZUccE0ARpIz3kKD6tW5FsuJCgOMVlxReTftI/CHgVV8U6kmkQCaFxk89aAMP4g35hl8mJ/uDnBrx7VLh7gtLk5U1ua3rEuo3ckrMTurJuIVFsNvVjzQBXtbdrqASAYOcVsR6G4iD9Vxk1LpVvsscjpWraXbLayK446UAXPBlzZadc/6SilenNbvjK20vV4I2slUP1OK4ua3WdVMZw3fFUze3FvcERMSFHrQBvxW6kLCmPl4rSvPIRIogBnHNctpN+6EySnBY960jKzXXmMcrjigBLjS4ZLjcFG3vXO6jp81vem4tGKhOeDXYJMPKYdzUEcIdGRhkmgDr/gr8RGnmbSNVkw54Uk17aLlLNhGrcv0Ir5A1bTZNOmF9ZkpLGcgivfvhZ4gTxdoMYnkxqNuMFSeTQB6lbXcWob9M1ABoZVxk188fFfwk3hfWsQg/Y5W3Iewr2yENICOk8Z61L430y28ZeDpYVAN7bKSD3BFAHi+halDq+mjTr/kbcAmuX8R+HxYyCHH7p8lTiq777OB4kJW4ibDfga73yR4l8FR3MPzXFuvzEdeKAPn/AFi1a3v3AztByK9i+B/iZJXksruT7owoNcH4psC9oJEH7xT8wrA0i8k0bU4biFiCCNwoA+wLBxJNIpPCjNWYWygjXu2a5D4a60muWss275woBFdraoMlh2oAkcMbdwudx+UV45+0xlPh1YRM25l1SMn/AL9S17O3Tj71eIftJRPH4FtDKTvfVEOD6eVLQB810UUUATWqeZKFOcewzVmRI5bjyotqZ7tVSH7xOFOBnkVbZVmdSsSxDGScZoAkhQWEu66WGVRwYm5z7iq9xMJCyxoI4c7gpP8AKrEEFu5/0x5OeEMYx+hpl9aLasFkMrDGV+lAEdqkB3i5ZojjKtg81VYljkkmrEMjwo+1Y5EYYO4Zx/hUMkbR43Y55GDmgCOnADjkdalktZ44EmeJ1if7rkcGoSMHBoAVwAxAIYeoptFb3hXw1d69fxQxxSCAn53Veg9qAMzTLCfUryO2tV3SOcew+te3eE/AemaCEnvS9zqDIChK5VW9MVa8OeFJdIvILDQLUTTzcN5rLuY+ue1bPiM3Phu8SLUbhlv15ZMblUfXvQB0nh7w/Y3lyB4jmntbYDPlopZT+XSvTIr7R4dKuNN0eO3iQRELMCBtGPvEHnNeDw69qItnm07VEV1G7DxliBVDw3fxapqTXXiYXMwJwPKcoG9iKAKet6bYvrBjuLxrx1k+S4gPAJPeunuNIjgWNdS1S4MZQbTEFyfbFdRfaPa/boPs2mpZ6SUz84x+Jya5/U/FPhXw/M8crW1xMp+Upksv9KALkWl2UGjC4igaEKeXZG3sPU1m61Y2Umitc22qxSSdBb27gSE+4xmsrWvipod1bNbQJfGZ+N4wFqXwlfeDdWl23OpLbTgcPsKtn8etAGLp9jqMthN5WkzYjOWmk6f4V1g1aLXtNsrS522ohGN78BiKg1eR9Miextbo6ppkzZLK+wmsOYqwT7PF5MEZ+WMsGJPpmgDct7WDRp2Et9u844XYM1m69bSXJdYPM2x/NlU2sfyrTsbS01MCaX/RrmAZKq27P0p1hcxx5ikILOSD5uRj8qAMSGeZrGGEWUhY9S5yWrmfG2j/ANoWqRJYxxXrsNrBeRXWSy/ZrmZZZnLKfkMfT6CqIuS94pMbC4fgO5ztoA8U1jRr7SJdl7AyDs2ODWcCV6Ej6V7f4k0myvoDFd3cs0h56dD7V41qVslrfTQRvvVGxuPFAFSilIwaSgBQM9Kn+zOsW+QhFPTd1NQAkcild2c5difrQAlJRRQAUUUUAFe+/CdCPBdi6Hn97n/v41eBV778ImI8FW4HJ/eYH/bRqAO6trwNGY5RwKcbc36gniNelUoF3QsJBtYnvV6SR4444LfqfSgBv2TyJN5+6BV5o4BHFMfyqpO0iQ+TJ1brV2C3j8hRK2B70AM1cx/2eJOBXjnjq/ndigbKdPpXs2vQJLpjRxH7q8YrxTV7aSQTLKD8poA5AT+RguPlIqVIpWki3Z2OeKW/SN4NgwWBqZZy8tuijiMUAdIkTW9ukWOtVnlwzRD8a0Fm8+GPj5sVT8jZclnHDHFAC6cQJWycjFSQ2amaVsZDVIbdY51KHINWjMkMLE4zQBzXiK0ls/LaMEJnOa1dAb7bYktztFdDNawato5j4M23Nc3Zg6JYzpL1OQKAHC8jS6EIOSDTZtXjS8PYLXT/AAq8B3OvNNq94Ctrn5Se9dX4j+EEUluZ7KQbn/hzQB5RLqcd8rJkYPas3wh4lufC3i+O8gYi2Bw4zwRWz4i+H+raKr3EcbNEOuBXEXMDyLJEeH70Afa3huaPWrG31W0YGOcDdjtXT6PZWmlasqmUEXfylCe9fPH7MPjGWOWXw9fsSu0mPcar/FzxlqnhrxCJYrhiUl3RgGgDovjx4Rg8L3x1K1/49r9iMH+Fqi+C3l28j6XeEbbxSUz0rptW8Q2vxR+DDXkm1dQtyG299w715hpk95YmxvF3K9oRkj2NAEnxA8PnQ/E01nIMRSnKZ7g15N4h097HU5Ff7nUV9D/HKaPU9M0HU7XHnMuWweTkV454ltJNQhEuzoME0AafwQ8Rix1RrSRziZtozX0fby4vxGv+rxmvizTp20rX4Jo2x5bDNfU/gnXxrWnCePl41AegDrfNZrwhO1eR/tRJI3guwlb7v9ooo/79S/4V6tZP++EmPrXl/wC1Ju/4QHTs9P7TQ/8AkKWgD5dooooAs2IjM+J87COccGtGzmgUsmwSQ54ycOKqaPCJrlwU3gISR+IqYWIa6Ux7VXrjOaAJ7yCOa3320olYH7jHay/getU2uZrpUjuMME4Axhvzq400wPkSxQNjowXBFQzwGV1coEdepz1oAr/ZmEg2xbF7GQ5FV7mN45P3iBCfQYBqdppmcguSgPccfpTJv3sp3zA4HFAGpfWkCaHDPDqrTFjg25B+U1hjkY4Huat2l0bYPE8Ecqt2YdPoaruhLgLGwLH5QR1oAsaZZT399DbWkDXE7Nwi9xX074eeDQNAto5oWfUnQAqMZX2rzT4YWUfhZ01LVrDzLmf5YgXGVB9BXuuh6Hqtw7axDp8cFuqE4usBiPpQBy0V39ld20vd9pkOZI2QZjPsawriWOPVJZdSl86Q8sZFy3054rrj5E9xeTeWUmz+8WHgfhVfVr/Sj4caC10OM3wOTNIdzAetAHOanfxTWqxBVtYmIAcqMkVh6trNr4escTgXKuMrtP3fer2i2EWoyNLcTfZ405O/kN/hXmvxLnRr3FqNkO4qQP4sd6AK3ibx/ret26Wj3s62MediFvmwfU1yBJJJJJJpKKAHI7I4ZCQw5BFXLLUprW/iu875IzkDOBVGnxRvK4SNSzHsKAPavh94p/tJpZZpIYJ8bQrqCCfbNdhqPhg/ZEvdQuIIw53bd+CfwFfN6x3FmyuHEbA/3q9w+HXivSNTEOn64sOVT/XLJj8MUAQM7GQx2MNuoU4+Vzub9au2mojCpfW6IVPQuRmtLXdN0aS8MGjx/ZovvNckFvyqnY6VZJvluL+S4I+6zLhR+FAGyuq20enyrY+TnGNrKOPxrnJLOK+YSREvL3IJGTUZvbLTzNeXC2s8KHIjYkbvwp138Xri5gjtodJtIbZe0a8/nQA1tOvrWVH+xSGNfvYBORWR4j0C38QWMssMS20sYyDtwSRXUWmt694gZVmWO30xRu2Qpgv7Zpl9dtCsttbW+12GAkmBj3NAHz1PE0MrxyDDqcGo66fxVoE1hcPK7oSx3HnH5VzJGOtACUUUUAFFFFABRVqCzkliMh+ROxYfePtTpLGWMJkjLDJx/CPU0AU6+hvgxbF/B1nIOQPMJH/bRq+fZUVcbH3A+2K+kPgSCngUO/3SkgX/AL+NQB0N2RcJugGMNg4qazhdLoSnJCin2sBhh2Y5kbIrZ0uOOGxuGucZA4zQBl7xKXmcdKtPCLyKNY2wV5NLZ2TXUYYDEeetXJ7D7PuaFuoxQBmlT5cig5IBBFee67bDyLgsMHnFej6dZvDeAynKsMnNcz400p7kyG2xsJ6CgDw8W3lyyNL68Cq7s1q4lI+UmumvdFuWumXacLWPrcZWPyZF2leaAOw0tY5tPjaPBbFQ6gASsPRyay/CmoCCx3OchapeKNTdp0uLf6cUAa5uo7YvFI2XUetZl9f7rXg85zWQqT3B8+QnLVJMhIYei9KANPwrrknmzuzfKnAFb1qkWu3SR3BCLnJNcPYQPbWpYDG9smtI3UsUKvASGJ7UAfWPhS6sLXw1Hp1mUXy06DvUGjz3bXMqzEmIZ25r520bxbdwzKElO5Bzz1r3Xwhr8WsaOm1lW4AwRQB1NvHBfF7K7jVo39RXy98ZvDknhTxQ5jT/AEed/lAr6Gk1OS0nQY+evPvjw0epadZNKAZgcg0AeOeHb59F11NUgJUxpjiqvxJ1ubWb+2uLnJVgTUI3XFu8CDDZrs7XwHceLPC1xc2Kkz2gAwPWgDG8H+JptB0QbZCtpK2WHY13i6gb7wsbiNNqzvhWrhPH3hK88PeCtDjmjIlkkJcY9elex6/4fGg/BrwzLHES7KrSHHfFAHBavr07+TaznMcKBVB7V0XijTls/BljJEg8yZck/WuV8QWgOl216oO6Rua9NvpoL/4eqcZkiiAH1FAHzXr1t9nui5z0yTXr/wCzxrkIhu7Sd/mk4Ga4nW7FJNIkyMztniuc8AX8umeJYU3bQXw1AH2bBGohATBJOa8v/apI/wCFe6WB21OP/wBFS16pb7Bp1pJEQxdAa8l/ahDf8K+04t1/tRB/5CloA+XqKKKALmlk/aCAQGZcDLYycjjNbV3HLAqCW2liJ/izwax9I8r7X+/jEi7TgE45rTvNXV2CxiWNk6biGFAEqrbvFlop42xzIDuBqKx0CXVLlzYPvReWL9arf2vLMAsqKv8AtINpP4d6ZbpPFcefCZ0PUHpu/KgB01tLC01pHIuM/Mue9U7i2MMce5NrE/eDgg/4Vc1HVGuWHmW6I69ccE1SmJnYEjZxwACc0AQKA8gDNtHqecV1PgnRDrGr+RE3mmNcjcvyiucjhyAfKlPr8vFfQ3w4sYfCWiw6p5ccz3UW3A7A+p9aAOw+GfhJbzxDZJqmnsbW3GWadht49K9H+Kev6NY6DPp9vOjXbptSONsqPriuGtvEWl2Ogz3V2775MkBXwRnt1ryhtVi1a/nubVhGqsSNxJY/jQB22mJLp+kmVvLIb5g0b4xWP4i1O4Fsu22izKuDJnLVP4bsNMurOW+1nW2RovmSFV5z71SvNS067v43uRcNt/1bBNg/GgDmNMhu2Zre7hlSPO7eVNc3460K7W6SW8iZIGH7uRBuyPevT9au21meNo1CrGuAsRwD9atR2k8+m/8AEwimuEAwAvLKP6UAfOUulzq5WLEoAySvGPzqrNBLCQJY2TPqK9+tvhcNZtmu9KuWjbJIRsZHsaqW3wf128dZ79IkijfDGQgEj6UAeEAEnAHJrr/Dfh/Wdjyw22zeOPMXBx+NfRvh74e+GvDbWuparItw8Lb0TYrxk9sitzVvG4u74C0s7afBwsaxABRQB8o3Xh3Ug5a9s5EBbOQud1N0hW0u9Z4oWZ+jJLwMfWvqHQrqPVtTurO5gi3dSnlgj8AKTXfCfg8QTxahbbLiQfu1wV59hQB5xoOuXOrWcdlaz2ts2MFB3qrcwXFrfKjQC6CMC+JCFP4CtHV/BU2jKl7o5cRKuSN4yB/OpdAuIr5GimJWc+pIz+NAFTx/qVndaLHBarp9vcBflht4Nzsfqa858IfDvxT4mvNsVleR22cyTMhIH0r16DRhaXhuGitopP4ZGwzH8K6bTvHmsaPG0aPFNCBwqx7cflQBj2+maV4VsI7O/ub2a7QfdP7vFcXqEvmapLdrHtU8KrNvbHua7BoY/FN8+p+I70QoeBHGhJA9zWVregeHLTc9hcX7Mf4nzj9aAOI8U+GZ9XtPtZuoINoy284GK8ruI/KmZAwcA8MOh+leh3bNHdukvmTW+eCzZH5dK47XrVbW8Y4z5nzBS3IFAGRRS9aSgBamtFjkuolkVyjMAQn3j9KbBF5r7dyoOpY9hXrXwqm0nQ0N/b2dve6l0Sa5ORH/ALq+tAGfqGnLY28OyyaNioKib5RjHcmuakZrm5YPLCHB6RdK7Px54iWe6nutSnhuL11wsfB2D0A6CvK5mlSVnzsMgzwe1AEmpxrHP8sgcknODnFfQfwNLTeDrOLogMhJ/wC2jV84t0ABB/CvoP4M6gtt4QsoujP5gz/20agD1SSOK5u/3RwsQ5qpcwS3UZiXgM1VHuhp6CMNl5j1rSW7ETpHkbguaALckhsrWK0iHzHgmtK2s3Maq5PzDPNc+l8JHLSY3A8GtS61QpaK4YBhQBFcbo7mWN+gGAaw9Ttrh4447cbiTzU0mqrcz4J+cVHo+rtHqTKw3KOlAGPf6Q4vYcRe7cVxXjPwy999qubddiIMV7vaSwTxzNIgy3ArhvFNhdTXC6fZodj5ZyB2oA8E0cpFFNayEZXNMkg325J6g0s1m1r4mu0Y/IXKinXIZb14kOVUZ4oAs2DB9kZ4A61WuCYb58j5W4FT6evmQOy/6zPStGG3S52mQYMfXNAFaCESqVYcY4FW7OxSX90B+87CrNg0D34GRtUVu+HdEln1g3iKTAufpQBxE+mSaff5kyAx710ujXd/b3fnaWzlYl3NtPAFS+MsHUjG67Rjiofhw95ZXmpNNCxtZIygYjigD0XwRr7eK7e6d1xcWxAOO9aHjbw7Jq2jCfGWhB4p/wADPDL2EWoXciZWdsj6V6TNp4eCSMDKtwaAPjAKNP1OSNxhiSOa9f8A2YPFCw+L7vQbvaUuuQG9a5r49eH4vDuuWFxDx5pyQKwvAguLX4naJPYA+ZI43baAPqz4m+DIPE1zFB5SiOAB+B3rT8Z6Nb3HwnurLYGFvZ7oz6Mo/wD110MwknuSIOWKDd9aq+IUGneBtT+0HIW3ct+NAHyWrF/CcYnPKNwD9a6XSJEfw3FApyGBLCuXvpVl0KUxkY3/AC/nU/ha9MY8lz/BgUAYdwsfm3ckp+RchRXmWoBrbVkmTKkvuBH1r0/7E174jkswfkUF3/nXEeIoBP5zRLkRyEAigD61+Gt4t74fs2Zt5SId64L9qbn4f2B/6isf/oqWj9nbVmm05oJmyQNvNJ+1Shj8B2A7HVI//RUtAHy1RRRQBs+FYrebUXF2YxGIi2X6ZyKs6rbWU1yRb529jGwIqv4UDtqMgiiSUmI5VjjjIrvNE8IWt4j3V5PbwMvIjOAfzoA4lLK4hgUmY+X/AArIhAH41Jcm6ihUOUusdFQEEfiK9Q0+eG5iOmCCGVidinAwa5n4g+Fm8OxRzCCS2kc5znK/higDj/Jtru22rb3Yu8ZG4kgVWhhEEUokXbcA8OCeK0dKXVbuXdYJI8uOf3XX6VQvodTs76R5re4hcnJ3xlQfwNAGh4ftm1G6itobuXzHYb0AAUivcJ4W0GxhgtLqC5iKhWSRQSleC+FlmuNdjeIRbwdxVsgEV7Pq8q3NpGbUwyyoo3RlcCgCv40tro6ImYYJ4yQ2VOCv5VneEbQuiEmOCJf9bK77gB9K5nxNq2rQWjJDPDbx/wAUSHOfzrHstZubiCOK6YmM/eEa7T+dAHutta6JdMkVrqFtcEEEzY5B9K2Lq1tIGWWR4XA48x2Xb+ANefeDYRDpT/ZtMWSKX+N3LMp9cVpXiSGNReQ3MoThDswFoA6S/wDsdnslt0XyWGGWIgE/hWnpFqFEU9pJKHkGWh38KPfNcfJpt3eWISOxmkXs6oUI/Grul2FroOnNeNdXrX4+6jHKIfegDsNK1FtO1F7i1t3lGdrAjagP1rVvri9lG+RJnMzAhIh8o9jmvPz4t1FpIpnS2aKLk+Wm3d+FdJb+OonXzJWmszJwuxN340Abk9lDZzJJrC20SuoxDE/zfUiufvdJ0W7vZG07ZHcN0XecfjUWsataQAyzXJmjlHzSFCW/lWDo2vwzXzwW0cu8/wCrfYASKANGfQLq2DXmm+dDcIcFomxmuf8AEU1/c3UEmpifzANqPzXZQaxqUUwivI57a2PSUsHB96p6lctqWsxQWdzNIUGd0kY5PtQBhK8mm6ZNNqLyCJhgDbyK5nS/EOnW8/yx8FuHYbj9eKz/AIm+IpzrbadMxRYxhsZwTXAxaiIbwLhmUHkg4FAH0HIsXiCxI027kDgcsUCj8O9Z1rps1oGS6eWVxxjOPyritC8QXEEsclpIIUxjj5s10S6peSzmd5QR2Y4zQBqaobqC3RrSJ4tvI83hQf61yGo6zq94rR3FsuF/jfkfgorq7K9mYSTXoSdVGV3An8hWJdXyTrI02QWPTy8ACgDhroNu+eQNg5wvRfrXHasyG6YxzGZ2+8ev4V6L4j0trm0DxXAROp+UfyrzrWNOfT5kWSQOZBuyBigCgCB/CDSU4Ywcrk+uelIVIAJGAelAElvO0BJUAg9jU0N1IC2JnjLf3SQB+VVAMmr+ly2FvJ5l9DJcEdI1IC/jQBreFfBWveLrpk0KyluVB+edvlRfqxroPE3haLwrAYtUnt7udFw6wHofTNLpvju/tNHkt7a6ksrJuBFD8pI9MiuL1nU5L+bO9zH/ALR6mgClcyRyPmGLy19M5r2j4WTwReEYGkIEiF9uf9814lXrfw8tPM8LW8rNhQzn/wAeNAHopklu7q2fkhTk1YlvXl1XcpwEGDWTpWqRx7gfvDgUy1kbzp2Y8tzzQB0Wp6jHFEjRckdaybrXjKqqrYPpWTa3DSXBhfLZNVbqxkfVP3PKJ1oA6CDeYzKG/ePwBVzRGlW7dWXJHWrHhbSDdziWVtsUYyc1W0fVIv7T1CVseQjlQ3bANAHdaJOtx5cW35s5qfxh5mmeH729gjBumXy4+O54rjW+IGi6RKzB1ZlGeK5/XvjBHqMUMUMX7sPk+4oA4LxPpNxZ3lms6kTP87H61mm3KXEkh5zxXoHivULbW9ObU48CRVwq9xXAXMzNYoUP7zvQAzTmWzu2Zz+796uavdLHZh7c/wCtNZkcZvLYqSQ5OKmlQHy7Vv4BQBHbiQXEYRjmQgdfWvqvwf4YgtfC1jG2C7Rh2Pevk69WS0EU6HhHBr7C+Fsv/CR+FLKeKUEiMKwz04oA5Dx54Dh1eBZ7MASwnLAdxXP+JdV0q28GxaboeyS/VgsoReeOte5tor2V08bvmGVSM/WvAda8PweAPiJHNduJ7S+clQecAnmgDuPh34sgt/DCw3CeXLGvzZ45rqdP1VDZvdTSAIeQSa8s+K0ljpWnQHSyomumzhT0Fef6t4zvY7OKzEhWNVweaAHfGDXU8WeKNiNmG1+Va3v2XdLXW/iDc3tyu6Gwj+XI/irx7VdR8qZRajfPMcetfTPwU8O3fhjwqL4oUnvcMxxzigD3qxuIVubhdw3Fs1n+PYRfeCdWjQnD25/xrnNFvGF7I8zHJHeuh8TXKw+A9UnPCraSH9DQB8dRoZPD1yy/cjl21Siuza3toc4DmrOh3WPDU1s2S08xfPtXKm+Fzrjx/wAFvQB1lpcm28TXkoP+uTYv5U2y0WPUNTOlwrumdS9Z2k3K3upRsOu/H1rqNBlOkePXu8ZHk4AoAf8ABFZLPxnc6VnHlEl/wrpP2pZRJ8PdOIOf+Jqn/oqWuY00XOgeIptQVf8AStRkwo7gE1v/ALTEDwfDLRFlOZPt8Zb6mKWgD5iooooA2/CQU6owdiqeWd2Dg4yK7qZFiiBtnaaDHII5X/GvOtGl8m6dsZGw5GcdxXofhXU7e5byYyYnIx+85U/jQBc8N27yX6XFtC2VPLDgCvVYPDnhvxlLHZ+J9XvLWTb8qBRtJ9jzXm+swzaNZNe2t1gnkquCKwbTxberNHdLdSCePlSOgoA9x8RLoXwjt7STSLtL9zwpdAXUfhWF4k8W6d4z8Pzz3dnELrbw6xDj8KoeGPFVl4qXb4t0sXRQYSeMDGPeszxXdaN4cmkFpDJDbTD93sPGaAPN9K01F1PfaY8sths8Y/CvVW0/R10JvLuJjdBcnDcA/SvGdP1Sd9Zcwlsu/wB1vT8K73Wb9lsY2tbq2F0AAVKEGgDntctWgEb3MYeAnkoQT+NWNP0W9uY/N01Y/KUZBYgZrPtEdtVgOrSbbZ2+cqNwx9K+pfh1pXhX+wA4jMlo/RtnzZ+lAHkfw/1S8s2nguo7mO4zgMkW9R+QrtbjxVfQGOKdopU/56fY2GK6NpYfDmss+hb2hY5AlUAV2SajY6vp+/Ur+yWUjiPIWgDxDXdc1i8lWPTpJrlCPmjjiwta/hvTLiWSC01hY7cS8gz8qfyr03Wtd0K10VreC5ja4UdI41bH4ivKj8QrDRr3zdQMWoxA/wCrk4KUAdb4h8NDS7RI9PXTpi335IVyQPyrhbTRtQg1SWa3CXEI6g4wPwqfWPjja3d9FHollBawkYYncQfwqzo8t/qk0upyW8n2iT/VmNNsePWgCqurzNJJZ3HlWqngNLESv4Vb0fw5FaP9re8dZXOcxoAjD24NbOs2MjaSpv7g/aByoHK5qr4L1m7lkfTrr7O2PuuSEx+B60AXL+C8nEaw7xbHjYWGW989qoz3sOm+bIkYikhXkbzz/WtXWLXUBeoserRLGfvN5fCj0HrUun6DHNcvFAba/mZfmeVCuPwoA+Y/GeprrWsXDygiRz2JrE0fSmk1COKVw8TMN2O31r2bxr8MNTi1WaeCygnDZO2EEBfzrP0HwbfxgpNpt6oHcRFVH4mgDp/APhOxlkFy0sDwwjCxjkA/SpPE1xYRatttok/d8kiPAJ+nerUVzp2k6W9vHZzW9wBhnWXHPr1rlZkkurje8zTZ53SHHFAFU6m1zqDBrhlLnAHQAV0VmumABbxflx0TJLVzt9p8i3EctvDGSvYHNF5q8u0peIAFGBsQA0AQ+JI7CNpnt4pEi/hDHcSf6V49qrTG+llmQ53cFugHoK9OvxPPYs4aVcjjc2BXnut2N1uUtuf+QoAyZ5zIoXII74FQU+RSmFYjPoO1XLHTJLqIysyxQr1Zu/0oAz6WrsdiZrpYoWJUnG4iursdB0my2TapNuwMiMfMz/gKAOUtrW7v93lxvLgdewrV07wtcTkNdyLbp6Hlj9BXV2RXUboxaZbSRQjgDp+eK37XSTA+2Qqp6nHWgDzHxTpcOmLaCAHD7sserYx/jXb+Cpn/AOERtIozj53z/wB9Gsf4qJCh0tYpQ7gSb1AwF+7itrwHEP8AhF7Rs8lnyP8AgTUAaswNvJFJu4J5regcXDblOBjFc42bqYRMeAavwyNayRICcZoA6SxtYUmdyMvtq9pGmSFZ52Xg1RhuI1kEoxsxiukN4tvp+0H/AFnSgDB8fDVNI8JzT6Vv+ZcNt9DXEa1cS6D8HrQyEjUtQlwc/eAzn+VezaXeQy2K2l6quj8YPpXmH7RHlm90eC2UC2tkyFHY0AeaDT2bT1luZDvIGcmrkemQxCDy+VIBNRzJJNpSO5I3tgVrW8BggUNyNvWgCxFC+Vt1b9y3HWpNa8KajZwfaoYWeArnI5xTLbc8kSp/er6T+GYs7nw5Jb6pGj5XHzDrQB8jWU0kV0u8FeeavSOslzJIp5A61618X/ho9qv9p6HEWgJJZVHSvDphcwHY6lGLYINAGhdMZ9Pkjzluorb+GHxL1nwdayQRb3i3/KPSsBI3ldvLPyheat6FAj3IimTK9TQB7LffG681TTPJ2lLk8AjtXK+KNdm1aa0bVX3TRrlDXJ6lYpb2r3ceBhuBVeTVI7yS3WRv33AAoAk1jVLwyiW9ZmA/1YbsKwb9ptQt3kwVJrZ8UXAuNUs4dn7uMc11nw78E3Pi3VjsXytNiOZZCOKAL3wE+F7eI9Rj1K/iLW0BGCw4r6j1iIWwt7OKMLAgwABXJTfEPwV8O9Fj02G6jMkK4KIRy3qTXP2Xx00HW7xEUquDjmgDsUsmS8LMMKx4qX4x366b8INXlQ43W4jH1JH/ANetrSbzT9f09ruzlRkjXJx2Nec/tSagul/CaC13fvLmeNAvrgZNAHgPguEXmntK+AlvEXOa8qN80OpXUg6SO3867vStXax8P3ixjl128V5/Lbs2XIIJ5oA7HwVJ5+rweWcqp3NXoehQPqniwADK5wfpXm/w6ikhupSV+ZxgfSvafhRCp1u6mcD5BQBd8dWv2LUrS9MeVtwNvHcVznx21CTV/hFpl/KeTq0aAeg8mavU/iNHbnwvO8qDcq5BNeNfFOQf8KL0ePPJ1dG/DyZaAPBaKKKANHRP+Ppxt3AxkEYz3FbVpcPbz+XbFAueVGRWLobRreN52NpQjn6itOW3jBLRyc+mc0Aek+HdF/4SW2+zpNtmI4BIxmsXxP4L1rw9PjULXzIG+7Kg4/MVxtlfXunXSz6dfTQzqc/u2xXpCfGLWJNF+waolrcErgSuuW/Ed6AF8P6bf2ekSXSzwwQFckDkj6159rN9LqVzILiaSaNDhTuGPyrUufEVzfOxhnii3cMg+QH8K5zUI0zu/dOxOSsbHNAE0TW1sizQTIXU5IK10aeIrO4tY4ja3fmtxvwCufYmuOY2ZCLbrcpL3DEYrdsJ5UiEaTBx3DAHFAHU6ZMsHyx2Pmu3VnIJFeheAbXU9QvoYIUlWAsN377ywBXksS3MTpLFLs55IJwa9L0aeSysUuJIrx0Zck27HA/OgD6GufDXhLTtMYXKRy3ezPzXTF847c/0rh/DukWU9/K+ohktlOUaX5hj8a57wj8R7bTryK3k0hrhJGwZbrDMK6zxl4s060HnRaZiKReTlcfgM0AT+IvDnhecqbYNHI3AKOqxmuR1b4aaHdDyrueOCRxlWWXOfwrj7/V5dUci2g+zxg5Xc3H5Vh2OsMuqst4k1wEODtbH5UAbz/CPQbS58631qdriM7jHsG0fQ55rTfXdc063NrFcwvYj5ULr8x+mKS+1K0ns0+xS3Sk/eSVR0+tc94plB0ouk6/LwqR/KfxNAHQDxBdw2pnvBbzIv3UkfJH4VijWtTS9W/gMEPORtTAx7iuBsbuazkMk22dGP3SeK7TT9anhtUa0MVojjlCN2fzoA6bWfG66raRo9ifNQc3CSFcH2HWsfRtb1fTL37TbXM3kydrgkbvzqjJfzXFuxkgtZJD/ABqgB/DFTaPbw3R26tOwjX7kfmf4UAeq6R4qiu7df7RmgE6/MTHgAfiakuvGMN4HSK8eQj5VRFXZ+LGvLtUTRYBtW0LOvQI7HP1zVDUr8jTCUhtLdQOFydxoA7bU10i5uVfVdU0+GcciFCGY/XFUNdMD26rG9s0I6CMY/M14rNriR3RRIgsjHkg5IrYEst2iReZJg9Y0zk/WgDsGis8bYZNsvXAlyD9RUI0me6dpZpIsjphgAtV9J0AmBiAI264IJP5097e1gcbo5Q2cEk/KaAEuNOwjebLE+P4mfNcN4njnso3lV4XHQMx6fSvVbOCxntQGjL+uF4/OvNfimum20kcFvE3nNzkyZxQB59D5bS5nZgucnAyTW1da1CtulvZQYjXqX7/hWDWjZ2buFby+D3IoAa+oyMcLtQf7I5rU0O9VnfzGGcfxcsaik0zEigKnPbG4/jW/4f0UzzqJHWOIckDqaANrw1f3sXy20VuEJ6Y5P1NdY7XEkDST4DYxiJcfqavaHBHBahLe2CAjjYm52/wqnqhdLjbcrIiryqMen4UAeY/Ey2+ztpxKlS4kPJyf4a2fh8HPh8c/KN2365NYXxJumubizyWKrvCk/wDAaueD7uRNO06JM7PNbd9MmgDs7dIzbhTgXHUjvQw8yBWJ+YNiqOuW9xZ68l6pIt2QCtWwhV0LOwGBuoA0leGC0iRjyxyautO96FWLOxOKxtIjS+imac4CtxWjp8q2zIFOUZ8E0AbPmPFcQZ42gZrk/ikY3himmOSwwK9H1KK0WyWTeuXAAry74mwM13aROcIqbgKAOPZvMtYox0TkVct7hrjTZl/jXgVmWTGW5aJecDinmf7IrIhy7HpQA/RLq6fXrO2jUld43H0FfSNvfQQ2caWsik4AO0968p8NWVnp/g+/1OdQb2RCE9R6Vn/DO71GI3LaizGN23LuoA+hdN8RRtJHZXShoyuMtyDXFfEH4a2uqyNc6UirIedoHem2d7HKVyOexrsLTVBBbIc52igD5hv/AAxrWjmdJLeQsWwOO1S6AkiM6zRnzQMcivqaS407ULVZriFD65HSub1/RdA03QdX8QbI8RRHGPWgD5y8a3+y2t4IDj5sMBTNP0lX1eyud3Ax8vvXJ6tf/bZ0lU8NJnHpzXSC+a3uLKRDkRsGYUAeo3Xgxb7X9MttmHuOWPoK2Piv4mPgXw4PD3hbC3cuFkdOq/l3rpNC1SF/CN34umAV7eExwj1PT+dfP+pa3LPqgurz95NOxc57UAczcaXLcK02oXTm5PzNuOarQWBgnV4JifcVu6ho9xLZXWpO2I3b5RWDbu9vIg5NAHtf7P8A4zvbDX7TQLyVvJvZ1DEn+HNav7VniRNc8Z6foVnKJINNjMku05HmN2/AYrx/wzfPbeIRqKcNbLlfrUVreTXuq319dszzTMXdmPagDR1CWy03QreGZl82Vske1dRo/haw1vRhdQMv7tctivHdVvWvrx5WJ29FHoK9F8BXN5YeDLyeN2EcrlFHt3oAs+FDb2dxqNzOAI4gVXNeofAmF9QS+vP+We7JPtXiGpThYBbo2PM5b3r6E/Z3hls/C12JFwknCn1oA7H4h2seoeBLjyR+8Zgox9a+cviq7x+A7Szbhbe+jGPfy5K+nZ7cPBHaEZRcswr5l+NQZNGkBGBJqSsPwSQf1oA8ZooooA2/CumXmqXlzHYQtM8Vu0rhRnCBlBP5kUy5ge0lKXMM0QHfGR+denfsqabPqnxGvYbZ1Rl0yR23Hgr5sQx79a9M+Mnw9trO4W6slaO4fmaBI/kYf3vagD5fjdWlPlq8pPTdxirCJEoJvJiHPRMZ/WtnX/DL2l3vhZQjdDjIqslxa2tv5F5YSvN2mibOfwoAzWk8v5bKOQf9dCCPwpoilkjMk06q/u23FTIqSSkyRXKjswIz+lEVpBJcBdhOem+TGfzoAhxAYtot/Ml/56rJUNjO8V0I3ZghOCM1c1K3eGVY/Jwh6hZAaWVbS3gUwlfOP8JYE0AdIkdtNZgbmUdipzj61bsl1yOFlsp5xH0DRuyj8jxWRpphe3VbicRZ67U5Fey+BNU0vSNI8p7u3nc8oXQZX86AOZ8G+CdY1ydftks7gn7yRscfl1rtde+H1rY2RX+27s3qjISSEnH4GvUvBXjUyolu0ikHp5MYbP5V1mr6Xb6lGHiRjI/LFgQ36UAfIw8M6ncOwt7G7vSv/LWOFhj8qn01bvSpjb3Nt9mdu84H9a+idV1rUvDVjNBpmLkAcLKApH+NeFeJr6/1/UhNqswabPyooxt/CgDS8PXV15roLcuP76qNtc1rmkGbW2a6eQoxyVQ7vwroCNRhsBaQO0cZGWO7n8PSsG3F5bzBreQhycZf5s/jQBqWPhrRLmB2TT7gOg5WZ9u76CqBtktVkdUWG2X/AJZswKj866vS/t0ERae4MkzDOw4A/XmuM12ztbyct9kn8wN+9AcnP0oAAtpcqHtldGJ7NgGrdi8VtI8QjRnI5JOSKzxYwRzRR26ygsOjHBWtOz0XfOxa4EZx0JyaALX9m6jexEadZsU7zPIABVOXw5qwmQXE8Fwx6Rs2dtbWlytpjEpdR5HYnC1Jqeux3gMcWyWYDBb0/lQAaP8ACex12aKTU9asNNOeQgBY/Tmuk1zwH4I8Laa0lvr89xfgYCI6tu/Bf8a5Gwhv5Y28uKbaO/AH5mmXOhanGv2mPyRnsxzQA97prm1EFujwA8dNzH39q5/UNPzcKt3ds23n0Aq5PHcg4uJEB/6ZvwPrWdeNImFScFD97nn9aAKmqaxBY2jRQpNPIOAQ+FryzXNRm1C8ZpsAKcAAdK9C1ZdMFnL56sFx98cn868wmVDO4g3NHnjPUigC3Zw28m0As8voeAP8a6q3tGaEeYjYx/CeTWf4XWIvh7WQsPTAz9Sa7vbLPCscKqG6LDbruP4nvQBhabpm6cyOCsQ6l811Gh2Kb3nMIZB90kfyFaGj+BvF+qkRwaVdnIzmVfLVR7k11mmfDrUbKQDWLhIwv8ELbv1oAzPD+szCf7Ha2Mis5+ediOB7V3C+HvtgAhCOSPmO3OfqazJ9I0xCIopP3i9ycAf41rWccmnWZe5u2ith/FI4iX/E0AeFftDaRFpF7o0cbBndZtwHQY2f41h+HVEPhG3uEGXEjZ/76Nbf7Quo21/faOLOZZo41mG5R8vOzp+VZngsKPCyiblJWZV/M0AdZqQuNS8PWkyL8o6msi6uZIVjRSQCME1XtfF32eaTRdn7qMH5vermoxLc6DDcQDLl+SKALcF3HCVt0OCVyasWVyslt5Ib94GzXMyh2u0IOG24qvYx3cV/M+W2Bc0Ad5qMtz5Fp+9JRXGcGsv4kO15JbyocBIwprF0y9vbhoreUnDPnn0rU161nvtOmMHLR8cUAcFYTPaaygIO1u9a08IS7Msv3TyKz5UKKEcYuFqYvPeRop6pQB0vha9e/wDMtZshB90GuktH32ssCptZDxXG+G9yavEUHyr96u+nMcMvmRDJfsKANmznhj0qMDmZetaNndO2Nx+UjpWRbxxQ2wmlON3an3VzsjDQ/doA662kWVTbqcAjjmsjVNPbUNAv9DmkPl3GR1qK0uTHNA2eozV62bfqLuWGeooA8KsfhdqVp4g230ZFlGc7yOormroF/GLWFsd0bTCJa+s9Un/tLR57VF2vsKhvevF/BnwvvbfxTFq182YIrjeAe/NAHrF1oKP4V0zwzBhRsDyY78ZNfMPiGK4tfGF5bvG2yJyiDHGBX1Zc3qweJvtStiNEx9OKy9S8K6Frcy3rBBKzbnIA5oA8C1bVEj8OwWko2c5rmTbS3aeZaxNJjgYHWvpHxj8K9K1yxtf7PkCOh+b6V2/w7+Gvh/SrZBcrHKIRvctjHHrQB8v6h4dm8NeFba91EGK4vGyFI5xWcFjtfDeoXe0fvU2I3ua6/wCOXiSDxn8QW0zSAP7Psz5cezoSKreKPDk1v8PFhhjLTLIrkDuKAPH1Uu4VRkk4ArvtL1Caz0tNJKfIil2PvXNaJp5MxmmUgxHIU+tem2Ojrd6I93sxK64BoA4i2s59TlBhBZjJgV9b+DIV0zwxpVkoCylQZPrXjvg3Q4NFMD3IDMfmx717D4ZnF47ScYUfLQB0c8qJNLLjgjaK8B/aj0+Ow0vTUiAANwpOPUo9e7ZCiJJB1bJrxn9qmFn8LWF2ejX6IP8Av3JQB8x0UUUAe1fsnSpB8R9QlkLgLpUpyj7D/rYu9fWU9nbaw6S3GpJGjDAG7cxHpzXyJ+y7dx2fxBvpZYUmT+zJFKOMg/vYq+rLG0XUYSYLRIbdjyN/K+4FAHEfEDwXbruto/s88LjIdY8Op+mefwr588WaadMnktGgzt6SAHn/AAr6t17SLRIEMerzXTxniMqfl/rXKa54QtNeg/0eeGS6x0wefYgjFAHyDEstvf4jLIzH+PpWzJbI6j7ReKGHIwua9I8ZfDOexhluLiI2hj5yeQfwFefnTGKExyNKo9FoA5fVHQXHyMrkfxYI/Q1XliVYw4bJP93oK6l7KCc7bhMY7gf1pp8L20qf6PdsGP8AC7LigDBhvlVV3Kd443ZroNG1CONgv2kZbvgkD8a5690q4s5/LdQ4HdCDV3w69pDegXKMCO+aAPbvBunWxiS8bxHY2brztjdlc10c3ii+iRhb+LXS3Tg5mYlq8pUWF4gFlN5rjqhJJpwsFdG3wND2O1d1AG54l8Sz3J3RXt456GRnyGrm7C6u7i6CxyEA9XJ5roLPwfa3ulNI9xDC56M7jP5VhjQpdMm2efb3Cg9UODQB6Fon9mw22NSu7g3BHMkScU2bUIYi1tFmW2Y/LIy4as3w3r0VlbtZyWEVwX6uW5qa0treS9zMRbw53FSD+QoAv2cV3qjNDbh/s6j/AFkoGR+NMgtNt00Ms6KYu4ViD+VO1LVrX7THbabDc2kK/fnfjd9BWYdaFpckub64tu7bMZ/GgDRU3iXTyQPp1yR03ZDD6CsfWNQluL0RQqtpc4wzq2Aappe2sl/LMkMsCN93J5/StfSre0cSXEjSyyfhj9aAKGk297biSSdBKv8Az1yDW5pUtmEzdmKFic5xuJ+tVpQt0CDOohX/AJZjC5/KqLiIjy4gBzyc5xQB1smq2lwghS5e3hHHmEcH6CremWOkzwyBrpJ1x/rJ5SMfhmuSgVzKiokcwA6Plv5U3U7eePbJLHCg7Ii4oApakhstRkWCaKeDPBXIX8KzrpA7F5UjQem01u3h1C6sCthbI0mMbjgY+grgtVs721D/AGkyrL3L8flQBmeI5dT1K7XT7aItCThUjXBb612/gj4Recqz67eLboeTHEMnHux4rz1LprRjLG8ol9Q5BP5VnajrOo377JL64KdNm9sUAfR6aV8N/DqiIRR3l505l8xv8BW9ZfEvRfDduE0rQ7KDH/LR2Bb+VfJ+lWF3PdD7K0jyHjEalmJ9OK7ax0W9WREv4JImPOJB81AHuknxZm1MmSS5c/7EC4A+rGsK98Zz3khLXJSMfwxsM/ia5W10+SRVgtrSWc+mPl/wp0nhK+84uzxweoByR9KAI7vxw+mXMhtVQzNzvk5IrkdV8Wapr13unnMka/xucKv0rsLfwfBLcLCiyzXUxwERDJI3ufQV7D4X+EHh3w5p6an4m+zGcDd/xMHAji+idCfrQB8keMJbiaKxeYs8PziNtuAfu5we/aui8ISeZoFjFjhJHY/ma6n9p/WtM1W/0GHRrk3FvarOu5YhHHyY+EA7cVy3hSWO38L27sPmZnH6mgCVdMt3ttU1JjiUnaK6/wAJvZz6BBaMw8772DXNBf8AQVtx92VsmqscT6R4htZkcmHoRQBpuqHULlSMNH0FVru9aKxZdn7xzjNdPLb2F9K09s6rK3VaqS6WkjMJQBsHGaAKFnIqxCZVw6Jj8a0vDlxJFD5Uw3Gds4NZV1byWunlv7zfpW5bFRBb3CjlBigDgvFUUlv4gmmVP3Yp9szyWwmiXqORXeeL9Mhl0+KQKPMkGTXO2Nt9ltGRl68AUAaHh2yFra/aZlyX6Gum0owGb9+Rg9Aai0C2+1aekNwCp6irP9k+XdozthAaALjot1dLbA4SoLpBDmAHKg0/UEMNyrW/LY6imwoZbORpDmYmgC5duLeO3GeccVHDcSqxlB6VSmjmuWVcnKCo/PaN0gIOR1oA7jR78XSCJOJO9bCXAhtnR8YXmuE0GZra4luF6AdK0ItSkutPn3Z3ucCgChrk1zLZzNa5LzPtGK17HR7qw06BZZTvZcsKqWDfY5LaGRd7E5FdFLLNdSSKfvEYVaAHafb3lsieS5cvwBVf4wa9/wAIT4Bnj+0f8TK9XaoB5GetdJp0Q8M6PLqetOFSNSyqx/Svlbx/4ovPHviG7vrpmFsjlIE7AdqAJPg7ov27VZdQuiSI8sSe9eq67rGnLYBFZWx1FYfh7TofDvgKaYPi5kjJP41x8kUraYszMS0p4FAEen6cNV1iV7dMRSSYwBXoOrPBothFaqRuxwK0fhz4XEOkrdMmQq73PpXlfjbXZLrX5yjHYjkCgDornXWe9ihJ9BXsvgtXisBKeflr5i06/wDtd8jE/OGGK+lPDWpRWnhuB5yAxwMZoA7SEJcWzSvwVHFeNftRTiT4f6Sg/h1Fc/8AfqSvVJL2MNbqjDy5AM15P+1EUTwXYRr/ANBGMj/v1LQB8x0UUUAelfAUIfFt9vRpMae5AU4/5aR19JeGGvJJ430rUYEZTgxNJ8y+1fOH7PrEeOJ9q7s2Tgj28yOvonVPC1uHF9Zy3FpIRztTgmgD0PV9c8iCKG9t7KSUj5mOM59hXP3d8jTK1uggI6mGHAP15rP0K0vkVTculwh4PnwnP1BFeoWWlW9rp3mGJJzs3bSMj6DNAHkHifVY720e3mVJB3Uko36V51P4TguN0lvKLbJzzuP9K9b8WNYahbyXEWiSiJDhmt58Pn6VyNrFp96PKtTqNvIf+Wd5GAPwJoA89msrqyJhZYb2L1SEj+lc3rOiec5kTS2hPaQKVH8q9i1W48V6In+is7246YVWI/LmucvfEGu3y7LsSxxH73mEEH8DQB4JrFlqFkWa6jlCdmBO3H1rB3HdkEg/Wvc/E/2GTT3WeaRBt5wgIryO7s4HZvspfaD1YDmgC/4buWtD5izwmTscjI/OvStB8XavbwbI/s8q4+95Kj9a8bltmjI8jLt7da2tKlv4Fy2m3jHH3wj/AOFAHotzqkF1dlr8Dz2/55rgD8qBJI86lGUp0AK5IrmtFuElm2X5aCRjwrrn9a9V8MeFHugksiSvFjI8s9aAOQlDy3OGuoI0XnLR4P6VdtXu76dIvLilVPusW25r1GLwLpWoD/S/tdtKOAHIIP6VqT/C67i04zWF7AI1GRuUMf0oA8skRFYnUIXUrwoCkj8zVa+1tkRILexWSMdpcfyFbmveEtXimVJpYrj3jJz+VOtfAHiO9Cm206Vgf42UgKKAORubmGRtzMkTkcoiEAVQRonnK+YXXsoY4r2WD4FanfWqNcapb2xbl/kLNXZeGvgT4R0yJG1CGbU7jqzTOyr/AN8g0AfMKyu2oJB9m3Lnor8V266Xey2wS104ImOvmAAfnXvd9oGheHyq6DpWnpdZwVjtwWA/3jmuf1h3ldnuRBEuOQdqk0AePf8ACN6jEoYyuFHXyicD8a0bGK1gYJJYz310BkmQkKK69IogruTclM8RopIP44pkFnZRRyXV9qItLUcmPeNx+poA5LULiWSYi3tD5i9I0AQD6nqa4HxARNcym+d1m6bOoFa3xB8aaMGkh0aybzV480ycn3ry+51m5uOZLpY/9lT/AFoA2ZLbSkXaYpGkPua1PD2laMp33cCSE/dR22rXH2d8AxaScBQe2STRqN/FImIEkZj/AMtJWwB+FAHrSeKrPw+PIs5rCyQ9VtYgWx7saraj4t0VyDYQXN9euctNKeK8UCszAArk85OcVq2UskMgJlJI7haAPVINcvQpee5FtH/dQ9Pwq/Y+ILJUyxu7mQ9FJ2jPuetcDpbG5kBk3uPcAA12Wh6S0j+YU+UdF5x+goA09K8Raxbam8mlb7bzBtJjToPrW1/Y19rl4Jr+5muZcZPnOT/P+laXhPQdQ1G+TybV1t0OS5XbH/8AXr0HU1sfD9i02o3NlZxHh7mQhB0JwGbqcA9PSgD5q/aBiitYPDlrFDHH5QuN2wdc+X1/KsfwnHHJ4Vt/M/hdsf8AfRq78evFHh/xHfaUnhq5e6W1WXzpTEUUltmMFsE/dOeMdMZpPh0babQ7eCdgCGb/ANCNAFyTY8IEa/MgzVS4iLzxGX681u25tSbzbg7OlY0hM4Mgxx2oAw71b/TLlb2Fm8jdXbeHr5vEbBE+R8fnULCK8gs7NgCCctWdrMF34d1BbvSQTCvXFAHQXlhJ/aDWso+SMc1a06OOKDbKfkU1H4d1IeILeeZvluNvemz2k8MBWfj0NAHSx2MWpRKwIKjgCsvXtCb7VCsS4ROTUXhi8nN4saEmKPk12ouY7m6OQDlcUAYsaxvpbzQ4DQDBAqgXnvbJZFyAp5q5bQyQ3k0OD5EjHNOQCCR7dB+7zQAQYji8xxkgU2whE7bs7ec4p93cRRzLD145p1rbM0wMJwrUARwzJBdyPIRg8Cqk8lvFO0jY3vwKk1HT5hekEny1GSaoXWnyXMkbRZO2gDQ08sXeP+Fq147YFFWLovJxWJaiS1JknBGK29HMt3Cy26ktJ0NAFu3CPqEbFdxTpiu306wttGibWtckWGBRuUMcVkaOmm+HdNuL7XZVWROQG/pXgHxJ+JGqfEfXotO08tBpMBwqqcZA7mgDb+IvxCvvGmrXdtBmLR4chAOMj1riNN00vaFoUJRG3HFbmqR28elwWNgMynHmMOp+teieC9Esrfw+wuQvCZJNAHnt1eXE+kbZXI3MFC+wre8K6IdU16ztJR/osa7mrDkt2v8AXmith/o0b59q9Y8MaebSy89Rh34z7UAdXYS2um6RqFlkL5kbBPyr5Q1e1eDV7yOUHO84r6M8bf6NpUcyORL3xXjWvQR3EglIHmseT60Acp4Zt0GroOpXkivV4zfXNrbqNwjLDArzrR7ZbHVXuZDlcYxXrthqVs1nbFQMKM0AaV1dXEcUS5IMYGK8/wDjzqUl94OsFlzlb1Of+2cldXea7bSQO+ehxXm3xZ1WPUPDcKRDiO8TP/fD0AeS0UUUAeu/syXVpa+PNQa/sFvom0yRBGxxg+bFhv07etfVGiwahqlnNFoZ+whR92eRmXH4ivlv9lyWyh+IV62o3P2aH+zZAHxnLeZFx/OvpSDxCYtQItZpVgBwshY4IoA0LfU9d8KjydZsIJQ5+WaJvlb/AD+FSDxHcX0+241ARo44jjG3H1rd/tjT57WI3bpdkfw4DEH8angsE1aEs0cawH7mwKrD64HFADPDGn2GGdYYHmzksj5B/DpV/XoNNmt/Ju7RLjd0RSFP55BrJg8MG3mkaGaZF/6Zy5/McVQu47lC8a27XKr38sE0AYus+G5lQi0t5Utz0jFzkgV5F4u8MyBpHxdQuvOZJCfy4r0jWNQkt2PnW08Sf3NhU/nXB+LvEirbMlraMufvF5M5oA8ov9PO1y8wY9Ms+DXPzG70lkmhlt3QngMgeulvY0uC05RQep5Nc/ewmdlzENgP1zQB1Gk+LtUuIVjTTNHY4/1n2cBq17GPWr0tKLy3RT1iRgn6VxERFsU2KVA/ACujtNQsD80lwVlI/wCeGf1oA0X022XdNdQs0uevmhhWhp/iTU9MeNdPdljXohGBWXFe27qURzt9s8/hTbeMzTZSRQM8bic0Aeq6R8RUmCR6yvlv/eiUEV6X4P8AGWntCI7fy5YM/NIpAI+ua8PtNHs/se43qxvjlWjJLVBBpStMN1wsQ7LEu0/jQB9If2x4cW7L+TG7sc+YUDHP40tx4406G48iCCeUjgbVCj9a8Y8NXt7aXfki73QgfekUEj6VrXuuXkQdbONJyDkyOvzfhQB6vP4titole4s5V3fdVGDk/hUsd3r2ow77S3trKJhlXudxfH+6P61weh/8JVfactzYG1hC877hQD+Gc1Wv/iDqmjjbqGqWckynBjjjVz+lAHb3/h/Xr4hrjVrQkcYS32/ryazrvw5aWMIk1i9s1cdGZcn8M1wknxL1jUcr9nnEf8L8Rr+IHWskrqev3B3J9qkP94McfQUASeMvG9rYST2lg8twU4VlXC/ia+ffHXifUdRm+Z8LngAcV7TrPw/1MTpJeW0cKt/D5mBj6Cmv8OdIlQC4u44mA7KDz+NAHzEySs++Y8noMU77PLJIGC/IOxr3fX/hc8rGWyLywRjIdkCrXI3Hgm6FtI7SRrGPQHJ+lAHm4EpkwoU+g610Wl6CZ4w88chPX0FdBpehrbrn7PMEX7zlePzqa68U6RokhjisxcTjgtJIDj8BQAzTPA15qDgWltFGD0aZzz9AOTXoOgfBoLKkmv3bLER02+WD7AHmuItfjZqGmRsuk2FtC/TzAgz+Zrl9a+KPivVpWebUniZs5MfB/M9PwxQB9MDwp4O8N2v2kiwtkT/lrcygL+LMcelcr4l+L3guztXgtpZ9QlXgJZw7UY4P8bY4yACQD14zXzFe3t1fS+bfXM9zLjG+aQufzNV6APXtc+PPiS4s3stAih0a1IwHQ+bMB/vngHHcKD6Yry7V9V1DWb1rvVr24vbluss8hdsZJxk9Bknj3qjRQAV6X4NsA3hu1utxB3t0/wB4ivNK7vwt4hsLHRoLa6uTGyFiV2MerE9h70AdlBbpFZXEiZyetZ15A0ViJIclscjFVT4v0oQsi3bHP/TNv8KltvF+ih/3t4dmOnlP1/KgBlm8xjV1Ded0HFbdpdyRxfY79CTKe4rCXxZoyTrIl2RtOceU/wDhS6l4y0u8mSUXJVlPTy2/woATWJLjw7dj7Duwx3YArtdI8Q23iLSVhuP3dwgxyMZrhrvxXpNzIrvdEkDGPLf/AArOfX9NhfzLS9YMeSPLb/CgD1jSdOlsPMaMhg/FbdsBbamgJyCnr3ryTRfiJDbI6XUxI7fKx/pXRWHxB8OSCSS8v2jkxhR5Ehz+S0AdpqMkiXEIjHBbJNWJgoEQx8zHk1xsfxE8LmMCTUTuHT/R5P8A4mnn4i+FSq51BtwP/PvJ/wDE0AdZ/Z0Ul+wdh83A5qS9sbm2nVbdhtUZzmuRT4h+Ey4dtTYEf9O0v/xNKfiT4ZaVydTO09D9nk/+JoA7uJUn0/bK6+cTzzUcZt4bmOGABmxzXEW3j3wekhaTV2IPb7NL/wDE1PD8R/BlsXmS/eSQfdX7PIM/+O0Ad9BoBvpibwrHDnPJFM8WeKtA8HRRQ2Uiz3KLyqc81474r+Ln9oWxg04+SnqFIP8AKuCtdYgmvGmv7xznnlWP9KAOo8e+KNX8YXSqN6wOcbBkCtbQfC8WiWKn71zMMse49qxrXxTottGNtyWcdP3bf4VoyeOtIdVZrttwGMeU/wDhQBd8P20ceoXD3XTOFzXQT6m/9nz21qxy3HFcS3i7RXljJvSozlj5T/4Vo6Z4x8NQyO09+3PT9xJ/8TQB13g7SRa6c0kwBkkbJJr0eaP7PZwRoVACg9a8ttfiN4PjsjG2otvzkf6PJ/8AE1Zl+KXhNwo/tFuOP+PeT/4mgDrvGKF9HzkM56AGvItYja1ty8gO89Biuqu/iV4Qmcf8TJtoX/n2l6/981xXiTxjot7Lm1u2KjoPKcf0oA523uZpGkEgbrxxW9a6xLaWZVt3C4HBrEh8Q6eIzunIb/cb/CpH8RaZIihrkj1+Rv8ACgDZM0klvbjn5juPFY/jhAnh0YHJu4//AEB60tN8U6IJgbm8KIowP3Tn+QrK8da5pOo6KkGnXJlm+0rIVMbLhQrjOSB3IoA4KiiigD0T4HFR4vuN4Ur9ifkk8fOnPFfRfhoSWl6Lgyx31qDny8j5fwr4wooA/SW0vrDUrDMCae3H+rYhWBqlYSSG+8nfbWsn8IDk5/HNfnPRQB+lF54lttKmEGoRbpyOJVOVb8e1ZEmpXGoSv9lEMe/ux4H41+d1FAH3nrVjfW6fNqdg7d1M5BFeYeMUuHUgyQXGOqIwJ/CvluigD1fU5/LVomVUHoc5FYKLC8m1nbjvg4rhqKAO7kwPlQu57fLxWzaQxG2Dyspf0znH4V5XRQB6t56xHEaLk9WUZq9p8iJcpI88vynJCjbivG6KAPqyw1fQry0Cw2kkl4o+9I5xmpdGjtbm/YXt3BbsPuheM18nUUAfbuPso8yO3trpV+64IBqte69G0sZuLUJITtBQgBfqa+K6KAPvFfD7XdsZLXxnBAHXJhiAfHtyf6V53q/hVYdSZkvI55s5Mshxn8K+UqKAPsTT0treEC8ureQqOiyBv0FS2esRQXTPpskyY67FIr42ooA+1pfG9pYxu+tXNmvy7wt1corFc4yFJyefQVg3vxO8B6eXnvNVhnuAodbexgebOT03YC5HXBYV8j0UAfTGu/tE6MYmttP0K8vIA4XEsqWwdMcngOQc44rzDXPi9rl+GTTrTTtLh6AQReYw5znc5POMA8Y9hXm1FAGrq3iHV9XctqOo3M4JJ2s5CjPXCjgDjoBWVRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fetus at 22 weeks of gestation.",
"    <br>",
"     (A) Axial ultrasound of the fetal abdomen shows a dilated stomach next to a dilated duodenum.",
"     <br>",
"      (B) Coronal T2w magnetic resonance image confirms the presence of a \"double bubble\" with high signal fluid in the stomach and dilated duodenum. Amniocentesis revealed Trisomy 21.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dorothy I Bulas, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36609=[""].join("\n");
var outline_f35_48_36609=null;
var title_f35_48_36610="MRI glioblastoma";
var content_f35_48_36610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of a glioblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The T2 axial image of this glioblastoma multiforme shows a heterogeneous infiltrating mass that fills large portions of the right temporal and parietal lobes. B) The axial flair image of this lesions shows the extensive edema and midline shift that have resulted from this mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36610=[""].join("\n");
var outline_f35_48_36610=null;
var title_f35_48_36611="Major pathways of T cell activation";
var content_f35_48_36611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Major pathways of T cell activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36611=[""].join("\n");
var outline_f35_48_36611=null;
var title_f35_48_36612="Apert syndrome syndactyly 1";
var content_f35_48_36612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apert syndrome: Syndactyly of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Dorsal view of partial thumb-index syndactyly (with complete, complicated finger syndactyly). B) Palmar view of partial thumb-index syndactyly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy;2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36612=[""].join("\n");
var outline_f35_48_36612=null;
var title_f35_48_36613="Diagnosis of wheezing illnesses other than asthma in adults";
var content_f35_48_36613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of wheezing illnesses other than asthma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Richard S Irwin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36613/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36613/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wheeze is a continuous musical sound that lasts longer than 250 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/1\">",
"     1",
"    </a>",
"    ]. It is produced by oscillation of opposing walls of an airway that is narrowed almost to the point of closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/2\">",
"     2",
"    </a>",
"    ]. It can be high or low pitched, consist of single or multiple notes, occur during inspiration or expiration, and originate from airways of any size, from the large extrathoracic upper airway to the intrathoracic small airways. Stridor refers to inspiratory wheezing that is loudest over the central airways.",
"   </p>",
"   <p>",
"    An overview of wheezing illnesses is presented here. The diagnosis of asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19653?source=see_link\">",
"     \"Epidemiology of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different conditions, which involve a variety of anatomic airway locations, can produce obstruction and expiratory or inspiratory wheezing (",
"    <a class=\"graphic graphic_table graphicRef67704 \" href=\"mobipreview.htm?10/36/10829\">",
"     table 1",
"    </a>",
"    ). Asthma is not the most common cause of wheezing. One study prospectively evaluated the acoustic spectrum and frequency of the causes of wheeze and noted that 65 percent of patients did not have evidence of airway hyperresponsiveness, based on the results of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge testing and response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postnasal drip syndrome was the most common cause of wheeze in patients referred to a pulmonary outpatient clinic (",
"    <a class=\"graphic graphic_figure graphicRef73019 \" href=\"mobipreview.htm?8/1/8221\">",
"     figure 1",
"    </a>",
"    ). The expiratory wheeze associated with the postnasal drip syndrome originates from the extrathoracic airway, most likely at the level of the vocal cords [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In evaluating patients with wheezing, it is important to be aware that \"All that wheezes is not asthma; all that wheezes is obstruction.\" Furthermore, there is no characteristic of the wheeze of asthma that reliably distinguishes it from other conditions. In comparison, the presence of the classic triad of wheeze, cough, and chronic dyspnea is highly suggestive of asthma; however, patients often present with only one element of the triad, and asthma is not the most common cause of any one of these symptoms. In prospective studies, for example, the percentages of patients presenting with persistent wheeze, chronic cough, and chronic dyspnea who were eventually given the diagnosis of asthma were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent wheeze &mdash; 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic cough &mdash; 24 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic dyspnea &mdash; 29 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic accuracy increased when more than one symptom was present. In patients presenting with chronic dyspnea, for example, a history of wheezing had positive and negative predictive values of 42 and 83 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful history may elicit signs and symptoms that distinguish the various conditions that can cause wheezing (",
"    <a class=\"graphic graphic_table graphicRef51034 graphicRef64862 \" href=\"mobipreview.htm?17/7/17534\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma should be considered likely when patients present with episodic wheezing and other symptoms that respond favorably to conventional asthma medications (eg, inhaled bronchodilators). These patients have reversible expiratory airflow obstruction demonstrated by spirometry. However, improvement after bronchodilators is not always indicative of asthma. A reversible restrictive lung disease has rarely been described that is clinically indistinguishable from asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The diagnosis of wheezing conditions other than asthma (such as cardiac asthma and vocal cord dysfunction) should be considered when the initial evaluation suggests their presence or when wheezing does not respond to conventional asthma medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Historical findings suggestive of nonasthma wheezing include a history of postnasal drip, sore throat, dyspnea on exertion, gastroesophageal reflux, flushing, foreign body aspiration, or hemoptysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of acute decompensated heart failure\", section on 'Clinical signs and symptoms'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical characteristics of the wheeze may provide some helpful information, although these findings are neither highly sensitive nor specific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Timbre",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timbre of the wheeze may provide a clue to its location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A polyphonic wheeze, consisting of multiple musical notes, is typically produced by dynamic compression of the large, more central airways.",
"     </li>",
"     <li>",
"      Monophonic wheezes, consisting of single musical notes, typically reflect disease in small airways and are suggestive of asthma, especially if multiple wheezes are heard. However, monophonic wheezes can also be produced by disorders involving the extrathoracic large airways.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Expiratory wheezing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expiratory wheezing, appreciated either by history or physical examination, is neither sensitive nor specific for asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ]. As an example, symptomatic asthma can present without wheeze, while wheezing associated with other conditions can mimic asthma. A prospective study evaluated patients referred to a pulmonary clinic because of wheezing: a history of wheeze was predictive of asthma 35 percent of the time; and the physical finding of expiratory monophonic wheezing was predictive 43 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inspiratory wheezing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspiratory wheezing on physical examination is neither a sensitive nor a specific sign of extrathoracic upper airway disease or obstruction. Inspiratory wheezing frequently accompanies expiratory wheezing during acute asthma; in some cases of asthma, however, wheezing may",
"    <strong>",
"     only",
"    </strong>",
"    be heard during inspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with upper airway obstruction &lt;8 mm in diameter develop dyspnea on exertion; when the diameter is &lt;5 mm, stridor is evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Thus, when a patient presents with stridor, urgent airway evaluation is indicated, and should be performed by clinicians with substantial experience in airway management. Inhalation of helium-oxygen mixtures may be a useful temporizing measure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to evaluating wheeze is to localize the site of the obstruction to large or small intrathoracic airways, or to the extrathoracic airway. This is done using the history, physical examination, lung function studies, chest imaging, and knowledge of the spectrum of differential diagnostic possibilities, especially those that have been shown to be the most common (",
"    <a class=\"graphic graphic_table graphicRef67704 \" href=\"mobipreview.htm?10/36/10829\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73019 \" href=\"mobipreview.htm?8/1/8221\">",
"     figure 1",
"    </a>",
"    ). Pulmonary function testing can be quite helpful in confirming a diagnosis once the diagnostic possibilities have been narrowed by history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction in the three anatomic areas of the airway can be physiologically differentiated, because each area has different physiologic characteristics. The three areas include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extrathoracic upper airway, which includes the nose, mouth, pharynx, larynx, and extrathoracic trachea.",
"     </li>",
"     <li>",
"      The intrathoracic upper airway, which includes the intrathoracic trachea to airways at least 2mm in diameter.",
"     </li>",
"     <li>",
"      The intrathoracic small airways, which include airways less than 2 mm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From a physiological standpoint, the distinguishing characteristics of these three anatomic areas are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extrathoracic and intrathoracic portions of the upper airway undergo different and opposite transmural pressure changes during the respiratory cycle (",
"      <a class=\"graphic graphic_figure graphicRef65386 graphicRef55931 \" href=\"mobipreview.htm?42/59/43967\">",
"       figure 2A-B",
"      </a>",
"      ). Because of these changes, flow-volume loops can be diagnostically useful in pinpointing the level of the airway at which the obstruction is located. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=see_link\">",
"       \"Flow-volume loops\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Air flow is predominantly turbulent through large airways and mostly laminar through small airways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=see_link&amp;anchor=H2#H2\">",
"       \"Physiology and clinical use of heliox\", section on 'Physiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstruction above the level of the carina (ie, upper airway obstruction) impedes all the air in a uniform manner, while obstruction in small airways is typically in multiple, scattered sites, thus impeding airflow in a non-uniform manner (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"mobipreview.htm?40/55/41853\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spirometry and flow-volume loops during helium and air breathing can be used to localize airway obstruction, because they are influenced by these phenomena. In addition, spirometry repeated after treatment with a bronchodilator or systemic corticosteroids may demonstrate the presence of a substantial component of reversible airways disease consistent with asthma. On the other hand, bronchoprovocation challenge testing may be helpful in patients with normal or nearly normal baseline spirometry, showing clinically significant bronchial hyperresponsiveness consistent with asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper airway obstructing lesions are best identified by flow-volume loops. Airflow is likely to remain constant during the middle portion of a maximum respiratory effort when there is only one site of obstruction, as usually occurs in the trachea (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"mobipreview.htm?40/55/41853\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An upper airway obstruction cannot be localized physiologically to an extrathoracic or intrathoracic location if it is fixed, because fixed lesions do not allow the airway to respond to normal transmural pressure changes (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"mobipreview.htm?40/55/41853\">",
"       figure 3",
"      </a>",
"      ). Nevertheless, the flow-volume loop will have a characteristic box shape that suggests the obstruction is in large rather than small airways. Airflow is uniformly impeded during inspiration and expiration, causing flattening of the maximum inspiratory and expiratory curves because there is no difference between the amount of narrowing in inspiration and expiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/20\">",
"       20",
"      </a>",
"      ]. Because expiratory as well as inspiratory flow rates are decreased in a fixed upper airway obstruction, spirometry will reflect the expiratory flow limitation.",
"     </li>",
"     <li>",
"      It is possible to distinguish extrathoracic and intrathoracic upper airway lesions if the obstruction is variable (ie, if it allows the airway to respond to the normal transmural pressure changes). A variable extrathoracic obstruction is typically apparent only during maximal inspiratory effort (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"mobipreview.htm?40/55/41853\">",
"       figure 3",
"      </a>",
"      ). The maximal expiratory flow-volume curve and spirometry are usually normal in this setting, because the extrathoracic airway will dilate during expiration. In contrast, a variable intrathoracic obstruction is apparent only during maximal expiratory effort (",
"      <a class=\"graphic graphic_figure graphicRef63544 \" href=\"mobipreview.htm?40/55/41853\">",
"       figure 3",
"      </a>",
"      ), and spirometry reveals values consistent with expiratory airflow obstruction. Spirometry alone cannot distinguish large from small intrathoracic airway diseases, because FEV1, peak expiratory flow rate, and",
"      <span class=\"nowrap\">",
"       FEV1/FVC",
"      </span>",
"      are reduced in both situations.",
"      <br/>",
"      <br/>",
"      The ratio of inspiratory to expiratory flow rates may distinguish variable extrathoracic from intrathoracic upper airway lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/21\">",
"       21",
"      </a>",
"      ]. Inspiratory flow rates are normally greater than expiratory flow rates when compared at lung volumes in the lower two-thirds of the vital capacity. Inspiratory flow rates are lower than expiratory (eg, FIF50",
"      <span class=\"nowrap\">",
"       percent/FEF50",
"      </span>",
"      percent is less than 1) when a variable extrathoracic lesion is present.",
"     </li>",
"     <li>",
"      It may also be possible to detect coexisting large and small airway intrathoracic obstructions by comparing maximal expiratory flow-volume curves while patients first breathe room air and then a 20 percent oxygen-80 percent helium mixture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/19\">",
"       19",
"      </a>",
"      ]. Expiratory flow will substantially increase with the helium mixture when an obstruction occurs in large airways, because the flow that occurs in this region improves when patients inhale the less dense helium mixture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36613/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protocol for evaluation of wheeze places great emphasis on findings during history and physical examination and pulmonary function testing. The following stepwise approach is recommended unless the patient appears to be in imminent danger of respiratory failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential causes should be identified by distinguishing characteristics in the history and physical examination.",
"     </li>",
"     <li>",
"      In the absence of distinguishing characteristics, the presence of the common causes of wheezing should be considered and evaluated.",
"     </li>",
"     <li>",
"      Pharmacologic bronchodilator therapy should be given in the absence of any differentiating features.",
"     </li>",
"     <li>",
"      Less common causes should be evaluated in a physiologically-oriented manner when common causes do not explain the symptoms and the symptoms do not respond to asthma therapy.",
"     </li>",
"     <li>",
"      Stridor is an ominous clinical finding, suggestive of impending airway obstruction, and requires urgent evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/1\">",
"      Loudon R, Murphy RL Jr. Lung sounds. Am Rev Respir Dis 1984; 130:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/2\">",
"      Forgacs P. The functional basis of pulmonary sounds. Chest 1978; 73:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/3\">",
"      Pratter MR, Hingston DM, Irwin RS. Diagnosis of bronchial asthma by clinical evaluation. An unreliable method. Chest 1983; 84:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/4\">",
"      Irwin RS, Pratter MR, Holland PS, et al. Postnasal drip causes cough and is associated with reversible upper airway obstruction. Chest 1984; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/5\">",
"      Curley FJ, Irwin RS, Pratter MR, et al. Cough and the common cold. Am Rev Respir Dis 1988; 138:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/6\">",
"      Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/7\">",
"      Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med 1989; 149:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/8\">",
"      Kaminsky DA, Irvin CG. Anatomic correlates of reversible restrictive lung disease. Chest 1993; 103:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/9\">",
"      Hudgel DW, Cooper D, Souhrada J. Reversible restrictive lung disease stimulating asthma. Ann Intern Med 1976; 85:328.",
"     </a>",
"    </li>",
"    <li>",
"     Smyrnios, NA, Irwin, RS. Wheeze and cough in the elderly. In: Pulmonary Disease in the Elderly Patient, Mahler, DA (Ed), Marcel Dekker, New York 1993. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/11\">",
"      Jorge S, Becquemin MH, Delerme S, et al. Cardiac asthma in elderly patients: incidence, clinical presentation and outcome. BMC Cardiovasc Disord 2007; 7:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/12\">",
"      Newman KB, Mason UG 3rd, Schmaling KB. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med 1995; 152:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/13\">",
"      Shim CS, Williams MH Jr. Relationship of wheezing to the severity of obstruction in asthma. Arch Intern Med 1983; 143:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/14\">",
"      Marini JJ, Pierson DJ, Hudson LD, Lakshminarayan S. The significance of wheezing in chronic airflow obstruction. Am Rev Respir Dis 1979; 120:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/15\">",
"      King DK, Thompson BT, Johnson DC. Wheezing on maximal forced exhalation in the diagnosis of atypical asthma. Lack of sensitivity and specificity. Ann Intern Med 1989; 110:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/16\">",
"      Al-Bazzaz F, Grillo H, Kazemi H. Response to exercise in upper airway obstruction. Am Rev Respir Dis 1975; 111:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/17\">",
"      Geffin B, Grillo HC, Cooper JD, Pontoppidan H. Stenosis following tracheostomy for respiratory care. JAMA 1971; 216:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/18\">",
"      Macklem PT. Airway obstruction and collateral ventilation. Physiol Rev 1971; 51:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/19\">",
"      Gelb AF, Klein E. The volume of isoflow and increase in maximal flow at 50 percent of forced vital capacity during helium-oxygen breathing as tests of small airway dysfunction. Chest 1977; 71:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/20\">",
"      Castells MC, Horan RF, Sheffer AL. Exercise-induced Anaphylaxis. Curr Allergy Asthma Rep 2003; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/21\">",
"      Miller RD, Hyatt RE. Obstructing lesions of the larynx and trachea: clinical and physiologic characteristics. Mayo Clin Proc 1969; 44:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36613/abstract/22\">",
"      Kryger M, Bode F, Antic R, Anthonisen N. Diagnosis of obstruction of the upper and central airways. Am J Med 1976; 61:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 563 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36613=[""].join("\n");
var outline_f35_48_36613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Timbre",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Expiratory wheezing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inspiratory wheezing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/563|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/1/8221\" title=\"figure 1\">",
"      Wheezing frequency and causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/3/17470\" title=\"figure 2A\">",
"      Effect of dynamic extrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/54/15214\" title=\"figure 2B\">",
"      Effects of dynamic intrathoracic airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/55/41853\" title=\"figure 3\">",
"      Flow volume loop airway lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/36/10829\" title=\"table 1\">",
"      Major causes of wheeze",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/56/25484\" title=\"table 2A\">",
"      History in wheeze I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/3/26685\" title=\"table 2B\">",
"      History in wheeze II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19653?source=related_link\">",
"      Epidemiology of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36614="Tuberculous peritonitis";
var content_f35_48_36614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberculous peritonitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Valerie Byrnes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36614/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal tuberculosis is an uncommon site of extrapulmonary infection caused by Mycobacterium tuberculosis (TB). The risk is increased in patients with cirrhosis, HIV infection, diabetes mellitus, underlying malignancy, following treatment with anti-tumor necrosis factor (TNF) agents, and in patients undergoing continuous ambulatory peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection occurs most commonly following reactivation of latent tuberculous foci in the peritoneum that were established from hematogenous spread from a primary lung focus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/1\">",
"     1",
"    </a>",
"    ]. It can also occur via hematogenous spread from active pulmonary or miliary TB. Much less frequently, the organisms enter the peritoneal cavity transmurally from an infected small intestine or contiguously from tuberculous salpingitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the disease progresses, the visceral and parietal peritoneum become increasingly studded with tubercles. Ascites develops secondary to \"exudation\" of proteinaceous fluid from the tubercles, similar to the mechanism leading to ascites in patients with peritoneal carcinomatosis. More than 90 percent of patients with TB peritonitis have ascites at the time of presentation, while the remainder present with a more advanced \"dry\" phase, representing a fibroadhesive form of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of patients have symptoms for more than four months before the diagnosis is established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This is due in part to the insidious onset of the disease and because the diagnosis is frequently unsuspected. In patients with renal failure, symptoms and signs typically develop within the first year of beginning continuous ambulatory peritoneal dialysis (CAPD) and are usually indistinguishable from bacterial peritonitis. TB peritonitis should be added to the differential diagnosis of any patient presenting with several weeks of abdominal pain, fever, and weight loss.",
"   </p>",
"   <p>",
"    One of the largest contemporary series included 60 patients who were identified during a 12-year period at a center in Hong Kong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean age at presentation was 55 with an approximately equal gender distribution. Risk factors (in descending order of frequency) included cirrhosis, CAPD, diabetes mellitus, underlying malignancy, use of systemic corticosteroids, and AIDS. However, 20 percent of patients had no risk factor.",
"   </p>",
"   <p>",
"    The most common features were ascites (93 percent), abdominal pain (73 percent), and fever (58 percent). Abdominal pain and ascites were also the most common presenting features in several other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Findings on physical examination were nonspecific in most reports. Many patients had a diffusely distended tender abdomen. The classic doughy abdomen is associated with the fibroadhesive form of tuberculous peritonitis and is rarely seen. The salient clinical findings reported in decreasing order of frequency were abdominal tenderness, hepatomegaly, and ascites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory studies showed a mild to moderate normochromic normocytic anemia in most patients (mean hemoglobin concentration 9.9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"     5",
"    </a>",
"    ]. Evidence of old tuberculosis was visible on chest x-ray in only 33 percent. Chronic hypercalcemia was described in the case report of a patient on CAPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tuberculosis can affect the upper female reproductive tract (fallopian tube, endometrium, ovaries) by extension from an intraabdominal focus, hematogenous seeding, or ascending from lower genital tract (cervix, vagina, vulva) infection. The fallopian tube and endometrium are most commonly involved. The finding of endometrial tuberculosis always means that the tubes are infected but tuberculous salpingitis can exist without associated endometritis. A variety of clinical manifestations have been reported including a pelvic mass, infertility, abnormal uterine bleeding, and pelvic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. In most cases, the diagnosis is made most readily by endometrial biopsy for histology and culture.",
"   </p>",
"   <p>",
"    Genital tuberculosis is an important cause of infertility in developing countries; in a report from India, it accounted for 7.5 percent of 492 patients who underwent a hysterosalpingogram for evaluation of infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/19\">",
"     19",
"    </a>",
"    ]. Unfortunately, the rate of successful conception after chemotherapy for the infection is relatively poor (19 percent in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=see_link\">",
"     \"Endometritis unrelated to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculous peritonitis should be considered in all patients presenting with unexplained lymphocytic ascites with a serum-ascites albumin gradient of &lt;1.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/24\">",
"     24",
"    </a>",
"    ]. The diagnosis can be difficult since the onset can be insidious, it can have a variable presentation, and since it can frequently be seen in patients with underlying liver or renal disease.",
"   </p>",
"   <p>",
"    The gold-standard for diagnosis is culture growth of Mycobacterium on ascitic fluid or a peritoneal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/24\">",
"     24",
"    </a>",
"    ]. The diagnosis usually requires a peritoneal biopsy performed under direct visualization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5,7,25-27\">",
"     5,7,25-27",
"    </a>",
"    ]. Blind peritoneal biopsies have a low success rate and have been associated with complications including death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In the United States, directed peritoneal biopsy via laparoscopy or mini laparotomy has surpassed blind percutaneous peritoneal biopsy. Laparoscopy appears to be relatively safe. The reported complication rate was 2.7 percent in four series comprising 110 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/26\">",
"     26",
"    </a>",
"    ]. These included bowel perforation, intraperitoneal bleed, and subcutaneous hematoma. Peritoneal biopsy via mini-laparotomy may be preferred by some surgeons and should be considered if laparoscopy is non-diagnostic.",
"   </p>",
"   <p>",
"    Visual diagnosis during laparoscopy or mini-laparotomy can be diagnostic in up to 95 percent of cases. Typically, the visceral and parietal peritoneum is studded with multiple whitish nodules or tubercles. Other findings include enlarged lymph nodes, \"Violin-string\" fibrinous strands, and omental thickening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/8,30\">",
"     8,30",
"    </a>",
"    ]. Targeted biopsies reveal caseating granulomas in up to 100 percent of patients and are positive for acid fast bacilli in 74 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/7,31\">",
"     7,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Routine laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory studies are nonspecific. A normal leukocyte count is present in most patients. A mild normocytic, normochromic anemia is present in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5,26\">",
"     5,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several reports describing increased serum CA-125 concentrations in patients with tuberculous peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a series of 10 patients, for example, the mean CA-125 level was 475",
"    <span class=\"nowrap\">",
"     unit/mL,",
"    </span>",
"    decreasing to normal levels (&lt;35",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/33\">",
"     33",
"    </a>",
"    ]. In some cases, the elevated levels combined with the clinical and radiologic picture can mimic ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/35\">",
"     35",
"    </a>",
"    ]. However, serum CA-125 can be increased in ascites due to any cause and is therefore more likely to cause confusion than to assist in diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, we do not measure serum CA-125 in the evaluation of patients with ascites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tuberculin skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculin testing with purified protein derivative (PPD) is positive in approximately 70 percent of patients, however a negative result is of no help in excluding the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with a known previous skin reaction to TB may be anergic at the time of PPD reading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray may show evidence of old tuberculosis in 20 to 30 percent of patients while features of active tuberculosis are much less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"     5",
"    </a>",
"    ]. Other radiologic features such as peritoneal thickening, omental caking, and the presence of ascites with fine mobile septations on ultrasound and CT imaging may suggest the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. One review suggested that the most common CT findings were the combination of ascites, peritoneal lesions and lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/39\">",
"     39",
"    </a>",
"    ]. There are isolated reports of intense FDG-activity on PET scanning in peritoneal TB mimicking peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peritoneal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the peritoneal fluid can be helpful in raising suspicion for the diagnosis. The majority of patients have an ascitic leukocyte count of 150 to 4000 mm3, with a relative lymphocytic pleocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. Interestingly, CAPD patients with tuberculous peritonitis may have a neutrophilic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The protein content of the ascitic fluid is usually &gt;3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/7,44\">",
"     7,44",
"    </a>",
"    ]. In patients without underlying cirrhosis, the serum-ascites albumin gradient (SAAG) is &lt;1.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/45\">",
"     45",
"    </a>",
"    ]. However, up to one-half of patients have underlying cirrhosis and therefore have a SAAG &ge;1.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of an acid fast stained smear of ascitic fluid has a disappointingly low yield. Direct smear for Ziehl-Neelson stain has a reported sensitivity of 0 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/31\">",
"     31",
"    </a>",
"    ]. In most series, the frequency of a positive ascites culture is disappointingly less than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/26\">",
"     26",
"    </a>",
"    ]. The utility of cultures is even more questionable when considering the delay of four to six weeks before a result is obtained. The delay can be associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"     5",
"    </a>",
"    ]. A review of 60 patients with tuberculous peritonitis reported a mortality rate of 53 percent (n = 31); 84 percent (n = 26) of patients died within six weeks of presentation, often before the result of mycobacterial culture was available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"     5",
"    </a>",
"    ]. One study suggested that the yield of culture may be increased to 83 percent if 1 liter of ascitic fluid, concentrated by centrifugation, is cultured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/47\">",
"     47",
"    </a>",
"    ], but this has not yet been confirmed and is not practical since such large culture volumes are not performed routinely by most clinical laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) assays, which amplify mycobacterial 16S ribosomal RNA, show promise of rapid detection of mycobacteria. However, the utility of ascitic fluid PCR assays in detecting TB peritonitis has not been well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. One review of 11 cases of abdominal tuberculosis revealed a positive PCR for M. Tuberculosis of the ascitic fluid in all cases, suggesting a role for PCR analysis prior to surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adenosine deaminase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine deaminase is a purine-degrading enzyme that is necessary for the maturation and differentiation of lymphoid cells. Adenosine deaminase activity (ADA) of ascitic fluid has been proposed as a useful non-culture method of detecting tuberculous peritonitis. A meta-analysis of 12 prospective studies encompassing 264 patients found that ADA levels had high sensitivity (100 percent) and specificity (97 percent) using cut-off values from 36 to 40 int.",
"    <span class=\"nowrap\">",
"     unit/L;",
"    </span>",
"    the optimal cut-off value was 39 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the sensitivity is substantially lower in patients with cirrhosis (approximately 30 percent) due to the characteristically poor humoral and T cell mediated response of cirrhotic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/46\">",
"     46",
"    </a>",
"    ]. As a result, ADA measurement has its greatest utility in settings where TB peritonitis is suspected in non-cirrhotic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     T-cell based testing for mycobacterium tuberculosis (ELISPOT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An FDA approved enzyme-linked immunospot assay (ELISPOT), measuring gamma producing T-cell responses to early secreted antigenic targets of mycobacterium tuberculosis, has shown promising results. A single study of 72 patients reported the sensitivity and specificity of ELISPOT in the diagnosis of extrapulmonary TB as 94 and 88 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/51\">",
"     51",
"    </a>",
"    ]. Another study demonstrated a positive ELISPOT test on ascitic fluid in six of six patients with confirmed abdominopelvic TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/52\">",
"     52",
"    </a>",
"    ]. The ELISPOT assay on peripheral blood or ascitic fluid may prove to be a useful adjunct in the diagnosis of active TB but is not available in many institutions within the United States and additional data are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of treatment regimens for tuberculous peritonitis is based upon the same principles as the selection for pulmonary tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of corticosteroids for the first two to three months of treatment may reduce the incidence of late complications arising from adhesive disease, such as small bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/12,47,53\">",
"     12,47,53",
"    </a>",
"    ]. However, most clinicians avoid using adjunctive steroid therapy since its efficacy has not been well established, and because of the risk of tuberculous dissemination in the setting of multi-drug resistance.",
"   </p>",
"   <p>",
"    Fever usually resolves within one week of commencing anti-tuberculous treatment. More than 90 percent of patients have improvement in abdominal ascites within weeks of initiating treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality ranged from 8 to 50 percent in various series. Advanced age, delay in initiating therapy, and underlying cirrhosis have been associated with higher mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36614/abstract/4,5,14,54\">",
"     4,5,14,54",
"    </a>",
"    ]. As mentioned above, some patients develop complications (such as small bowel obstruction) related to adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7875348\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal tuberculosis is an uncommon site of extrapulmonary infection caused by Mycobacterium tuberculosis. The risk is increased in patients with cirrhosis, HIV infection, diabetes mellitus, underlying malignancy, following treatment with anti-tumor necrosis factor agents, and in patients undergoing continuous ambulatory peritoneal dialysis.",
"     </li>",
"     <li>",
"      Infection occurs most commonly following reactivation of latent tuberculous foci in the peritoneum that were established from hematogenous spread from a primary lung focus.",
"     </li>",
"     <li>",
"      The most common clinical features are ascites, abdominal pain, and fever. Approximately 70 percent of patients have symptoms for more than four months before the diagnosis is established. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculous peritonitis should be considered in all patients presenting with unexplained lymphocytic ascites with a serum-ascites albumin gradient of &lt;1.1",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The diagnosis can be difficult since the onset can be insidious, it can have a variable presentation, and it is frequently seen in patients with underlying liver or renal disease. Up to one-half of patients can have underlying cirrhosis, usually due to alcohol. The gold-standard for diagnosis is culture growth of Mycobacterium on ascitic fluid or a peritoneal biopsy. The diagnosis usually requires a peritoneal biopsy performed under direct visualization. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selection of treatment regimens for tuberculous peritonitis is based upon the same principles as the selection for pulmonary tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prognosis is variable depending upon the underlying condition, comorbidities, and rapidity of diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/1\">",
"      Mehta JB, Dutt A, Harvill L, Mathews KM. Epidemiology of extrapulmonary tuberculosis. A comparative analysis with pre-AIDS era. Chest 1991; 99:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/2\">",
"      Braun MM, Byers RH, Heyward WL, et al. Acquired immunodeficiency syndrome and extrapulmonary tuberculosis in the United States. Arch Intern Med 1990; 150:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/3\">",
"      Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/4\">",
"      Aguado JM, Pons F, Casafont F, et al. Tuberculous peritonitis: a study comparing cirrhotic and noncirrhotic patients. J Clin Gastroenterol 1990; 12:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/5\">",
"      Chow KM, Chow VC, Hung LC, et al. Tuberculous peritonitis-associated mortality is high among patients waiting for the results of mycobacterial cultures of ascitic fluid samples. Clin Infect Dis 2002; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/6\">",
"      Tang LC, Cho HK, Wong Taam VC. Atypical presentation of female genital tract tuberculosis. Eur J Obstet Gynecol Reprod Biol 1984; 17:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/7\">",
"      Manohar A, Simjee AE, Haffejee AA, Pettengell KE. Symptoms and investigative findings in 145 patients with tuberculous peritonitis diagnosed by peritoneoscopy and biopsy over a five year period. Gut 1990; 31:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/8\">",
"      Bhargava DK, Chopra P, Nijhawan S, et al. Peritoneal tuberculosis: laparoscopic patterns and its diagnostic accuracy. Am J Gastroenterol 1992; 87:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/9\">",
"      Lisehora GB, Peters CC, Lee YT, Barcia PJ. Tuberculous peritonitis--do not miss it. Dis Colon Rectum 1996; 39:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/10\">",
"      Gitt S, Haddad F, Levenson S. Tuberculous peritonitis: an overlooked diagnosis. Hosp Pract (Off Ed) 1992; 27:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/11\">",
"      Jakubowski A, Elwood RK, Enarson DA. Clinical features of abdominal tuberculosis. J Infect Dis 1988; 158:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/12\">",
"      Demir K, Okten A, Kaymakoglu S, et al. Tuberculous peritonitis--reports of 26 cases, detailing diagnostic and therapeutic problems. Eur J Gastroenterol Hepatol 2001; 13:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/13\">",
"      Tanrikulu AC, Aldemir M, Gurkan F, et al. Clinical review of tuberculous peritonitis in 39 patients in Diyarbakir, Turkey. J Gastroenterol Hepatol 2005; 20:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/14\">",
"      al-Quorain AA, Satti MB, al-Freihi HM, et al. Abdominal tuberculosis in Saudi Arabia: a clinicopathological study of 65 cases. Am J Gastroenterol 1993; 88:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/15\">",
"      Lee CT, Hung KH, Lee CH, et al. Chronic hypercalcemia as the presenting feature of tuberculous peritonitis in a hemodialysis patient. Am J Nephrol 2002; 22:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/16\">",
"      Ilhan AH, Durmu��o��lu F. Case report of a pelvic-peritoneal tuberculosis presenting as an adnexial mass and mimicking ovarian cancer, and a review of the literature. Infect Dis Obstet Gynecol 2004; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/17\">",
"      Aliyu MH, Aliyu SH, Salihu HM. Female genital tuberculosis: a global review. Int J Fertil Womens Med 2004; 49:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/18\">",
"      Namavar Jahromi B, Parsanezhad ME, Ghane-Shirazi R. Female genital tuberculosis and infertility. Int J Gynaecol Obstet 2001; 75:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/19\">",
"      Chavhan GB, Hira P, Rathod K, et al. Female genital tuberculosis: hysterosalpingographic appearances. Br J Radiol 2004; 77:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/20\">",
"      Parikh FR, Nadkarni SG, Kamat SA, et al. Genital tuberculosis--a major pelvic factor causing infertility in Indian women. Fertil Steril 1997; 67:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/21\">",
"      Liomba NG, Chipangwi JD. Female Genital Tuberculosis in Malawi--a report of 90 cases. J Obstet Gynaecol East Cent Africa 1982; 1:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/22\">",
"      Sutherland AM. Gynaecological tuberculosis since 1951. J Obstet Gynaecol 1997; 17:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/23\">",
"      Tripathy SN, Tripathy SN. Infertility and pregnancy outcome in female genital tuberculosis. Int J Gynaecol Obstet 2002; 76:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/24\">",
"      Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis--presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther 2005; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/25\">",
"      Inadomi JM, Kapur S, Kinkhabwala M, Cello JP. The laparoscopic evaluation of ascites. Gastrointest Endosc Clin N Am 2001; 11:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/26\">",
"      Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/27\">",
"      Chahed J, Mekki M, Mansour A, et al. Contribution of laparoscopy in the abdominal tuberculosis diagnosis: retrospective study of about 11 cases. Pediatr Surg Int 2010; 26:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/28\">",
"      Shukla HS, Bhatia S, Naitrani YP, et al. Peritoneal biopsy for diagnosis of abdominal tuberculosis. Postgrad Med J 1982; 58:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/29\">",
"      Bastani B, Shariatzadeh MR, Dehdashti F. Tuberculous peritonitis--report of 30 cases and review of the literature. Q J Med 1985; 56:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/30\">",
"      Uzunkoy A, Harma M, Harma M. Diagnosis of abdominal tuberculosis: experience from 11 cases and review of the literature. World J Gastroenterol 2004; 10:3647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/31\">",
"      Chow KM, Chow VC, Szeto CC. Indication for peritoneal biopsy in tuberculous peritonitis. Am J Surg 2003; 185:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/32\">",
"      Candocia SA, Locker GY. Elevated serum CA 125 secondary to tuberculous peritonitis. Cancer 1993; 72:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/33\">",
"      Mas MR, C&ouml;mert B, Sa��lamkaya U, et al. CA-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver Dis 2000; 32:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/34\">",
"      Younossian AB, Rochat T, Favre L, Janssens JP. Ascites and highly elevated CA-125 levels in a case of peritoneal tuberculosis. Scand J Infect Dis 2006; 38:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/35\">",
"      Koc S, Beydilli G, Tulunay G, et al. Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases. Gynecol Oncol 2006; 103:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/36\">",
"      Runyon BA. Malignancy-related ascites and ascitic fluid \"humoral tests of malignancy\". J Clin Gastroenterol 1994; 18:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/37\">",
"      Demirkazik FB, Akhan O, Ozmen MN, Akata D. US and CT findings in the diagnosis of tuberculous peritonitis. Acta Radiol 1996; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/38\">",
"      Akhan O, Pringot J. Imaging of abdominal tuberculosis. Eur Radiol 2002; 12:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/39\">",
"      V&aacute;zquez Mu&ntilde;oz E, G&oacute;mez-Cerezo J, Atienza Saura M, V&aacute;zquez Rodriguez JJ. Computed tomography findings of peritoneal tuberculosis: systematic review of seven patients diagnosed in 6 years (1996-2001). Clin Imaging 2004; 28:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/40\">",
"      Takalkar AM, Bruno GL, Reddy M, Lilien DL. Intense FDG activity in peritoneal tuberculosis mimics peritoneal carcinomatosis. Clin Nucl Med 2007; 32:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/41\">",
"      Shimamoto H, Hamada K, Higuchi I, et al. Abdominal Tuberculosis: peritoneal involvement shown by F-18 FDG PET. Clin Nucl Med 2007; 32:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/42\">",
"      Quantrill SJ, Woodhead MA, Bell CE, et al. Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001; 16:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/43\">",
"      Gupta N, Prakash KC. Asymptomatic tuberculous peritonitis in a CAPD patient. Perit Dial Int 2001; 21:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/44\">",
"      Kim NJ, Choo EJ, Kwak YG, et al. Tuberculous peritonitis in cirrhotic patients: comparison of spontaneous bacterial peritonitis caused by Escherichia coli with tuberculous peritonitis. Scand J Infect Dis 2009; 41:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/45\">",
"      Poyrazoglu OK, Timurkaan M, Yalniz M, et al. Clinical review of 23 patients with tuberculous peritonitis: presenting features and diagnosis. J Dig Dis 2008; 9:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/46\">",
"      Hillebrand DJ, Runyon BA, Yasmineh WG, Rynders GP. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology 1996; 24:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/47\">",
"      Singh MM, Bhargava AN, Jain KP. Tuberculous peritonitis. An evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures. N Engl J Med 1969; 281:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/48\">",
"      Pfyffer GE, Kissling P, Jahn EM, et al. Diagnostic performance of amplified Mycobacterium tuberculosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J Clin Microbiol 1996; 34:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/49\">",
"      Lye WC. Rapid diagnosis of Mycobacterium tuberculous peritonitis in two continuous ambulatory peritoneal dialysis patients, using DNA amplification by polymerase chain reaction. Adv Perit Dial 2002; 18:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/50\">",
"      Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol 2006; 40:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/51\">",
"      Kim SH, Choi SJ, Kim HB, et al. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med 2007; 167:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/52\">",
"      Tinelli A, Malvasi A, Vergara D, et al. Abdominopelvic tuberculosis in gynaecology: laparoscopical and new laboratory findings. Aust N Z J Obstet Gynaecol 2008; 48:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/53\">",
"      Alrajhi AA, Halim MA, al-Hokail A, et al. Corticosteroid treatment of peritoneal tuberculosis. Clin Infect Dis 1998; 27:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36614/abstract/54\">",
"      Wang HK, Hsueh PR, Hung CC, et al. Tuberculous peritonitis: analysis of 35 cases. J Microbiol Immunol Infect 1998; 31:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1238 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36614=[""].join("\n");
var outline_f35_48_36614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7875348\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Routine laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tuberculin skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peritoneal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adenosine deaminase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      T-cell based testing for mycobacterium tuberculosis (ELISPOT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7875348\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36615="Reactions to bites from kissing bugs (Triatoma)";
var content_f35_48_36615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reactions to bites from kissing bugs (Triatoma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Jerome Goddard, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Richard D deShazo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36615/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatomine insects (colloquial names include kissing bug, Mexican bed bug, and cone-nosed bug) are found primarily in the western and southern United States (US), in Central and South America, and in Mexico (",
"    <a class=\"graphic graphic_picture graphicRef80447 \" href=\"mobipreview.htm?36/0/36879\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82769 \" href=\"mobipreview.htm?35/39/36464\">",
"     picture 2",
"    </a>",
"    ). These insects feed on blood and will bite various animals and people, although humans are not a primary host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triatoma bites are generally painless and asymptomatic. However, reactions can occur, ranging from local irritation at the site to allergic and anaphylactic reactions.",
"   </p>",
"   <p>",
"    Triatoma are also of medical interest because they are an insect vector for the protozoan Trypanosoma cruzi, which causes Chagas disease. Triatoma species found in the US infrequently transmit T. cruzi, whereas the infection is endemic in some parts of South America. They do not transmit other human disease agents.",
"   </p>",
"   <p>",
"    Local and allergic reactions to Triatoma bites are discussed in this topic review. Chagas disease and public health measures to control populations of kissing bugs in endemic areas are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19975?source=see_link\">",
"     \"Pathology and pathogenesis of Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23880?source=see_link\">",
"     \"Epidemiology and control of Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatoma bites are among the most common causes of insect-bite related allergy and anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2\">",
"     2",
"    </a>",
"    ]. Bite-induced anaphylaxis is less common than sting-related anaphylaxis, such as that induced by Hymenoptera species such as bees, wasps, and fire ants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons at risk for Triatoma bites are those living in poorly constructed houses in endemic areas, those sleeping with windows open at night, and people with homes situated in areas with an abundance of wild mammal hosts nearby, such as wood-rats, opossums, and armadillos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENTOMOLOGY OF TRIATOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kissing bugs belong to the insect family Reduviidae (sometimes called reduviid bugs), subfamily Triatominae, genus Triatoma (",
"    <a class=\"graphic graphic_figure graphicRef65111 \" href=\"mobipreview.htm?19/17/19742\">",
"     figure 1",
"    </a>",
"    ). Within the Triatominae subfamily, some (but not all) species are in the genus Triatoma. Thus, not all kissing bugs are Triatoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatoma are winged insects that are approximately 1.3 to 2.5 cm long with flattened, shield-shaped bodies (",
"    <a class=\"graphic graphic_picture graphicRef80447 \" href=\"mobipreview.htm?36/0/36879\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82769 \" href=\"mobipreview.htm?35/39/36464\">",
"     picture 2",
"    </a>",
"    ). The head is elongated and sometimes cone-shaped. They are various shades of brown or black, and some have prominent stripes of red, orange, or yellow color at the edges of the abdomen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Worldwide distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatoma are primarily distributed throughout the western and southern US, Central and South America, and in Mexico. Within the US, there are at least 10 Triatoma species, but only about six of these are common (",
"    <a class=\"graphic graphic_table graphicRef61997 \" href=\"mobipreview.htm?21/15/21756\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Most reports of allergic reactions to bites have originated in the Southwest and West [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Kissing bugs may rarely be found in the northern US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Habitat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatoma feed on blood from a variety of vertebrate hosts, such as opossums, other small and medium-sized mammals, birds, and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/7\">",
"     7",
"    </a>",
"    ]. They usually live with their animal hosts in rodent burrows, wood piles, or caves. As an example, T. protracta can frequently be found in wood-rat nests.",
"   </p>",
"   <p>",
"    Triatoma periodically fly away from their usual locations in nocturnal flights. During these flights, they may be attracted to porch lights on houses and, when daylight comes, they can crawl indoors through cracks around doors or windows in search of shelter from the sun and heat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/8\">",
"     8",
"    </a>",
"    ]. Once indoors, they may feed on pets and people.",
"   </p>",
"   <p>",
"    In the United States, human interactions with Triatoma are considered to be incidental encounters. Triatoma do not easily enter modern homes and, when they do, there is usually one or a small number of insects per home. However, large infestations can occur in homes in developing countries that have cracks and crevices, mud walls, and thatched roofs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,5,7,9\">",
"     2,5,7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biting behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kissing bugs are active primarily at night, and are rarely sighted during the day. In addition, feeding takes place almost exclusively at night. The name kissing bugs arose from the tendency of certain species to bite near the lips, but the bugs will bite any area of exposed skin. They will not bite through clothing or bed sheets.",
"   </p>",
"   <p>",
"    Bites are typically multiple, ranging from 2 to 15 in a cluster on one part of the body, most commonly the hands, arms, feet, head, and trunk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/10\">",
"     10",
"    </a>",
"    ]. A full blood meal may take more than 30 minutes to complete, but the insect may be interrupted during this process and reinsert its proboscis several times in one area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The life cycle includes an egg stage, five nymphal stages, and an adult stage. Maturation takes 5 to 12 months, depending on availability of blood meals and temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/5\">",
"     5",
"    </a>",
"    ]. All stages of nymphs and both sexes of adults require blood meals to survive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people who are bitten by Triatoma have no adverse reaction and are usually unaware that they were bitten [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the following reactions are possible:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bite or the debris left in the skin by the insect can cause local irritation (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Local reactions'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Allergenic salivary proteins can cause allergic reactions, including anaphylaxis (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Allergic reactions'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triatoma bites most commonly leave a small, non-erythematous puncture in the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,3,6,12\">",
"     2,3,6,12",
"    </a>",
"    ]. More extensive local reactions develop in some patients and may include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/3,6,10,13\">",
"     3,6,10,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Variable degrees of erythema and edema around the puncture sites (",
"      <a class=\"graphic graphic_picture graphicRef55766 \" href=\"mobipreview.htm?12/52/13123\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Papules or vesicles around the bite, which may be grouped",
"     </li>",
"     <li>",
"      Hemorrhagic bullous lesions, usually on the hands and feet",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local reactions usually persist for days to a week.",
"   </p>",
"   <p>",
"    Delayed local reactions to bites may include urticarial or cellulitic lesions surrounding the bite site, which are sometimes associated with tender, swollen lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the type of local reaction, the differential of Triatoma bite include herpes zoster, cutaneous infections, and other bites and stings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Herpes zoster &mdash; Local reactions that consist of grouped vesicles may be mistaken for herpes zoster, which presents as vesicles or vesicopustules with pain and surrounding edema and erythema. A dermatomal distribution can be an important distinguishing feature of herpes zoster. The clinical manifestations and culture and serologic methods for diagnosing herpes zoster are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"       \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=see_link\">",
"       \"Diagnosis of varicella-zoster virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections &mdash; Staphylococcal and streptococcal infections, especially skin infections due to community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), can begin with a single papule or pustule. Papules and pustules should be carefully unroofed and cultured if an infectious etiology is suspected. CA-MRSA occurs both sporadically and as institutional epidemics in nursing homes, prisons, military barracks, and athletic facilities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other bites and stings &mdash; A variety of insects may sting or bite humans, including ants, fleas, bed bugs, ticks, mites, mosquitoes, and biting flies (",
"      <a class=\"graphic graphic_table graphicRef69989 \" href=\"mobipreview.htm?33/10/33964\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/14\">",
"       14",
"      </a>",
"      ]. Some of these cause immediate pain, which does not occur with Triatoma bites. However, with the possible exception of some tick bites, identifying the insect inflicting the bite is of little clinical importance because local care is all that is required unless complications arise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of local reactions from kissing bug bites should be based upon symptoms. There are no studies evaluating efficacy. Topical or oral antihistamines and topical glucocorticoids may be helpful for itching and local irritation, respectively. Oral or parenteral antibiotics should be considered if the lesion appears to be superinfected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bites of Triatoma have been recognized as a cause of allergic reactions for more than a century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/15\">",
"     15",
"    </a>",
"    ]. Not all species have been reported to cause allergic reactions, but at least five are regularly implicated (",
"    <a class=\"graphic graphic_table graphicRef61997 \" href=\"mobipreview.htm?21/15/21756\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T. protracta (most often reported to cause allergic reactions in California) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      T. gerstaeckeri",
"     </li>",
"     <li>",
"      T. sanguisuga",
"     </li>",
"     <li>",
"      T. rubida (most often reported to cause allergic reactions in Arizona) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      T. rubrofasciata",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of allergic reactions and anaphylaxis to Triatoma bites may include itching, flushing, burning, urticaria, angioedema, wheezing, stridor, or hypotension. Gastrointestinal and abdominal symptoms may include nausea, vomiting, diarrhea, and abdominal cramping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,6,9,14,17\">",
"     2,6,9,14,17",
"    </a>",
"    ]. Vaginal bleeding was described in several cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,14\">",
"     2,14",
"    </a>",
"    ], and it is not clear if this is a unique feature of Triatoma reactions, or simply a reflection of uterine contractions, which can be seen with anaphylaxis of any cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Anaphylaxis identification and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death. It usually develops within a few minutes to two hours of exposure to the causative trigger. As a result, anaphylaxis from Triatoma bites characteristically awakens the patient from sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/14\">",
"     14",
"    </a>",
"    ]. This nocturnal presentation is rarely seen with other causes of anaphylaxis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis of anaphylaxis is clinical and based primarily upon symptoms and signs, as well as a detailed description of the acute episode, including antecedent activities and events. Clinical criteria for the diagnosis and immediate management of anaphylaxis from all causes are discussed separately. There is no \"antivenom\" or other specific antidote for Triatoma-induced anaphylactic reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients survive, but a fatal case of anaphylaxis from a Triatoma bite on the leg was reported in a 54 year-old woman with no significant past medical history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/18\">",
"     18",
"    </a>",
"    ]. She awakened from sleep with pruritus and shortness of breath and was comatose by the time she reached the emergency department 30 minutes later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Identification of the insect",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to locate and identify the insect is important for the diagnosis of Triatoma bite as the cause of anaphylaxis. Since most patients do not know that they have been bitten, the only other clues implicating Triatoma are identification of a bite on physical examination and, in patients in endemic areas for Triatoma, nocturnal anaphylaxis (which is otherwise uncommon).",
"   </p>",
"   <p>",
"    The patient (or a family",
"    <span class=\"nowrap\">",
"     member/caregiver)",
"    </span>",
"    should carefully search the location where the bite took place as soon as possible, and try to retrieve the bug for identification. The engorged insect may be found in bedding, between mattresses, or",
"    <span class=\"nowrap\">",
"     in/under",
"    </span>",
"    upholstered furniture. Successful location of the insect as a result of a thorough search was accomplished in &gt;95 percent of cases in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/6,10,15\">",
"     6,10,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to definitive identification, finding the insect is important in preventing further bites. Even low populations of Triatoma may lead to multiple biting events through time. However, blood-sucking insects usually require a period of digestion after feeding, so additional bites from the same insect are less likely to occur immediately. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Avoidance measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquitoes, bed bugs, and various biting flies have also been implicated in rare cases of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. Visual identification and knowledge of the insects that are endemic to the area are critical for distinguishing between bites of these different insects.",
"   </p>",
"   <p>",
"    Anaphylaxis occurring in the middle of the night has also been reported in adults with allergy to red meats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/26\">",
"     26",
"    </a>",
"    ]. The responsible allergen is a carbohydrate, and this may underlie the atypical timing of these reactions, which occur three to six hours after ingestion. In contrast, most food-induced anaphylactic reactions are caused by allergy to proteins and occur within minutes to two hours of ingestion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of anaphylaxis of uncertain etiology is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link&amp;anchor=H4433858#H4433858\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\", section on 'Testing for allergen trigger(s)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT OF TRIATOMA ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having Triatoma allergy should be equipped with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epinephrine for self-administration (preferably two or more autoinjectors)",
"     </li>",
"     <li>",
"      Educational material about Triatoma avoidance",
"     </li>",
"     <li>",
"      Referral to an allergist for evaluation, to ensure that other possible causes of anaphylaxis have been considered and excluded",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no commercially available skin testing solutions or laboratory tests for the diagnosis of Triatoma allergy, or extracts for use in immunotherapy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Diagnostic tests and immunotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Access to epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who has experienced anaphylaxis should have access to an epinephrine autoinjector in the future, as prompt administration of epinephrine is the most effective treatment for anaphylaxis. They should be advised to fill the prescription immediately. Patients should keep this medication at the bedside, as this is the most likely site of a repeat reaction. Several patient information topics concerning anaphylaxis and the proper use of epinephrine autoinjectors are available. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other interventions for patients with anaphylaxis include the completion of an anaphylaxis emergency action plan that can be carried with the patient and used to facilitate future treatment, and some form of medical identification jewelry. These measures are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H39#H39\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Discharge care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should also be advised to keep a supply of oral antihistamines (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) available for treatment of mild allergic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Avoidance measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical avoidance measures include sealing cracks and crevices in the house to eliminate entry points for the insects. Stacks of wood or other materials should not be located near the house. Outdoor lights that are directed onto the exterior of homes should be turned to shine away from the house, so that the insects drawn to them are less likely to contact the building. Outdoor plantings near homes should be kept neatly trimmed to prevent nesting of woodrats and other natural hosts for Triatoma.",
"   </p>",
"   <p>",
"    Bedrooms should be free of clutter on the floor, and bedding should not be allowed to touch the floor. Bed nets can be used, and long-sleeved and long-legged pajamas are suggested, since Triatoma rarely bite covered skin. Some recommend wearing insect repellent on the skin while sleeping in endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pesticide application",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic areas of the world, kissing bugs are controlled with pesticides for the purpose of reducing the incidence of Chagas disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23880?source=see_link\">",
"     \"Epidemiology and control of Chagas disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the US, the Environmental Protection Agency (EPA) has stringent laws concerning pesticide use. Although over-the-counter pesticides are available, control of kissing bugs is best performed by a licensed pest management professional using only EPA-registered products. We suggest consulting such a professional if Triatoma are present or suspected to be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnostic tests and immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no commercial products available for use in diagnostic skin testing and immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This is true despite the identification of the causative allergens in salivary gland extracts from Triatoma in the 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2,3,14,16,17,27\">",
"     2,3,14,16,17,27",
"    </a>",
"    ]. Procalin, a member of the lipocalin family of proteins that also includes salivary allergens of other invertebrates and vertebrates, is a major allergen, and has even been expressed recombinantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of immunotherapy with experimental Triatoma salivary gland extracts has been described in two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient allergic to T. protracta bites was treated with immunotherapy in 1982, which was considered partially successful because the reaction to a post-treatment challenge bite was milder than several reactions sustained prior to treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another five patients with histories of systemic allergic reactions to bites and positive skin tests and radioimmunoassays to salivary gland extracts were given immunotherapy with the same material used for diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/3\">",
"       3",
"      </a>",
"      ]. When challenged with a T. protracta bite between 28 and 32 weeks into treatment,",
"      <span class=\"nowrap\">",
"       4/5",
"      </span>",
"      patients had no reaction. The one remaining patient developed mild urticaria to a bite challenge at week 14 of immunotherapy, but had no reaction when challenged again after 33 weeks of treatment. Thus, these early attempts were encouraging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADVICE ABOUT CHAGAS DISEASE AFTER A TRIATOMA BITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the risk of contracting T. cruzi infection from kissing bug bites is low; only about a dozen cases of local transmission from Triatomine bite to human have been reported. Thus, patients who have sustained bites do not routinely require follow-up or evaluation for T. cruzi infection.",
"   </p>",
"   <p>",
"    Most patients infected with T. cruzi by Triatomine bites are asymptomatic during the acute stage of infection. In a minority of patients, acute infection may be associated with a persistent local reaction, a Chagoma (swelling and local lymphadenopathy), or for bites involving the orbit, Roma&ntilde;a's sign (persistent unilateral edema, conjunctivitis, and lymphadenopathy).",
"   </p>",
"   <p>",
"    Patients with Roma&ntilde;a's sign should undertake prompt conferral with the local health department",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the US Centers for Disease Control regarding diagnosis and treatment of acute Chagas disease (as well as evaluating entomologic specimens for evidence of disease carriage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36615/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16184?source=see_link&amp;anchor=H372251532#H372251532\">",
"     \"Treatment and prognosis of Chagas heart disease\", section on 'T.cruzi infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triatoma insects (colloquial names include kissing bug, Mexican bed bug, and cone-nosed bug) are found primarily in the western and southern United States, Central and South America, and Mexico (",
"      <a class=\"graphic graphic_picture graphicRef80447 \" href=\"mobipreview.htm?36/0/36879\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82769 \" href=\"mobipreview.htm?35/39/36464\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kissing bug bites are usually painless and undetected by the victim. However, these insects are of medical importance both because they can transmit the protozoan T. cruzi, which causes Chagas disease, and because people can develop life-threatening allergic reactions to their bites. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Allergic reactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19975?source=see_link\">",
"       \"Pathology and pathogenesis of Chagas disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23880?source=see_link\">",
"       \"Epidemiology and control of Chagas disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergic",
"      <span class=\"nowrap\">",
"       reactions/anaphylaxis",
"      </span>",
"      to Triatoma bites typically occur in the middle of the night, as Triatoma are nocturnal and bite while the victim sleeps. With the exception of this one distinguishing feature, the signs and symptoms of Triatoma anaphylaxis may be identical to those resulting from other triggers. Fatal and near fatal cases of anaphylaxis have been reported. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Allergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute treatment of anaphylaxis following a Triatoma bite is identical to acute treatment of anaphylaxis of any etiology. Upon discharge, all patients with anaphylaxis should be equipped with an epinephrine autoinjector and an anaphylaxis emergency action plan to manage initial treatment of recurrent episodes. Epinephrine should be kept at the bedside in the future. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once a patient with anaphylaxis has been stabilized, the home (or relevant site) should be thoroughly searched for the blood-engorged insect as soon as possible. If necessary, pest management professionals may be called upon to aid in the inspection process. Identification of the insect is important for diagnosis because reagents for skin testing and laboratory diagnosis are not available. Proper insect identification can be obtained from a local college or university entomology department or the Extension Service at participating land-grant universities nationwide. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Identification of the insect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be given information about how to prevent future contact with Triatoma, including modifications of their homes, bedrooms, and surrounding environment. If kissing bugs are suspected to be present or found in the home, a pest management professional should be contacted. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Avoidance measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific immunotherapy to reduce an allergic patient's sensitivity to Triatoma is not commercially available. Thus, avoidance and education about early recognition and treatment of recurrent allergic reactions is critical. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnostic tests and immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of local reactions are also possible following Triatoma bites, which may be managed symptomatically. Serious complications have not been reported. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Local reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goddard J. Physician's guide to arthropods of medical importance, 5th ed, CRC Press Inc, Boca Raton 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/2\">",
"      Marshall NA, Street DH. Allergy to Triatoma protracta (Heteroptera: Reduviidae). I. Etiology, antigen preparation, diagnosis and immunotherapy. J Med Entomol 1982; 19:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/3\">",
"      Rohr AS, Marshall NA, Saxon A. Successful immunotherapy for Triatoma protracta-induced anaphylaxis. J Allergy Clin Immunol 1984; 73:369.",
"     </a>",
"    </li>",
"    <li>",
"     Schofield CJ, Dolling WR. Bedbugs and kissing-bugs. In: Medical insects and arachnids, Lane RP, Croskey RW (Eds), Chapman and Hall, London 1993. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/5\">",
"      Ryckman RE. Host reactions to bug bites: literature review and annotated bibliography. Calif Vector Views 1979; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/6\">",
"      Edwards L, Lynch PJ. Anaphylactic reaction to kissing bug bites. Ariz Med 1984; 41:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/7\">",
"      Goddard J. Kissing bugs and Chagas' disease. Infect Med 1999; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     The University of Arisona, Cooperative Extension. The Conenose Bug (AKA \"The kissing bug\"). ag.arizona.edu/pubs/insects/az1109.pdf (Accessed on March 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/9\">",
"      Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/10\">",
"      Vetter R. Kissing bugs (Triatoma) and the skin. Dermatol Online J 2001; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/11\">",
"      Ryckman RE. Dermatological reactions (Hemiptera: Cimicidae). Bull Soc Vector Ecol 1985; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/12\">",
"      Burnett JW, Calton GJ, Morgan RJ. Triatoma: the \"kissing bug\". Cutis 1987; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/13\">",
"      Klotz JH, Dorn PL, Logan JL, et al. \"Kissing bugs\": potential disease vectors and cause of anaphylaxis. Clin Infect Dis 2010; 50:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/14\">",
"      Pinnas JL, Lindberg RE, Chen TM, Meinke GC. Studies of kissing bug-sensitive patients: evidence for the lack of cross-reactivity between Triatoma protracta and Triatoma rubida salivary gland extracts. J Allergy Clin Immunol 1986; 77:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/15\">",
"      Riley CV, Howard LO. The \"blood sucking conenose\". Dept Agric Div Entomol Insect Life 1894; 6:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/16\">",
"      Marshall N, Liebhaber M, Dyer Z, Saxon A. The prevalence of allergic sensitization to Triatoma protracta (Heteroptera: Reduviidae) in a Southern California, USA, community. J Med Entomol 1986; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/17\">",
"      Lynch PJ, Pinnas JL. \"Kissing bug\" bites. Triatoma species as an important cause of insect bites in the southwest. Cutis 1978; 22:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/18\">",
"      Lo Vecchio F, Tran TV. Allergic reactions from insect bites. Am J Emerg Med 2004; 22:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/19\">",
"      Goddard J, deShazo R. Bed bugs (Cimex lectularius) and clinical consequences of their bites. JAMA 2009; 301:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/20\">",
"      Hoffman DR. Allergy to biting insects. Clin Rev Allergy 1987; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/21\">",
"      Simons FE, Peng Z. Mosquito allergy: recombinant mosquito salivary antigens for new diagnostic tests. Int Arch Allergy Immunol 2001; 124:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/22\">",
"      Hassoun S, Drouet M, Sabbah A. [Anaphylaxis caused by a mosquito: 2 case reports]. Allerg Immunol (Paris) 1999; 31:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/23\">",
"      Vidal C, Armis&eacute;n M, Bartolom&eacute; B, et al. Anaphylaxis to Hippobosca equina (louse fly). Ann Allergy Asthma Immunol 2007; 99:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/24\">",
"      Hrabak TM, Dice JP. Use of immunotherapy in the management of presumed anaphylaxis to the deer fly. Ann Allergy Asthma Immunol 2003; 90:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/25\">",
"      Stevens WJ, Van den Abbeele J, Bridts CH. Anaphylactic reaction after bites by Glossina morsitans (tsetse fly) in a laboratory worker. J Allergy Clin Immunol 1996; 98:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/26\">",
"      Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/27\">",
"      Tavares MG, deAzeredo-Oliveira MT, Ceron CR. Tissue-specific expression of esterases in Triatoma infestans (Triatomine, Heteroptera). Genet Mol Biol 1998; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/28\">",
"      Chapman MD, Marshall NA, Saxon A. Identification and partial purification of species-specific allergens from Triatoma protracta (Heteroptera:Reduviidae). J Allergy Clin Immunol 1986; 78:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36615/abstract/29\">",
"      Paddock CD, McKerrow JH, Hansell E, et al. Identification, cloning, and recombinant expression of procalin, a major triatomine allergen. J Immunol 2001; 167:2694.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/chagas/hcp/tx.html (Accessed on April 21, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4087 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36615=[""].join("\n");
var outline_f35_48_36615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENTOMOLOGY OF TRIATOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Worldwide distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Habitat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biting behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Anaphylaxis identification and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Identification of the insect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LONG-TERM MANAGEMENT OF TRIATOMA ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Access to epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Avoidance measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pesticide application",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnostic tests and immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADVICE ABOUT CHAGAS DISEASE AFTER A TRIATOMA BITE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4087|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/17/19742\" title=\"figure 1\">",
"      Family reduviidae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4087|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/0/36879\" title=\"picture 1\">",
"      Triatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/39/36464\" title=\"picture 2\">",
"      Kissing bug on hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/52/13123\" title=\"picture 3\">",
"      Kissing bug bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/15/21756\" title=\"table 1\">",
"      Triatoma Spp in US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/10/33964\" title=\"table 2\">",
"      Arthropod bite and infestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23880?source=related_link\">",
"      Epidemiology and control of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16184?source=related_link\">",
"      Treatment and prognosis of Chagas heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36616="Hematologic manifestations of rheumatoid arthritis";
var content_f35_48_36616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic manifestations of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Michael Ehrenfeld, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Yehuda Shoenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36616/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most chronic inflammatory rheumatic diseases are complicated by hematologic abnormalities, including anemia, disorders of leukocytes, platelets, and the coagulation system, and hematologic malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with rheumatoid arthritis (RA) may suffer from a variety of hematologic disorders, particularly anemia, leukopenia, and thrombocytosis.",
"   </p>",
"   <p>",
"    An overview of the hematologic manifestations of rheumatoid arthritis (RA) is presented here. The clinical manifestations, diagnosis, and treatment of Felty&rsquo;s syndrome; large granular lymphocyte leukemia in rheumatoid arthritis; and hematologic disorders observed in patients with other autoimmune disorders, such as systemic lupus erythematosus, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25572?source=see_link\">",
"     \"Indications for splenectomy in Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the most common hematologic abnormalities in patients with rheumatologic disorders are the anemia of chronic disease (a mild anemia that is generally asymptomatic) and iron deficiency anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In patients with RA, the prevalence of anemia ranges from 30 to 70 percent in various studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anemia of chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the anemia of chronic disease is incompletely understood. Two major factors appear to be important: trapping of iron in macrophages, making it relatively unavailable for new hemoglobin synthesis; and inability of the morphologically normal marrow to increase erythropoiesis in response to the anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Inflammatory mediators, particularly tumor necrosis factor-alpha (TNF-alpha), interleukin-1, interleukin-6, interleukin-10, and interferon gamma, contribute to these changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. Hepcidin, an acute phase reactant produced by the liver, may play a key role in cytokine-mediated anemia, as this protein decreases intestinal iron absorption and iron release from macrophages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TNF-alpha and polymorphisms in TNF receptor genes may be particularly important in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    .) TNF-inhibition with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a chimeric mouse human monoclonal antibody in RA patients with anemia of chronic disease leads to a dose-dependent increase in hemoglobin levels compared to placebo. These changes were also accompanied by a reduction in serum levels of both erythropoietin and IL-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low erythropoietin levels and a diminished response to erythropoietin contribute to the anemia in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/3,14,15\">",
"     3,14,15",
"    </a>",
"    ]. These observations led to the use of erythropoietin, resulting in improvement of the anemia in a few patients without apparent change in overall arthritic status was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/3,14,16\">",
"     3,14,16",
"    </a>",
"    ]. In one report, for example, 10 of 11 patients treated for 24 weeks had at least a 6 percentage point increase in hematocrit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, therapy is optimally directed at improving the arthritis and not the anemia, since the severity of the anemia may correlate with disease activity and patients often require high doses of erythropoietin, which is extremely expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Thus, consideration of the use of erythropoietin should be limited to patients with marked, symptomatic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anemia of chronic disease is associated with the following laboratory abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two red cell indices, MCV and MCHC, tend to be normal (ie, normocytic and normochromic) but can be decreased due to concurrent iron deficiency, often to values characteristic of microcytic hypochromic anemias.",
"     </li>",
"     <li>",
"      The serum levels of ferritin are elevated and the levels of transferrin and iron are low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced iron absorption and impaired release of iron from the reticuloendothelial system are typically observed.",
"     </li>",
"     <li>",
"      Bone marrow examination usually reveals the presence of hemosiderin and normal cellularity, with increased numbers (in most cases) of plasma cells that are associated with lymphoid aggregates. However, bone marrow findings are unpredictable and usually reflect the diverse causes of cytopenias in patients with rheumatic diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency is present in up to 50 to 75 percent of patients with RA who have chronic active disease. It is most often caused by chronic blood loss from gastritis (induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/20\">",
"     20",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal antiinflammatory drugs), peptic ulcer, or gastroesophageal reflux due to a diaphragmatic hernia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .) As with all patients, occult blood found in the stool should not be neglected. An upper gastrointestinal endoscopic examination is warranted in the patient with some combination of iron deficiency anemia, epigastric pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occult blood in the stool.",
"   </p>",
"   <p>",
"    The diagnosis of iron deficiency anemia in patients with RA may be difficult since the routine laboratory indices with mild to moderate iron deficiency may overlap with the anemia of chronic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Thus, if iron deficiency is suspected, it may be most reliably verified by the absence of iron stores on bone marrow examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/21\">",
"     21",
"    </a>",
"    ]. However, bone marrow examination may be unnecessary if the patient has clear signs of iron deficiency such as a mean cell volume below 85, serum ferritin concentration below 40",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    and transferrin saturation &le;7 percent (",
"    <a class=\"graphic graphic_table graphicRef76236 \" href=\"mobipreview.htm?32/58/33708\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef56354 \" href=\"mobipreview.htm?26/1/26654\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with RA frequently have concurrent iron deficiency anemia and anemia of chronic disease. When this occurs, the hemoglobin level usually drops to below 9.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and the MCV is less than 80.",
"   </p>",
"   <p>",
"    Measurement of serum soluble transferrin receptor (TfR) may be useful in differentiating iron deficiency anemia from anemia of chronic disease. This was illustrated in a study of 27 patients with RA and anemia who had bone marrow aspiration that provided diagnostically useful specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Among the 15 patients with iron deficiency anemia (absent stainable iron) elevated serum levels (&gt;28.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    of soluble TfR were found in 14 (sensitivity 93 percent) while only one of 12 patients with adequate iron stores had an elevated soluble TfR level (specificity 92 percent). RA patients with iron deficiency anemia show a rise in their serum erythropoietin levels as the hemoglobin concentration falls, contrary to patients with anemia of chronic disease and RA, who do not increase their erythropoietin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Macrocytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less frequently, a megaloblastic anemia due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B12 deficiency,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is found in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/2\">",
"     2",
"    </a>",
"    ]. One study of 25 patients with RA noted vitamin B12 and folic acid deficiency in 29 and 21 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/2\">",
"     2",
"    </a>",
"    ]. The characteristic morphologic changes of a macrocytic anemia may be masked by the changes induced by other causes of anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    deficiency anemia in RA is usually due to the combination of increased requirements and reduced intake (eg, pregnancy in a patient on a restricted diet) or to concurrent iron deficiency. The diagnosis is established by demonstrating a reduced folate level, preferably in red blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia is not a typical feature of RA, although antibody-mediated, Coombs positive hemolytic anemia has been described, primarily in Felty's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/26\">",
"     26",
"    </a>",
"    ]. Drug-induced hemolysis may also occur. As an example, autoimmune hemolytic anemia has been induced by non-steroidal anti-inflammatory agents. Although extremely rare, this anemia may be severe. The condition tends to be reversible when the offending drug is withdrawn, but most patients require corticosteroid therapy. In some cases, the hemolytic anemia is accompanied by signs of hypersensitivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone marrow hypoplasia with anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow hypoplasia with anemia is another rare but serious complication of RA. When present, it is principally observed in association with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Felty's syndrome",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      The administration of gold,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , or other immunosuppressive agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pure red cell aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure red cell aplasia is a rare but treatable cause of anemia in RA. It should be considered when there is a severe normochromic anemia with a very low absolute reticulocyte count in the absence of obvious blood loss or hemolysis. Autoimmune suppression of erythroid stem cells, antirheumatic drugs, and parvovirus infection has been implicated in this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], although single case reports suggest that pure red cell aplasia could be an extraarticular manifestation of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/27\">",
"     27",
"    </a>",
"    ]. Isolated case reports have noted improvement in patients treated with corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective therapy of the patient with RA and anemia is based upon an accurate determination of the cause of the anemia. As a result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin deficiencies leading to anemia should be corrected by the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      or vitamin B12.",
"     </li>",
"     <li>",
"      Iron should not be given unless iron deficiency has been documented. In juvenile idiopathic arthritis, eight severely anemic children who were unresponsive to oral iron therapy responded to intravenous iron saccharate with an increase in the median hemoglobin value from 8 to 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We recommend starting with a combination of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      , which is usually given with 250 to 325 mg of ascorbic acid and on an empty stomach to enhance iron absorption. Alternatively,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/37/38485?source=see_link\">",
"       ferrous gluconate",
"      </a>",
"      300 mg tid may be used. Patients with persistent gastric intolerance to iron tablets may tolerate elixir of Feosol. If oral therapy fails, we switch to intramuscular iron, and only very rarely would we use parenteral iron as a slow IV infusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=see_link\">",
"       \"Treatment of anemia due to iron deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemolysis should be treated with corticosteroids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      If no response is observed after one to two weeks, an immunosuppressive agent may be administered, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (50 to 150",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      Antirheumatic drug-induced bone marrow suppression should be treated by dose alteration or complete withdrawal of the suspected drug.",
"     </li>",
"     <li>",
"      The anemia of chronic disease often responds to therapy directed against RA, including a disease modifying antirheumatic drug,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      corticosteroids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several controlled trials have demonstrated the efficacy of erythropoietin in treating the anemia of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/18\">",
"     18",
"    </a>",
"    ]; however, only a limited number of patients with RA and anemia of chronic disease may require this treatment. High doses (300 to 800",
"    <span class=\"nowrap\">",
"     units/kg/week",
"    </span>",
"    given subcutaneously once or twice a week) are required, making this an expensive form of therapy. One specific role for erythropoietin among patients with RA may be in the preparation for elective surgery. Correction of the anemia in this setting may obviate the need for transfusion or may facilitate the donation of blood for autologous transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FELTY'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal leukopenic disorder among patients with rheumatoid arthritis is Felty's syndrome, which is the triad of neutropenia, splenomegaly, and deforming RA. Splenomegaly, however, is not necessarily present. This disorder occurs in about 1 percent of patients with RA. Patients who develop Felty's syndrome often have a severe and long-standing form of nodular RA, with high levels of rheumatoid factor, which may be accompanied by vasculitis, ulcers, neuropathy, pulmonary fibrosis, Sj&ouml;gren's syndrome, hepatomegaly, and lower extremities hyperpigmentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4247?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although leukopenia is a common consequence of many rheumatic diseases, it is most frequently caused by the administration of antirheumatic medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , gold salts,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/1,31-36\">",
"     1,31-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocytopenia among patients with patients with Felty's syndrome may be due to multiple causes in addition to sequestration by splenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune complexes (which can also cause hypocomplementemia) coating granulocytes, thereby leading to sequestration and reduced survival",
"     </li>",
"     <li>",
"      Antigranulocyte antibodies directed against cell surface antigens",
"     </li>",
"     <li>",
"      Increased white blood cell margination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone marrow abnormalities, including a maturation arrest of the granulocyte cell line (most common), hypoplasia, and rarely a lymphocytic infiltration. Overall cellularity is either normal or reveals myeloid hyperplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infections and granulocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocytopenia (absolute neutrophil count below",
"    <span class=\"nowrap\">",
"     2000/mm3)",
"    </span>",
"    in Felty's syndrome does not cause symptoms unless it leads to infection. As a result, it may not be detected for a prolonged period unless blood counts are being monitored for some other reason, such as the detection of possible toxicity to antirheumatic drugs. In addition, the diagnosis may be masked in patients who present with infection, because active bacterial infection can raise the white blood cell count to a normal or even slightly elevated level. The granulocytopenia typically reappears within a short time after successful treatment of the infection.",
"   </p>",
"   <p>",
"    Serious infections are frequent and most commonly affect the skin, lungs (pneumonia), and the urinary tract. Risk factors include a neutrophil count below",
"    <span class=\"nowrap\">",
"     1000/mm3,",
"    </span>",
"    skin ulcers, corticosteroid therapy, and increasing overall disease severity and functional impairment. A 12-fold increased risk of developing non-Hodgkin lymphoma was reported in patients with Felty's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Felty's syndrome is aimed at suppressing the inflammatory rheumatoid disease. Additional approaches are required in selected patients. The treatment of Felty&rsquo;s syndrome is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25572?source=see_link\">",
"     \"Indications for splenectomy in Felty's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Large granular lymphocyte syndrome and pseudo-Felty's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large granular lymphocyte (LGL) leukemia associated with rheumatoid arthritis (RA), which has also been referred to as large granular lymphocyte syndrome in RA, is a clonal lymphoproliferative disease. It appears to represent one part of a spectrum of polyclonal and clonal disorders of LGL, including at least a subset of patients with Felty&rsquo;s syndrome. In patients with rheumatologic disease, LGL leukemia is almost always the T-LGL type. Nearly one-third of patients with LGL leukemia also have RA, and some fulfill the clinical criteria for Felty's syndrome. RA often precedes the development of T-LGL leukemia, but both conditions may present concurrently. LGL leukemia in RA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One-third of patients are asymptomatic, other than from RA, but others experience fever, bacterial infections, fatigue, night sweats, or weight loss. Approximately 85 percent of patients with the LGL syndrome have neutropenia which, in 40 percent of cases, is severe enough to result in recurrent pyogenic infections. The bone marrow is infiltrated with lymphocytes in almost 90 percent of patients, three-fourths of whom have mild to moderate absolute lymphocytosis. Anemia (50 percent) and thrombocytopenia (20 percent) occur with about the same frequency as in Felty&rsquo;s syndrome. Splenomegaly may be present in up to one-half of patients, and hepatomegaly may be present in up to 20 percent. Autopsy information is limited, but lymphocytic infiltration of various organs can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link&amp;anchor=H2#H2\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical constellation, with increased large granular lymphocytes, polyarthritis, neutropenia, and splenomegaly, has also been termed pseudo-Felty&rsquo;s syndrome, given the clinical similarities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The condition has twice the prevalence of classic Felty&rsquo;s syndrome. Most patients have positive tests for rheumatoid factor and anticyclic citrullinated peptide antibodies; many patients also have antinuclear antibodies.",
"   </p>",
"   <p>",
"    Clinical differences between Felty&rsquo;s syndrome and the LGL or pseudo-Felty&rsquo;s syndrome lack specificity and, therefore, have limited diagnostic value. The distinction between these disorders is based mainly upon demonstration of an expanded lymphocyte population in the peripheral blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow and upon the identification of typical LGL cells; it requires careful observation of lymphocyte number and morphology. The diagnosis of LGL leukemia is based upon the findings of an elevated lymphocyte count and marrow infiltration with lymphocytes, a distinctive immunophenotype, and demonstration of clonality by molecular studies. LGLs in the setting of rheumatoid arthritis are typically CD3+, CD8+, and TCR-&alpha;&beta;+ T cells. Clonality can be confirmed by evaluating for monoclonal rearrangements of the T cell receptor by polymerase chain reaction or by Southern blotting. Clonality is the feature that is generally considered to distinguish this condition from Felty&rsquo;s syndrome associated with LGL, although these conditions are sometimes considered as parts of a single disease spectrum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link&amp;anchor=H24860473#H24860473\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link&amp;anchor=H8862195#H8862195\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Relationship to Felty's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for the LGL syndrome associated with rheumatoid arthritis is discussed separately. Patients with RA-associated T-LGL leukemia usually have a chronic, indolent course with a median survival of over 10 years, although most eventually require therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link&amp;anchor=H24860672#H24860672\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LEUKOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis with a proliferation of polymorphonuclear leukocytes and a predominance of early forms (eg, a shift to the left) can occur during an inflammatory flare of rheumatoid arthritis. However, an associated bacterial infection must be considered and rigorously excluded in such patients. Leukocytosis is a common finding in systemic onset juvenile idiopathic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EOSINOPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant eosinophilia occurs in some patients with RA. It usually correlates with the presence of vasculitis, pleuropericarditis, pulmonary fibrosis, subcutaneous nodules, or gold-induced skin rashes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PLATELET ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytosis is common in RA, and a positive correlation has been found between the platelet count and disease activity. Extreme thrombocytosis has been noticed with extraarticular manifestations of the disease, in particular pulmonary involvement, peripheral neuropathy, and vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/47\">",
"     47",
"    </a>",
"    ]. Although the mechanism of thrombocytosis is uncertain, increased intravascular coagulation with a compensatory increase in platelet production has been suggested as a possible cause.",
"   </p>",
"   <p>",
"    Thrombocytopenia is rare in RA, except when related to drug treatment or Felty's syndrome. Among the drugs that can produce thrombocytopenia are gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and TNF antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/35,48-50\">",
"     35,48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19525?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of gold\", section on 'Hematologic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEMATOLOGICAL MALIGNANCIES IN RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various studies have suggested an increased risk of malignancy among patients with RA, and malignant diseases contribute significantly to the morbidity and mortality of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Most large population-based studies found an increased risk for the development of lymphoproliferative diseases, particularly non-Hodgkin lymphoma (NHL). A study of nearly 18,000 RA patients noted a risk of lymphoma in patients with RA compared to the general population (the standardized incidence ratio or SIR) to be increased (SIR of1.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/55\">",
"     55",
"    </a>",
"    ]. Although the risk in those treated with anti-tumor necrosis factor alpha agents was greater than that for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (SIRs of 2.9 and 1.7, respectively), the authors of the study noted that this difference could result if patients with more active disease, who are at an increased risk of developing lymphoma, were more often treated with anti-TNF therapy than those with less active RA.",
"   </p>",
"   <p>",
"    The results of studies that have addressed the question of whether TNF inhibitor use is associated with increased cancer risk are mixed, and large observational studies were unable to demonstrate a significant increase in either hematologic malignancies or solid tumors for patients taking biologic DMARDs compared with those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36616/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The possible risk of malignancy associated with the use of TNF inhibitors is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17176236\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the most common hematologic abnormalities in patients with rheumatologic disorders are the anemia of chronic disease (anemia of chronic inflammation), a mild anemia that is generally asymptomatic, and iron deficiency anemia. Other less frequent causes include megaloblastic anemias from vitamin deficiency or medications. In patients with rheumatoid arthritis (RA), the prevalence of anemia ranges from 30 to 70 percent in various studies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Anemia of chronic disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Iron deficiency anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Macrocytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal leukopenic disorder among patients with RA is Felty&rsquo;s syndrome, the triad of neutropenia, splenomegaly, and deforming RA; it occurs in about 1 percent of patients with RA. Patients who develop Felty&rsquo;s syndrome often have a severe and longstanding form of nodular RA, with various other extraarticular manifestations and high levels of rheumatoid factor. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Felty's syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4247?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Felty's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large granular lymphocyte (LGL) leukemia associated with RA, which has also been referred to as large granular lymphocyte syndrome, is a clonal lymphoproliferative disease; when seen in RA, it is almost always the T-LGL type. Nearly one-third of patients with LGL leukemia also have RA, and some fulfill the clinical criteria for Felty&rsquo;s syndrome. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Large granular lymphocyte syndrome and pseudo-Felty's syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link\">",
"       \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leukocytosis with a proliferation of polymorphonuclear leukocytes and a predominance of early forms (eg, a shift to the left) can occur during an inflammatory flare of RA. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Leukocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant eosinophilia occurs in some patients with RA. It usually correlates with the presence of vasculitis, pleuropericarditis, pulmonary fibrosis, subcutaneous nodules, or drug-induced skin rashes. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Eosinophilia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombocytosis is common in RA, and a positive correlation has been found between the platelet count and disease activity. Thrombocytopenia is rare in RA, except when related to drug treatment or Felty&rsquo;s syndrome. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Platelet abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various studies have suggested an increased risk of malignancy among patients with RA, particularly for the development of lymphoproliferative diseases, especially non-Hodgkin lymphoma (NHL). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hematological malignancies in rheumatoid arthritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/1\">",
"      Hamilton PJ. The haematology laboratory and the rheumatologist. Clin Rheum Dis 1983; 9:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/2\">",
"      Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990; 49:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/3\">",
"      Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 1990; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/4\">",
"      Hansen NE. The anaemia of chronic disorders. A bag of unsolved questions. Scand J Haematol 1983; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/5\">",
"      Rajapakse CN, Holt PJ, Perera B. Diagnosis of true iron deficiency in rheumatoid arthritis. Ann Rheum Dis 1980; 39:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/6\">",
"      Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/7\">",
"      Swaak A. Anemia of chronic disease in patients with rheumatoid arthritis: aspects of prevalence, outcome, diagnosis, and the effect of treatment on disease activity. J Rheumatol 2006; 33:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/8\">",
"      Baynes RD, Bothwell TH, Bezwoda WR, et al. Hematologic and iron-related measurements in rheumatoid arthritis. Am J Clin Pathol 1987; 87:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/9\">",
"      Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/10\">",
"      Voulgari PV, Kolios G, Papadopoulos GK, et al. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/11\">",
"      Davis D, Charles PJ, Potter A, et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/12\">",
"      Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002; 100:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/13\">",
"      Glossop JR, Dawes PT, Hassell AB, Mattey DL. Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes. J Rheumatol 2005; 32:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/14\">",
"      Boyd HK, Lappin TR. Erythropoietin deficiency in the anaemia of chronic disorders. Eur J Haematol 1991; 46:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/15\">",
"      Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis Rheum 1988; 31:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/16\">",
"      Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/17\">",
"      Vreugdenhil G, L&ouml;wenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992; 22:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/18\">",
"      Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996; 55:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/19\">",
"      Porter DR, Sturrock RD, Capell HA. The use of serum ferritin estimation in the investigation of anaemia in patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/20\">",
"      Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/21\">",
"      Doube A, Davis M, Smith JG, et al. Structured approach to the investigation of anaemia in patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/22\">",
"      Mulherin D, Skelly M, Saunders A, et al. The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures. J Rheumatol 1996; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/23\">",
"      Fitzsimons EJ, Houston T, Munro R, et al. Erythroblast iron metabolism and serum soluble transferrin receptor values in the anemia of rheumatoid arthritis. Arthritis Rheum 2002; 47:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/24\">",
"      Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for iron deficiency. Clin Lab Haematol 2003; 25:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/25\">",
"      Takashina N, Kondo H, Kashiwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. J Rheumatol 1990; 17:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/26\">",
"      Hansen OP, Hansen TM, Jans H, Hippe E. Red blood cell membrane-bound IgG: demonstration of antibodies in patients with autoimmune haemolytic anaemia and immune complexes in patients with rheumatic diseases. Clin Lab Haematol 1984; 6:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/27\">",
"      Dessypris EN, Baer MR, Sergent JS, Krantz SB. Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med 1984; 100:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/28\">",
"      Kamper AM, Malbrain M, Zachee P, Chew SL. Parvovirus infection causing red cell aplasia and leukopenia in rheumatoid arthritis. Clin Rheumatol 1994; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/29\">",
"      Rodrigues JF, Harth M, Barr RM. Pure red cell aplasia in rheumatoid arthritis. J Rheumatol 1988; 15:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/30\">",
"      Martini A, Ravelli A, Di Fuccia G, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/31\">",
"      Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis 1982; 41 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/32\">",
"      Williams GT, Johnson SA, Dieppe PA, Huskisson EC. Neutropenia during treatment of rheumatoid arthritis with levamisole. Ann Rheum Dis 1978; 37:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/33\">",
"      Amos RS, Bax DE. Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy. Br J Rheumatol 1988; 27:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/34\">",
"      Camp AV. Hematologic toxicity from penicillamine in rheumatoid arthritis. J Rheumatol Suppl 1981; 7:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/35\">",
"      Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003; 139:W.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/36\">",
"      Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford) 2008; 47:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/37\">",
"      Starkebaum G, Arend WP, Nardella FA, Gavin SE. Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty's syndrome. J Lab Clin Med 1980; 96:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/38\">",
"      Dancey JT, Brubaker LH. Neutrophil marrow profiles in patients with rheumatoid arthritis and neutropenia. Br J Haematol 1979; 43:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/39\">",
"      Abdou NI. Heterogeneity of bone marrow-directed immune mechanisms in the pathogenesis of neutropenia of Felty's syndrome. Arthritis Rheum 1983; 26:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/40\">",
"      Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty's syndrome. Br J Rheumatol 1988; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/41\">",
"      Juby A, Johnston C, Davis P, Russell AS. Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in the sera of patients with Felty's syndrome. Br J Rheumatol 1992; 31:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/42\">",
"      Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994; 120:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/43\">",
"      Loughran TP Jr, Starkebaum G, Kidd P, Neiman P. Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1988; 31:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/44\">",
"      Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/45\">",
"      Barton JC, Prasthofer EF, Egan ML, et al. Rheumatoid arthritis associated with expanded populations of granular lymphocytes. Ann Intern Med 1986; 104:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/46\">",
"      Panush RS, Franco AE, Schur PH. Rheumatoid arthritis associated with eosinophilia. Ann Intern Med 1971; 75:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/47\">",
"      Farr M, Scott DL, Constable TJ, et al. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983; 42:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/48\">",
"      Coblyn JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/49\">",
"      Thomas D, Gallus AS, Brooks PM, et al. Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis 1984; 43:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/50\">",
"      Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996; 15:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/51\">",
"      Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/52\">",
"      Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/53\">",
"      Baecklund E, Askling J, Rosenquist R, et al. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/54\">",
"      Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/55\">",
"      Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/56\">",
"      Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36616/abstract/57\">",
"      Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 2011; 41:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7512 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36616=[""].join("\n");
var outline_f35_48_36616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17176236\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anemia of chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Macrocytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone marrow hypoplasia with anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FELTY'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infections and granulocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Large granular lymphocyte syndrome and pseudo-Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LEUKOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EOSINOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PLATELET ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEMATOLOGICAL MALIGNANCIES IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17176236\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7512|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?26/1/26654\" title=\"algorithm 1\">",
"      Iron deficiency anemia and RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7512|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/58/33708\" title=\"table 1\">",
"      Lab tests in iron deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4247?source=related_link\">",
"      Clinical manifestations and diagnosis of Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25572?source=related_link\">",
"      Indications for splenectomy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36617="Treatment of urethral stricture disease in men";
var content_f35_48_36617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of urethral stricture disease in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Andrew Peterson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     George Webster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36617/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1310601282\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral stricture disease is relatively common in men with most patients acquiring the disease due to injury or infection. The most common etiology for stricture is iatrogenic injury due to urologic instrumentation (eg, oversized resectoscope at the time of transurethral surgery) or the placement of indwelling catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/1\">",
"     1",
"    </a>",
"    ]. These and other causes of urethral stricture are given in the table (",
"    <a class=\"graphic graphic_table graphicRef60938 \" href=\"mobipreview.htm?25/11/25787\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although some patients are able to relate a definitive history of prior instrumentation, injury or infection, the etiology of the stricture often remains unknown due to the lag time between an inciting event and the development of symptoms. Most patients present with chronic voiding symptoms, but acute urinary obstruction can occur without significant warning, requiring emergent urethral dilation or urinary diversion.",
"   </p>",
"   <p>",
"    Pretreatment evaluation identifies the location, length and severity of the stricture and guides the choice of treatment which can include minimally-invasive therapies, urinary diversion, or urethral reconstruction. A single treatment strategy is not appropriate for all the different types of strictures.",
"   </p>",
"   <p>",
"    The treatment of urethral stricture disease in men will be reviewed here. The clinical features and diagnosis of the various pathologies that may result in urethral stricture are discussed in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293655215\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urethra conveys urine from the bladder to the exterior of the body. It is important to understand the urethral anatomy in the male because urethral stricture disease differs in its etiology, diagnosis and management based upon stricture location. Iatrogenic injury may affect any segment of the urethra. Pelvic fractures can cause distraction defects in the posterior urethra, whereas blunt perineal trauma injures the bulbar urethra. (See",
"    <a class=\"local\" href=\"#H293654703\">",
"     'Urethroplasty technique by location'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The male urethra is divided into two major segments: the anterior urethra and the posterior urethra (",
"    <a class=\"graphic graphic_figure graphicRef76039 \" href=\"mobipreview.htm?30/15/30965\">",
"     figure 1",
"    </a>",
"    ). By convention, the surfaces of the penis are defined with the penis extended cranially. Thus, the urethra is located ventrally.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior urethra begins at the meatus of the penis and includes the fossa navicularis, the pendulous urethra, and the bulbar urethra. The suspensory ligament of the penis delineates the pendulous and bulbar urethra. The anterior urethra consists of an endothelial layer that is surrounded by the urethral spongiosum. The spongiosum is concentrically located around the urethra in the distal pendulous urethra. In the bulbar urethra, it becomes eccentrically located with a larger component on the ventral surface.",
"     </li>",
"     <li>",
"      The posterior urethra includes the membranous urethra, prostatic urethra and the bladder neck; the spongiosum is absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The male urethra is supplied proximally by the bulbar arteries which are branches of the penile artery (",
"    <a class=\"graphic graphic_figure graphicRef53027 \" href=\"mobipreview.htm?40/3/41009\">",
"     figure 2",
"    </a>",
"    ), whereas the distal urethra is perfused by retrograde flow from the dorsal penile artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H755485300\">",
"    <span class=\"h2\">",
"     Spongiofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spongiofibrosis refers to the deposition of collagen and fibrous tissue deep to the urethral mucosa of the injured region. Spongiofibrosis results in a much longer effective urethral stricture compared with the length of the mucosal segment that can be seen on imaging or urethroscopy. Thus, some authors feel that better outcomes are obtained by including the area of spongiofibrosis in the repair even though this leads to a more extensive repair. (See",
"    <a class=\"local\" href=\"#H1310601326\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698386\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are referred to a urologist for treatment of urethral stricture disease for a variety of reasons that include obstructive voiding symptoms, acute urinary retention, recurrent urinary tract infection, or more rarely, hydronephrosis, urethral fistula or periurethral abscess. The clinical diagnosis and evaluation of these problems are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is indicated in patients with urethral stricture associated with severe voiding symptoms, acute urinary retention, bladder stones, high postvoid residual or recurrent urinary tract infection. There is no absolute American Urologic Association (AUA) score (",
"    <a class=\"graphic graphic_table graphicRef81331 \" href=\"mobipreview.htm?4/5/4189\">",
"     table 2",
"    </a>",
"    ) with respect to voiding symptoms that indicates a need to pursue repair. Many patients with urethral stricture have low unexplained AUA scores but are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699047\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than patient refusal, there are no absolute contraindications to the treatment of urethral stricture disease. Patients who are not candidates for surgical intervention can often be managed with minimally-invasive techniques, and if the stricture no longer responds to therapy, urinary diversion is always an option. (See",
"    <a class=\"local\" href=\"#H699767\">",
"     'Urinary diversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601305\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of urethral stricture disease depends upon the location, etiology and length of the stricture. The available data to guide the treatment of urethral stricture disease come primarily from observational studies in generally heterogenous populations with a variety of etiologies, locations and severity of stricture. The approach to the treatment of urethral stricture disease that is presented below (except that due to Lichen sclerosis) is based upon the available observational data and expert opinion. The treatment of penile disease due to Lichen Sclerosis is beyond the scope of this discussion and will not be addressed in this topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=see_link&amp;anchor=H16#H16\">",
"     \"Balanitis and balanoposthitis in adults\", section on 'Lichen sclerosus or balanitis xerotica obliterans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options for urethral stricture include several minimally-invasive therapies (dilation, endoscopic urethrotomy), urinary diversion procedures (suprapubic tube, perineal urethrostomy), and surgical reconstruction of the urethra using flaps or grafts. No single procedure is appropriate to manage all strictures, and multiple techniques may be used in the same patient during the course of treatment to manage recurrent stricture. (See",
"    <a class=\"local\" href=\"#H1310601312\">",
"     'Minimally-invasive therapies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1310601326\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Urethral dilation and urethrotomy, which are minimally-invasive techniques, continue to be the most commonly-employed initial treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/2\">",
"     2",
"    </a>",
"    ]. Endoscopic urethrotomy is quick, widely available and safe. Long-term success rates are overall poor but are improved for strictures &lt;1 cm, those located in the mid-bulbar urethra, and those with at least 5 mm of preserved lumen. Many patients eventually progress to surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1310601312\">",
"     'Minimally-invasive therapies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H293656380\">",
"     'Outcomes of minimally-invasive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the high rate of recurrence with minimally-invasive techniques and the overall superior outcomes of surgical reconstruction, we attempt endoscopic urethrotomy only",
"    <strong>",
"     once",
"    </strong>",
"    , and if unsuccessful, progress directly to surgical reconstruction (urethroplasty) in appropriately-selected men, rather than multiple, repeated endoscopic procedures. (See",
"    <a class=\"local\" href=\"#H293656277\">",
"     'Outcomes of urethroplasty'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Urethral reconstruction involves varying degrees of stricture incision or excision (urethroplasty) with or without augmentation using a flap or graft for reconstruction. The potential effects of the chosen surgical technique on erectile function are important to consider. Penile elongation during erection requires that surgical repairs of the penile urethra be elastic; local flaps in this location are superior to grafts.",
"    <strong>",
"    </strong>",
"    Similarly, primary anastomotic urethroplasty, which is useful for repairing the bulbar urethra, can result in chordee with erection when used in the penile urethra. Specific surgical techniques that are most appropriate for each of the segments of the urethra are described in detail below. (See",
"    <a class=\"local\" href=\"#H293654703\">",
"     'Urethroplasty technique by location'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients are not candidates for, or will elect not to undergo, surgical reconstruction of the urethra. For these patients, several nonreconstructive options for urinary diversion are available, including suprapubic tube placement, perineal urethrostomy, and permanent urinary diversion. (See",
"    <a class=\"local\" href=\"#H699767\">",
"     'Urinary diversion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8421895\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to instrumentation or surgery, the bladder must be decompressed and sterile urine should be verified. Prior to treatment, the anatomic site, length, and severity of the strictured segment must be defined. Retrograde urethrogram alone is often all that is needed to define the extent of the stricture disease; urethroscopy may be helpful, both antegrade and retrograde (if a suprapubic tube is in place), to help define the extent of urethral mucosal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8422039\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended for all procedures involving cystourethroscopy with manipulation and surgical treatment of urethral strictures to minimize the potential for infection (",
"    <a class=\"graphic graphic_table graphicRef60938 \" href=\"mobipreview.htm?25/11/25787\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with colonization or symptomatic urinary tract infection should be treated with broad-spectrum oral antibiotics, and instrumentation or surgery should be delayed, if possible, until the urine is clear. Positive urine cultures are associated with a higher rate of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/6\">",
"     6",
"    </a>",
"    ]. However, urinary tract infection sometimes cannot be completely cleared until urethral obstruction is treated and the bladder completely decompressed. For these patients, antibiotic therapy is continued following instrumentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699571\">",
"    <span class=\"h2\">",
"     Bladder decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with long-standing symptoms who have maintained urine flow are generally able to decompress their bladder adequately. However, patients who present with acute urinary obstruction may require retrograde serial dilation and catheter placement for complete bladder decompression. At times, urologic expertise to open the stricture may not be immediately available. Under these circumstances, a percutaneous suprapubic tube should be placed by an appropriately-trained individual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute urinary retention\", section on 'Acute management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H21#H21\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Suprapubic catheter placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699578\">",
"    <span class=\"h2\">",
"     Defining the stricture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial diagnosis of urethral stricture is often made with a retrograde urethrogram (RUG) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57667 graphicRef75050 graphicRef72649 \" href=\"mobipreview.htm?27/31/28152\">",
"     image 1A-C",
"    </a>",
"    ) performed in a setting of trauma or the inability to pass a urinary catheter. In patients with acute urinary retention requiring suprapubic tube placement, a voiding cystourethrogram (VCUG) can be performed through the tube. (See",
"    <a class=\"local\" href=\"#H699571\">",
"     'Bladder decompression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prior to treatment and regardless of the findings of the initial study that established a diagnosis of urethral stricture, cystourethroscopy should be performed to define the caliber and extent of the urethral stricture.",
"   </p>",
"   <p>",
"    In patients for whom the etiology of the stricture is a pelvic fracture urethral distraction defect, it is important to evaluate the bladder neck and outlet for evidence of concomitant injury. In patients with a suprapubic catheter, antegrade cystourethroscopy can be performed through the suprapubic tract. The bladder should also be examined for stones which can be associated with long-term bladder outlet obstruction.",
"   </p>",
"   <p>",
"    Some clinicians have advocated the adjunctive use of ultrasound to define the extent of spongiofibrosis and thus determine the absolute length of the urethra that needs to be repaired. Specially-designed probes are available for intraurethral examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H755485300\">",
"     'Spongiofibrosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601312\">",
"    <span class=\"h1\">",
"     MINIMALLY-INVASIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several minimally-invasive techniques are available for the initial management of urethral strictures including dilation with balloons or serial axial dilators (filiforms and followers), cold knife incision, incision with electrocautery or laser, and self-catheterization (ie, self-calibration).",
"   </p>",
"   <p>",
"    Any of these procedures may be performed safely in the clinic (self-calibration is performed by the patient at home) using local anesthesia consisting of viscous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    jelly instilled into the urethra, and a mild sedative. Various local blocks have been described, including penile blocks and periurethral spongiosum blocks. To perform a spongiosum block, 1 or 2% lidocaine",
"    <strong>",
"     without epinephrine",
"    </strong>",
"    is injected directly into the glans penis to provide anesthesia for instrumentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of minimally-invasive technique to initially open a stricture is left to the urologist&rsquo;s experience and the availability of urologic tools because no one of the minimally-invasive methods has been proven superior to any other. (See",
"    <a class=\"local\" href=\"#H293656380\">",
"     'Outcomes of minimally-invasive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698687\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293654928\">",
"    <span class=\"h3\">",
"     Urethral dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial dilation of urethral strictures in the office or clinic setting is most commonly performed using filiforms and followers under endoscopic control. Urethral dilation is an appropriate initial treatment when the history and imaging evaluation have found a stricture less than 2 cm with no associated spongiofibrosis, and no complex features such as a fistula or a diverticulum. (See",
"    <a class=\"local\" href=\"#H755485300\">",
"     'Spongiofibrosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following successful dilation, the patient can be taught self-calibration with a soft 14 to 16 French catheter to maintain urethral patency. The patient typically performs self-calibration once a day for a week after the initial dilation and then at decreasing intervals over time. Few patients are compliant with self calibration in the long term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293654935\">",
"    <span class=\"h3\">",
"     Endoscopic urethrotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer to use direct vision internal urethrotomy (DVIU) after axial dilation for the initial treatment of simple strictures. Urethrotomy can be performed safely in the office setting using a penile block or in an ambulatory setting with local, spinal, or general anesthetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. The procedure is aided by a guidewire placed through the stricture. The urethrotomy incision is made at the 12 o&rsquo;clock, or at the 3 and 9 o&rsquo;clock positions with a cold-knife urethrotome. The method to perform the incision (cold knife, electrocautery, laser) and location of incision(s) is a surgeon preference since outcomes are similar regardless of method. (See",
"    <a class=\"local\" href=\"#H293656380\">",
"     'Outcomes of minimally-invasive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Urethrotomy is especially well-suited for short strictures (&lt;2 cm) of the bulbar urethra. Longer strictures, strictures involving the pendulous urethra, or strictures associated with significant spongiofibrosis are associated with high failure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H755485300\">",
"     'Spongiofibrosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H293656380\">",
"     'Outcomes of minimally-invasive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733682315\">",
"    <span class=\"h3\">",
"     Urethral stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UroLume&reg; stent, introduced in 1988, is approved in the United States for the treatment of urethral stricture, prostatic bladder outlet obstruction, and detrusor sphincter dyssynergia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/11\">",
"     11",
"    </a>",
"    ]. When used to treat urethral stricture, this device is associated with high recurrence rates and complications such as postvoid dribbling, perineal pain, erectile pain, and recurrent urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Thus, we rarely use this device other than for unique circumstances. As an example, urethral stenting may be useful to manage a recalcitrant anastomotic bladder neck contracture following radical prostatectomy in conjunction with an artificial urinary sphincter, but recurrent stricture may still be a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293656380\">",
"    <span class=\"h2\">",
"     Outcomes of minimally-invasive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscopic treatment of urethral stricture is associated with high recurrence rates that range from 30 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The wide variability of reported recurrence rates is due to the heterogeneity within the patient populations that are studied. No minimally-invasive technique has proven superior to any other. In one study that compared urethral dilation with urethrotomy, equivalent long-term success rates were found for the treatment of short (&lt;2 cm) urethral strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/19\">",
"     19",
"    </a>",
"    ]. The advantage of endoscopic methods, in spite of these recurrence rates, is that they are quick, widely available and safe.",
"   </p>",
"   <p>",
"    The likelihood of success (defined as no need for further intervention) of initial treatment of urethral strictures using endoscopic treatment (urethrotomy) depends upon stricture length, degree of luminal narrowing and the urethral segment that is treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strictures &lt;1 cm in length respond well to minimally-invasive therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/17,20\">",
"       17,20",
"      </a>",
"      ]. In one study, strictures with a length &lt;1 cm had a recurrence rate of 27 percent compared with 50 percent for those &ge;1 cm in length [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bulbar strictures with a preserved luminal diameter &gt;15 French (5 mm) had the best overall outcomes in a retrospective review of 224 patients who underwent internal urethrotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mid-bulbar urethra appears to respond the best to dilation, incision, or ablation with laser. The bulbar urethra has an abundant corpus spongiosum, which helps to decrease scarring. Direct vision internal urethrotomy (DVIU) is most likely to be successful in this segment of the urethra.",
"     </li>",
"     <li>",
"      Recurrence rates are higher for treatment of strictures involving the pendulous urethra, or strictures associated with significant spongiofibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H755485300\">",
"       'Spongiofibrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of high recurrence rates, some clinicians argue that an initial urethrotomy is not cost-effective or beneficial in the long-term care of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Urethrotomy is appropriate in selected patients (those with short, mid-bulbar strictures) and we are in agreement with others that the patient should be offered one endoscopic attempt to open the stricture prior to embarking on a definitive surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/23\">",
"     23",
"    </a>",
"    ]. A single initial urethrotomy appears to be cost-effective and, in general, should be included in the initial treatment algorithm for urethral stricture in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been suggested that multiple endoscopic treatments predispose to a more difficult definitive open repair and reduced overall success rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. However, the experience of others, as well as our own, has shown that patients with a prior endoscopic treatment do not have significantly higher late failure rates. The subsequent surgical urethroplasty procedure may, however, be more complicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601326\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical management of urethral stricture disease in men can be nonreconstructive (urinary diversion) or involve various degrees of stricture incision or excision without (anastomotic urethroplasty) or with augmentation using a flap or graft for reconstruction (substitution urethroplasty).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699767\">",
"    <span class=\"h2\">",
"     Urinary diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who wish to avoid urethral reconstruction, or those patients who have nonreconstructible severe stricture, urinary diversion is an option. From least to most invasive, these options include suprapubic catheter placement, perineal urethrostomy and supravesical ureteral diversion (urostomy, continent ileal conduit). These are each discussed briefly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H699775\">",
"    <span class=\"h3\">",
"     Suprapubic catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A suprapubic catheter can be used for temporary or permanent urinary diversion. The catheter will need to be replaced monthly to avoid calcification and chronic infection. The main disadvantages of a suprapubic catheter are the need to frequently empty the urinary bag, daily care for the ostomy site, and the potential for recurrent urinary tract infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H21#H21\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Suprapubic catheter placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H755484016\">",
"    <span class=\"h3\">",
"     Perineal urethrostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who wish to avoid urethral reconstruction, an alternative solution to a permanent suprapubic catheter is urinary diversion using a perineal urethrostomy (",
"    <a class=\"graphic graphic_picture graphicRef64813 \" href=\"mobipreview.htm?23/6/23654\">",
"     picture 1",
"    </a>",
"    ). Perineal urethrostomy is an appealing solution, particularly in the elderly population, since it offers a simple solution that improves the quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/30\">",
"     30",
"    </a>",
"    ]. Perineal urethrostomy is a good option for patients with extensive or recurrent strictures, or for men who are already accustomed to voiding while seated.",
"   </p>",
"   <p>",
"    A perineal urethrostomy is created by making a flap in the perineal skin with an inverted U-incision, and suturing the bulbar urethra proximal to the stricture to the perineal skin with interrupted, absorbable suture. This flap-based technique decreases the likelihood of stenosis compared with a \"puncture\" technique for which the urethrostomy is created by direct cut-down onto the bulbar urethra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164138296\">",
"    <span class=\"h3\">",
"     Permanent urinary diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a last resort for refractory, recurrent or nonreconstructible, severe urethral stricture disease, permanent urinary diversion can be performed with supravesical ureteral diversion (urostomy). The procedure is performed in a similar manner as following cystectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/34/32298?source=see_link\">",
"     \"Urinary diversion and reconstruction following cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293655504\">",
"    <span class=\"h2\">",
"     Penile flaps and grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal urethral graft has a thick epithelial layer, a thin lamina propria, is easy to harvest with minimal donor site problems, has adequate tissue availability, and shrinks minimally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/31\">",
"     31",
"    </a>",
"    ]. Buccal grafts have all these qualities and are naturally resistant to infection and skin diseases such as Lichen Sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/32\">",
"     32",
"    </a>",
"    ]. The mouth donor site heals quickly with minimal morbidity and complications, and thus, buccal grafts are the graft tissue of choice for urethral reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The risk of buccal donor site complications is increased in smokers, tobacco chewers and others with poor oral hygiene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penile or scrotal skin can be used as flap tissue for onlay reconstruction but are less desirable when used as a urethral graft due to failure rates of 20 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. Bladder mucosa is another alternative but harvest requires laparotomy and more prolonged recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/37\">",
"     37",
"    </a>",
"    ]. Other free graft tissues harvested from the rectum, bladder, thigh, or the postauricular area can be used but should only be reserved in cases where more optimal tissues are not available for the reconstruction, which is rare.",
"   </p>",
"   <p>",
"    Whether a urethral graft should be placed in a ventral or dorsal position remains controversial. We prefer dorsal graft placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The dorsal graft bed is well-vascularized (from the corporal bodies) and inelastic which prevents pseudodiverticulum formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/40\">",
"     40",
"    </a>",
"    ]. Spread fixation, in which the graft is attached to the corporal body with fine absorbable stitches may preserve dorsal graft width, and thus, urethral caliber [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/40\">",
"     40",
"    </a>",
"    ]. On the other hand, ventral grafts have the advantage of ease of exposure while still maintaining the ability to excise the stricture, if needed. Some studies have reported stricture-free outcomes for ventral grafts that are equal to those of dorsal grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/4,41-43\">",
"     4,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293654703\">",
"    <span class=\"h2\">",
"     Urethroplasty technique by location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for urethroplasty include excision with primary anastomosis (anastomotic urethroplasty), incision with onlay graft or flap repair, and stricture excision with an anastomosis that is augmented with a graft (excisional augmented anastomotic urethroplasty). Repairs can be staged, if needed. The chosen surgical technique depends upon the segment of urethra that is affected and length of the stricture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601333\">",
"    <span class=\"h3\">",
"     Meatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meatal strictures in adults most commonly arise from instrumentation injury, skin disorders, or failed juvenile hypospadias repair (meatotomy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=see_link&amp;anchor=H15#H15\">",
"     \"Hypospadias\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meatal strictures often initially respond well to minimally-invasive techniques such as dilation or urethrotomy. When minimally-invasive techniques fail, we use extended meatoplasty as a definitive treatment of most meatal strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/5\">",
"     5",
"    </a>",
"    ]. Other surgical techniques include flap-based repairs, various plastic operations of the glans of the penis and staged grafting repairs using buccal mucosa.",
"   </p>",
"   <p>",
"    To perform and extend meatoplasty, an incision is made on the ventral surface of the penis and the meatus opened as far proximal as needed to identify normal urethral tissue, which essentially creates a hypospadiac meatus (",
"    <a class=\"graphic graphic_picture graphicRef78629 \" href=\"mobipreview.htm?3/41/3735\">",
"     picture 2",
"    </a>",
"    ). A triangle of tissue is removed and fine interrupted absorbable sutures are used to attach the urethral edges to the skin.",
"   </p>",
"   <p>",
"    Patients with failed juvenile hypospadias repair generally require staged reconstructive surgical operations. In the first stage, the prior reconstructed neourethra is excised and replaced with a buccal mucosa graft that is sutured to the corpora cavernosa to construct a urethral plate. After six months to a year after this repair has healed, the graft is tubularized in a second operation to form a new urethra.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601340\">",
"    <span class=\"h3\">",
"     Pendulous urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred management of strictures of the pendulous urethra (other than those due to Lichen Sclerosus) is an onlay flap using penile skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]. The stricture is incised along its entire length to include an additional centimeter proximal and distal into normal urethral tissue. The scar tissue is generally left in place but can be excised. The urethral lumen is augmented with the penile skin flap, which is rolled over and sutured into place.",
"   </p>",
"   <p>",
"    Circumcised men usually have ample penile skin that allows harvesting of a longitudinal flap of sufficient width to lay over the stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/51\">",
"     51",
"    </a>",
"    ]. In uncircumcised men, a transverse flap of foreskin is an alternative source of onlay tissue, but the technique is more complicated. Other flaps harvested from the prepuce or the shaft of the penis (J flaps) allow repair of pendulous urethral strictures up to 15 cm in length.",
"   </p>",
"   <p>",
"    Optimal results are achieved with excision of narrowed segments prior to placing the onlay graft, but the risk of penile chordee during erection is increased with urethral excision in the pendulous urethra. If excision is performed, a lengthy mobilization of the penoscrotal urethra may be needed, which relies on adequate proximal and distal blood supply. If the blood supply is normal, this technique works well (",
"    <a class=\"graphic graphic_figure graphicRef53027 \" href=\"mobipreview.htm?40/3/41009\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H293655215\">",
"     'Anatomy and pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601347\">",
"    <span class=\"h3\">",
"     Bulbar urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulbar urethral strictures are preferably managed with excision of the tightest segment of the stricture, when possible, removal of the majority of the associated spongiofibrosis, and, if needed, onlay coverage with a buccal graft. (See",
"    <a class=\"local\" href=\"#H755485300\">",
"     'Spongiofibrosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The graft augments the anastomosis or the stricture in its entirety. Prior to the development of this technique, flap-based repairs (using pedicled islands of penile skin or even scrotal skin) and tubularized graft urethroplasties were used to repair bulbar urethral strictures; however, these repairs failed in up to 56 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/36,52\">",
"     36,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stricture length is not a strict determinant for the use of this technique since larger genitalia may allow lengthier urethral mobilization, or a greater tolerance for penile shortening. In general, based upon the length of the stricture, management is as follows (lengths given are approximations and intraoperative findings dictate the choice of procedure):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For strictures &lt;2 cm in length (including adjacent spongiofibrosis) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57667 \" href=\"mobipreview.htm?13/40/13953\">",
"       image 1A",
"      </a>",
"      ), stricture excision and primary re-anastomosis (anastomotic urethroplasty) (",
"      <a class=\"graphic graphic_figure graphicRef67397 \" href=\"mobipreview.htm?34/11/34992\">",
"       figure 3",
"      </a>",
"      ) is ideal and has excellent long-term results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For strictures measuring 2 to 4 cm (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75050 \" href=\"mobipreview.htm?0/18/288\">",
"       image 1B",
"      </a>",
"      ), excisional augmented anastomotic urethroplasty is used (",
"      <a class=\"graphic graphic_figure graphicRef56084 \" href=\"mobipreview.htm?1/37/1617\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/52\">",
"       52",
"      </a>",
"      ]. The narrowest portion of the stricture is segmentally excised. The ventral urethra is re-anastomosed while the dorsal urethra is spatulated and augmented with an onlay graft (usually buccal) applied with a spread-fixed technique to the corporal body.",
"     </li>",
"     <li>",
"      Longer strictures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72649 \" href=\"mobipreview.htm?17/60/18369\">",
"       image 1C",
"      </a>",
"      ) that are not amenable to repair with segmental resection alone can be managed with a dorsal onlay repair (",
"      <a class=\"graphic graphic_figure graphicRef67840 \" href=\"mobipreview.htm?1/57/1937\">",
"       figure 5",
"      </a>",
"      ) or excisional augmented anastomotic urethroplasty, which requires excision of the tightest part of the stricture and augmented anastomosis utilizing penile skin or buccal tissue graft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/31\">",
"       31",
"      </a>",
"      ]. Excisional augmented anastomotic urethroplasty has more favorable long-term results compared with dorsal onlay alone. In a study involving 250 men, excisional augmented anastomotic urethroplasty was used to manage long strictures in 11 men which remained successful in 10 at 22 months follow up, and without resulting in the chordee with erection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1310601361\">",
"    <span class=\"h3\">",
"     Posterior urethra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strictures of the posterior urethra include those of the bladder neck, prostatic urethra and membranous urethra. Bladder neck and prostatic strictures, which can be the result of radiation therapy, are managed primarily with urethral dilation, transurethral tissue resection and placement of stents in recalcitrant cases. (See",
"    <a class=\"local\" href=\"#H293654928\">",
"     'Urethral dilation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H733682315\">",
"     'Urethral stenting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stricture of the membranous urethra is due to iatrogenic or traumatic injury. The remainder of the discussion focuses on traumatic injury which occurs in approximately 10 percent of pelvic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/55\">",
"     55",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The severity of the traumatic injury determines the severity of the urethral defect, ranging from elongation without disruption of the urethra to complete transection (",
"    <a class=\"graphic graphic_picture graphicRef72110 \" href=\"mobipreview.htm?12/16/12550\">",
"     picture 3",
"    </a>",
"    ). The resulting &ldquo;stricture&rdquo; is technically a distraction defect characterized by obliteration of the urethral lumen. When urethral injury is suspected (blood at the meatus, high-riding prostate) in the patient with pelvic trauma, a retrograde urethrogram should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18425?source=see_link&amp;anchor=H12#H12\">",
"     \"Blunt genitourinary trauma\", section on 'Retrograde urethrogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no extravasation is seen, a Foley catheter is inserted and a cystogram is performed. An upper tract study is performed, as indicated. When a posterior urethral injury is present and a urethral catheter cannot be placed across the defect, the conservative option for management is placement of a suprapubic drainage catheter and delayed definitive urethroplasty three to six months later. The interval period allows resolution of hematoma and descent of the prostate, thus shortening the length of the defect. (See",
"    <a class=\"local\" href=\"#H293655869\">",
"     'Delayed secondary repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8424253\">",
"    <span class=\"h4\">",
"     Primary realignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute surgical intervention is indicated if the posterior urethral distraction defect is very long, such as in the uncommon situation when pelvic fracture is associated with rectal injury, large pelvic hematoma, or concomitant bladder or bladder neck injury. When immediate repair is indicated, the urethra can be realigned immediately or after a short delay. These options are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate realignment &ndash; Immediate",
"      <strong>",
"      </strong>",
"      (primary) realignment of urethral injury has been performed with good success using a variety of techniques. In patients with urethral continuity on retrograde urethrogram but with extravasation (partial disruption), endoscopic guidance is used to position a guidewire over which a stenting catheter is placed. Other techniques use magnetic guides, interlocking urethral sounds and a combination of endoscopic or fluoroscopic guidance to position the stenting catheter. Recurrent stricture occurs in 50 to 100 percent of patients who undergo immediate realignment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Additional procedures are often needed.",
"     </li>",
"     <li>",
"      Delayed realignment &ndash; Delayed (secondary) management is an alternative for selected patients who are medically stable and who can be taken to the operating room within 5 to 10 days. Urethral realignment is accomplished using two flexible endoscopes. The antegrade endoscope is passed through the suprapubic tube tract and through the bladder neck into the injury hematoma. The suprapubic tube would have been placed for bladder decompression percutaneously or during an associated open surgical procedure at the time of the injury. A retrograde endoscope provides irrigation that helps in identifying the urethral defect. A linking guidewire is passed antegrade, over which the stenting catheter is passed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293655869\">",
"    <span class=\"h4\">",
"     Delayed secondary repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed (secondary) repair",
"    <strong>",
"    </strong>",
"    is undertaken three or more months after injury and acute placement of a suprapubic catheter. Prior to surgery, a combined retrograde urethrogram and antegrade cystogram (&ldquo;up and down o-gram&rdquo;) is performed to identify the length of the defect and any associated pathology, such as bladder neck incompetence, fistula to the rectum or skin, or bladder stones.",
"   </p>",
"   <p>",
"    The majority of posterior urethral distraction defects are reconstructed with a one-stage perineal anastomotic urethroplasty, which is a surgical approach. This procedure can manage long obliterative strictures. An abdominoperineal approach is needed to manage complex strictures using substitution urethroplasty in fewer than 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The perineal anastomotic repair involves mobilization of the urethra as a distally-based urethral flap. The urethra is transected at the proximal point of its obliteration by cutting down onto the tip of a sound passed through the suprapubic catheter tract into the proximal urethral stump. The bulbar urethra is then anastomosed to the prostatomembranous urethra proximal to the obliteration. We spatulate the bulbar urethra dorsally and the prostatic urethra posteriorly and perform the anastomosis with interrupted 4&ndash;0 polyglycolic acid sutures over a supporting 12 French fenestrated silastic catheter.",
"   </p>",
"   <p>",
"    A tension-free anastomosis can be accomplished by mobilizing an adequate length of urethra using a combination of techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/57\">",
"     57",
"    </a>",
"    ]. In our series of 40 patients, circumferential mobilization of the distal urethra to the suspensory ligament of the penis provided 2 to 3 cm of length sufficient for anastomosis in 8 percent of patients. Separation of the proximal corporal bodies shortened the defect by 1 to 2 cm and was sufficient for anastomosis in 41 percent. Inferior pubectomy, which is performed by resecting a 1.5 to 2 cm wide wedge of bone from the inferior surface of the pubis, further shortened the defect by 1 to 2 cm and was used to facilitate anastomosis in 28 percent. Rerouting the urethra around the lateral surface of a corporal body provided another 1 to 2 cm of length and was needed in the remaining 23 percent. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293656277\">",
"    <span class=\"h2\">",
"     Outcomes of urethroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethroplasty in adult patients can be a challenging and difficult problem despite its apparent simplicity. The overall failure rate was 15 percent in a study involving 252 males (median follow up 37 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/60\">",
"     60",
"    </a>",
"    ]. Failure rates were lowest for anastomotic urethroplasty (12 percent), intermediate for free graft repairs (16 percent) and highest for flap and more complicated repairs (20 percent). In a study with 15 year follow-up, anastomotic urethroplasty was found to be durable, whereas substitution urethroplasty (graft or flap) was associated with increasing rates of recurrent stricture over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Representative outcomes are presented below for each segment of the urethra.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meatal stricture repairs are associated with complications in up to 50 percent of cases, including the development of fistula, recurrent stenosis and breakdown of the repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pendulous urethral stricture repairs with onlay flaps have recurrence rates between 20 and 30 percent. Fistula, penile curvature with erection (chordee), penile paresthesias, and penile urethral diverticulum can also complicate these repairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/44-48\">",
"       44-48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bulbar urethral strictures using anastomotic urethroplasty and augmented anastomotic urethroplasty with buccal tissue have overall success rates greater than 90 percent when performed by an experienced surgeon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/18,21,30,52,53,60,62\">",
"       18,21,30,52,53,60,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posterior urethroplasty similarly has high success rates (&gt;90 percent). Failed posterior urethral repairs can generally be salvaged using the same procedure using additional steps for urethral mobilization. Urinary continence is preserved if the patient has a competent bladder neck and de novo erectile dysfunction is low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293654735\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last decade, the duration of hospitalization for patients undergoing urethroplasty has progressively shortened. Outpatient surgery for urethral stricture disease has lowered cost and increased patient satisfaction without compromising patient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36617/abstract/65\">",
"     65",
"    </a>",
"    ]. We plan for same-day surgery as the norm with only those patients undergoing posterior urethroplasty admitted overnight.",
"   </p>",
"   <p>",
"    A small, 12 to 14 French Foley catheter is left in place following urethroplasty. The catheter is maintained for 10 days following primary anastomotic urethroplasty, or three weeks after augmented or posterior repairs. The patient is discharged with no activity restrictions.",
"   </p>",
"   <p>",
"    The catheter is removed in the clinic provided a pericatheter retrograde urethrogram does not show extravasation of contrast. The patient should be seen in follow-up at three months postoperatively, and then yearly thereafter, for a physical examination, a Uroflow test, and American Urologic Association (AUA) symptom score (",
"    <a class=\"graphic graphic_table graphicRef81331 \" href=\"mobipreview.htm?4/5/4189\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293653333\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urethral strictures in men are common and are most often due to trauma or instrumentation of the urethra. Other frequent causes of urethral stricture include injury (pelvic fracture) and infection. (See",
"      <a class=\"local\" href=\"#H1310601282\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The male urethra is divided into two major segments; the anterior urethra and the posterior urethra. The anterior urethra begins at the meatus of the penis and includes the fossa navicularis, the pendulous urethra, and the bulbar urethra. The posterior urethra includes the membranous urethra, prostatic urethra, and the bladder neck. (See",
"      <a class=\"local\" href=\"#H293655215\">",
"       'Anatomy and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally-invasive techniques to manage urethral strictures include dilation with balloons or serial dilators, and endoscopic-guided stricture incision (urethrotomy) using cold knife incision, electrocautery, or laser. Many of these procedures may be performed safely in the office using local anesthesia and a mild sedative. Serial urethral dilation is commonly used to acutely manage urinary obstruction due to urethral stricture. (See",
"      <a class=\"local\" href=\"#H1310601312\">",
"       'Minimally-invasive therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H699571\">",
"       'Bladder decompression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antibiotic prophylaxis prior to cystourethroscopy or surgery for the treatment of urethral strictures (",
"      <a class=\"graphic graphic_table graphicRef60938 \" href=\"mobipreview.htm?25/11/25787\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Antibiotics for routine cystoscopy without urinary tract manipulation (eg, dilation) are not necessary. Patients with colonization or symptomatic urinary tract infection should be treated and instrumentation or surgery delayed until the urine is clear. Sterile urine should be verified prior to the procedure. (See",
"      <a class=\"local\" href=\"#H8422039\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest a single attempt to treat urethral stricture using endoscopic urethrotomy prior to surgical reconstruction instead of multiple, repeated endoscopic procedures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endoscopic urethrotomy is quick, widely available, and safe. Long-term success rates (freedom from recurrent symptomatic stricture) are overall poor, but are improved when treatment is limited to strictures that are &lt;1 cm and located in the mid-bulbar urethra and have at least 5 mm of preserved lumen. Some patients may not be candidates for other forms of treatment and multiple endoscopic approaches may be appropriate. (See",
"      <a class=\"local\" href=\"#H1310601312\">",
"       'Minimally-invasive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with long strictures, an obliterated urethral lumen, or strictures involving the meatus, posterior urethral or pendulous urethra, surgical urethroplasty provides superior outcomes. The choice of surgical technique is based upon the length of the stricture and anatomic segment of the urethra that is affected. Long-term success rates (freedom from recurrent symptomatic stricture) for anastomotic urethroplasty are &gt;90 percent. (See",
"      <a class=\"local\" href=\"#H1310601326\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who cannot or who are unwilling to undergo urethroplasty or those with nonreconstructible severe urethral stricture disease, the perineal urethrostomy and sometimes urinary diversion are options. (See",
"      <a class=\"local\" href=\"#H699767\">",
"       'Urinary diversion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/1\">",
"      Lumen N, Hoebeke P, Willemsen P, et al. Etiology of urethral stricture disease in the 21st century. J Urol 2009; 182:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/2\">",
"      Bullock TL, Brandes SB. Adult anterior urethral strictures: a national practice patterns survey of board certified urologists in the United States. J Urol 2007; 177:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/3\">",
"      Barbagli G, Palminteri E, Lazzeri M, et al. Long-term outcome of urethroplasty after failed urethrotomy versus primary repair. J Urol 2001; 165:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/4\">",
"      Barbagli G, Palminteri E, Guazzoni G, et al. Bulbar urethroplasty using buccal mucosa grafts placed on the ventral, dorsal or lateral surface of the urethra: are results affected by the surgical technique? J Urol 2005; 174:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/5\">",
"      Morey AF, Lin HC, DeRosa CA, Griffith BC. Fossa navicularis reconstruction: impact of stricture length on outcomes and assessment of extended meatotomy (first stage Johanson) maneuver. J Urol 2007; 177:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/6\">",
"      Steenkamp JW, Heyns CF, de Kock ML. Outpatient treatment for male urethral strictures--dilatation versus internal urethrotomy. S Afr J Surg 1997; 35:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/7\">",
"      Morey AF, McAninch JW. Sonographic staging of anterior urethral strictures. J Urol 2000; 163:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/8\">",
"      Ather MH, Zehri AA, Soomro K, Nazir I. The safety and efficacy of optical urethrotomy using a spongiosum block with sedation: a comparative nonrandomized study. J Urol 2009; 181:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/9\">",
"      Munks DG, Alli MO, Goad EH. Optical urethrotomy under local anaesthesia is a feasible option in urethral stricture disease. Trop Doct 2010; 40:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/10\">",
"      Stone AR, Randall JR, Shorrock K, et al. Optical urethrotomy--a 3-year experience. Br J Urol 1983; 55:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/11\">",
"      Badlani GH, Press SM, Defalco A, et al. Urolume endourethral prosthesis for the treatment of urethral stricture disease: long-term results of the North American Multicenter UroLume Trial. Urology 1995; 45:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/12\">",
"      Parikh AM, Milroy EJ. Precautions and complications in the use of the urolume wallstent. Eur Urol 1995; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/13\">",
"      Wilson TS, Lemack GE, Dmochowski RR. UroLume stents: lessons learned. J Urol 2002; 167:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/14\">",
"      Hussain M, Greenwell TJ, Shah J, Mundy A. Long-term results of a self-expanding wallstent in the treatment of urethral stricture. BJU Int 2004; 94:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/15\">",
"      Chapple CR, Bhargava S. Management of the failure of a permanently implanted urethral stent-a therapeutic challenge. Eur Urol 2008; 54:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/16\">",
"      Elliott DS, Boone TB. Combined stent and artificial urinary sphincter for management of severe recurrent bladder neck contracture and stress incontinence after prostatectomy: a long-term evaluation. J Urol 2001; 165:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/17\">",
"      Albers P, Fichtner J, Br&uuml;hl P, M&uuml;ller SC. Long-term results of internal urethrotomy. J Urol 1996; 156:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/18\">",
"      Pansadoro V, Emiliozzi P. Internal urethrotomy in the management of anterior urethral strictures: long-term followup. J Urol 1996; 156:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/19\">",
"      Steenkamp JW, Heyns CF, de Kock ML. Internal urethrotomy versus dilation as treatment for male urethral strictures: a prospective, randomized comparison. J Urol 1997; 157:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/20\">",
"      Rourke KF, Jordan GH. Primary urethral reconstruction: the cost minimized approach to the bulbous urethral stricture. J Urol 2005; 173:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/21\">",
"      Anger JT, Buckley JC, Santucci RA, et al. Trends in stricture management among male Medicare beneficiaries: underuse of urethroplasty? Urology 2011; 77:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/22\">",
"      Morey A. Urethral stricture is now an open surgical disease. J Urol 2009; 181:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/23\">",
"      Heyns CF, Steenkamp JW, De Kock ML, Whitaker P. Treatment of male urethral strictures: is repeated dilation or internal urethrotomy useful? J Urol 1998; 160:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/24\">",
"      Wright JL, Wessells H, Nathens AB, Hollingworth W. What is the most cost-effective treatment for 1 to 2-cm bulbar urethral strictures: societal approach using decision analysis. Urology 2006; 67:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/25\">",
"      Greenwell TJ, Castle C, Andrich DE, et al. Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective. J Urol 2004; 172:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/26\">",
"      Wessells H. Cost-effective approach to short bulbar urethral strictures supports single internal urethrotomy before urethroplasty. J Urol 2009; 181:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/27\">",
"      Roehrborn CG, McConnell JD. Analysis of factors contributing to success or failure of 1-stage urethroplasty for urethral stricture disease. J Urol 1994; 151:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/28\">",
"      Singh BP, Andankar MG, Swain SK, et al. Impact of prior urethral manipulation on outcome of anastomotic urethroplasty for post-traumatic urethral stricture. Urology 2010; 75:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/29\">",
"      Breyer BN, McAninch JW, Whitson JM, et al. Multivariate analysis of risk factors for long-term urethroplasty outcome. J Urol 2010; 183:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/30\">",
"      Barbagli G, De Angelis M, Romano G, Lazzeri M. Clinical outcome and quality of life assessment in patients treated with perineal urethrostomy for anterior urethral stricture disease. J Urol 2009; 182:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/31\">",
"      Wessells H, McAninch JW. Current controversies in anterior urethral stricture repair: free-graft versus pedicled skin-flap reconstruction. World J Urol 1998; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/32\">",
"      Andrich DE, Leach CJ, Mundy AR. The Barbagli procedure gives the best results for patch urethroplasty of the bulbar urethra. BJU Int 2001; 88:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/33\">",
"      Dubey D, Vijjan V, Kapoor R, et al. Dorsal onlay buccal mucosa versus penile skin flap urethroplasty for anterior urethral strictures: results from a randomized prospective trial. J Urol 2007; 178:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/34\">",
"      Barbagli G, Vallasciani S, Romano G, et al. Morbidity of oral mucosa graft harvesting from a single cheek. Eur Urol 2010; 58:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/35\">",
"      Sinha RJ, Singh V, Sankhwar SN, Dalela D. Donor site morbidity in oral mucosa graft urethroplasty: implications of tobacco consumption. BMC Urol 2009; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/36\">",
"      Mundy AR. The long-term results of skin inlay urethroplasty. Br J Urol 1995; 75:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/37\">",
"      Monfort G, Bretheau D, Di Benedetto V, Bankole R. Urethral stricture in children: treatment by urethroplasty with bladder mucosa graft. J Urol 1992; 148:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/38\">",
"      Barbagli G, Selli C, di Cello V, Mottola A. A one-stage dorsal free-graft urethroplasty for bulbar urethral strictures. Br J Urol 1996; 78:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/39\">",
"      Wang K, Miao X, Wang L, Li H. Dorsal onlay versus ventral onlay urethroplasty for anterior urethral stricture: a meta-analysis. Urol Int 2009; 83:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/40\">",
"      Iselin CE, Webster GD. Dorsal onlay graft urethroplasty for repair of bulbar urethral stricture. J Urol 1999; 161:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/41\">",
"      Elliott SP, Metro MJ, McAninch JW. Long-term followup of the ventrally placed buccal mucosa onlay graft in bulbar urethral reconstruction. J Urol 2003; 169:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/42\">",
"      Kane CJ, Tarman GJ, Summerton DJ, et al. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol 2002; 167:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/43\">",
"      Wessells H. Ventral onlay graft techniques for urethroplasty. Urol Clin North Am 2002; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/44\">",
"      McAninch JW. Reconstruction of extensive urethral strictures: circular fasciocutaneous penile flap. J Urol 1993; 149:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/45\">",
"      Mundy AR, Stephenson TP. Pedicled preputial patch urethroplasty. Br J Urol 1988; 61:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/46\">",
"      Orandi A. One-stage urethroplasty. Br J Urol 1968; 40:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/47\">",
"      Orandi A. One-stage urethroplasty: 4-year followup. J Urol 1972; 107:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/48\">",
"      Quartey JK. One-stage penile/preputial cutaneous island flap urethroplasty for urethral stricture: a preliminary report. J Urol 1983; 129:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/49\">",
"      Reid RE. Turner-Warwick urethroplasty and urethral stricture. Results in 60 patients. Urology 1975; 6:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/50\">",
"      Zinman L, Libertino JA. Turner-Warwick urethroplasty for membranous urethral stricture. Revised technique. Urology 1973; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/51\">",
"      Schulte-Baukloh H, St&uuml;rzebecher B, Bl&ouml;mers F, et al. Orandi one-stage urethroplasty using the subcutaneous pedicle graft modification of Raatzsch--long-term results. Scand J Urol Nephrol 2004; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/52\">",
"      Guralnick ML, Webster GD. The augmented anastomotic urethroplasty: indications and outcome in 29 patients. J Urol 2001; 165:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/53\">",
"      Santucci RA, Mario LA, McAninch JW. Anastomotic urethroplasty for bulbar urethral stricture: analysis of 168 patients. J Urol 2002; 167:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/54\">",
"      Morey AF, Kizer WS. Proximal bulbar urethroplasty via extended anastomotic approach--what are the limits? J Urol 2006; 175:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/55\">",
"      Glass RE, Flynn JT, King JB, Blandy JP. Urethral injury and fractured pelvis. Br J Urol 1978; 50:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/56\">",
"      Elliott DS, Barrett DM. Long-term followup and evaluation of primary realignment of posterior urethral disruptions. J Urol 1997; 157:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/57\">",
"      Webster GD, Sihelnik S. The management of strictures of the membranous urethra. J Urol 1985; 134:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/58\">",
"      Flynn BJ, Delvecchio FC, Webster GD. Perineal repair of pelvic fracture urethral distraction defects: experience in 120 patients during the last 10 years. J Urol 2003; 170:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/59\">",
"      Webster GD, Ramon J, Kreder KJ. Salvage posterior urethroplasty after failed initial repair of pelvic fracture membranous urethral defects. J Urol 1990; 144:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/60\">",
"      Lumen N, Hoebeke P, Oosterlinck W. Urethroplasty for urethral strictures: quality assessment of an in-home algorithm. Int J Urol 2010; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/61\">",
"      Andrich DE, Dunglison N, Greenwell TJ, Mundy AR. The long-term results of urethroplasty. J Urol 2003; 170:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/62\">",
"      Barbagli G, Guazzoni G, Lazzeri M. One-stage bulbar urethroplasty: retrospective analysis of the results in 375 patients. Eur Urol 2008; 53:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/63\">",
"      Koraitim MM. The lessons of 145 posttraumatic posterior urethral strictures treated in 17 years. J Urol 1995; 153:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/64\">",
"      Iselin CE, Webster GD. The significance of the open bladder neck associated with pelvic fracture urethral distraction defects. J Urol 1999; 162:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36617/abstract/65\">",
"      Lewis JB, Wolgast KA, Ward JA, Morey AF. Outpatient anterior urethroplasty: outcome analysis and patient selection criteria. J Urol 2002; 168:1024.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15175 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36617=[""].join("\n");
var outline_f35_48_36617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H293653333\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601282\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293655215\">",
"      ANATOMY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H755485300\">",
"      Spongiofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698386\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699047\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601305\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8421895\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8422039\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699571\">",
"      Bladder decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699578\">",
"      Defining the stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601312\">",
"      MINIMALLY-INVASIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H698687\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H293654928\">",
"      - Urethral dilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H293654935\">",
"      - Endoscopic urethrotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H733682315\">",
"      - Urethral stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293656380\">",
"      Outcomes of minimally-invasive therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601326\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H699767\">",
"      Urinary diversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H699775\">",
"      - Suprapubic catheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H755484016\">",
"      - Perineal urethrostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164138296\">",
"      - Permanent urinary diversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293655504\">",
"      Penile flaps and grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293654703\">",
"      Urethroplasty technique by location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601333\">",
"      - Meatus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601340\">",
"      - Pendulous urethra",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601347\">",
"      - Bulbar urethra",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1310601361\">",
"      - Posterior urethra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8424253\">",
"      Primary realignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H293655869\">",
"      Delayed secondary repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293656277\">",
"      Outcomes of urethroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293654735\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293653333\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15175|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/40/13953\" title=\"diagnostic image 1A\">",
"      Retrograde urethrogram with short stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/18/288\" title=\"diagnostic image 1B\">",
"      Retrograde urethrogram with moderate stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/60/18369\" title=\"diagnostic image 1C\">",
"      Retrograde urethrogram with severe stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15175|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/15/30965\" title=\"figure 1\">",
"      Urethral anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/3/41009\" title=\"figure 2\">",
"      Blood supply to the urethra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/11/34992\" title=\"figure 3\">",
"      Primary repair of urethral stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/37/1617\" title=\"figure 4\">",
"      Augmented urethroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/57/1937\" title=\"figure 5\">",
"      Dorsal onlay repair of urethral stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15175|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/6/23654\" title=\"picture 1\">",
"      Perineal urethrostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/41/3735\" title=\"picture 2\">",
"      Extended meatoplasty repair of meatal stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/16/12550\" title=\"picture 3\">",
"      Traumatic urethral injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/11/25787\" title=\"table 1\">",
"      Etiology of urethral stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/5/4189\" title=\"table 2\">",
"      AUA Urinary Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14872?source=related_link\">",
"      Balanitis and balanoposthitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/34/32298?source=related_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36618="Epithelial ovarian cancer: Initial surgical management";
var content_f35_48_36618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epithelial ovarian cancer: Initial surgical management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Eva Chalas, MD, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Fidel A Valea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/48/36618/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/48/36618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of women with ovarian cancer is surgical. However, many women with ovarian cancer, particularly early stage disease, do not receive optimal surgical staging and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Consultation with a gynecologic oncologist experienced in ovarian cancer surgery is crucial. Studies have consistently shown that surgical treatment by nongynecologic oncologists and by low volume providers contributes to suboptimal surgical management and shorter median survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/1,3-14\">",
"     1,3-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial surgical management of women with epithelial ovarian cancer (EOC) will be reviewed here. Clinical manifestations, diagnosis and staging, second look surgery, and chemotherapy (both postoperative and prior to initial surgery) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25847?source=see_link\">",
"     \"Epithelial ovarian cancer: Second look surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to some other types of cancer, surgery is almost always performed in women with suspected EOC, even when advanced. A surgical procedure is necessary to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain tissue to confirm the diagnosis",
"     </li>",
"     <li>",
"      Assess the extent of disease (ie, staging)",
"     </li>",
"     <li>",
"      Attempt optimal cytoreduction, which is crucial for successful treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Confirmation of clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small subset of women suspected of having primary ovarian cancer will prove to have a different primary or synchronous tumor at exploration, including tumors of the:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peritoneum",
"     </li>",
"     <li>",
"      Endometrium",
"     </li>",
"     <li>",
"      Fallopian tube",
"     </li>",
"     <li>",
"      Gastrointestinal tract (eg, gastric cancer with Krukenberg ovarian metastases)",
"     </li>",
"     <li>",
"      Breast",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete discussion of confirmation of a diagnosis of ovarian cancer is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H13733905#H13733905\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Excluding a synchronous primary cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H13733674#H13733674\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Excluding an extraovarian primary cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Peritoneal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal carcinoma (also known as serous carcinoma of the peritoneum) is another entity closely associated with, but distinct from, epithelial ovarian cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Histologically, this tumor is indistinguishable from serous ovarian carcinoma, but morphologic distinctions have been described.",
"   </p>",
"   <p>",
"    The pattern of spread is similar to that in women with EOC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Women with serous carcinoma of the peritoneum are treated similarly to those with EOC. Optimal surgical cytoreduction may be more difficult to achieve in the setting of widespread peritoneal disease without a predominant ovarian or pelvic mass.",
"   </p>",
"   <p>",
"    Peritoneal carcinoma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of EOC is determined by the stage of disease at the time of diagnosis, as expressed by the International Federation of Gynecology and Obstetrics",
"    <span class=\"nowrap\">",
"     (FIGO)/TNM",
"    </span>",
"    staging system (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients present with tumor confined to the ovary (stage I) or tumor beyond the ovary but confined to the pelvis (stage II). These patients are managed initially with a maximal cytoreductive procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Systemic chemotherapy may or may not be recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26231?source=see_link\">",
"     \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other 75 percent of women with EOC present with tumor that has spread throughout the peritoneal cavity or involves paraaortic or inguinal lymph nodes (stage III) or tumor that has spread to more distant sites (stage IV). The standard of care for these patients is surgery followed by systemic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/23\">",
"     23",
"    </a>",
"    ]. The combination of optimal cytoreductive surgery and effective platinum-based chemotherapy has led to significant improvements in survival for these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Exceptions to initial surgical staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary surgical cytoreduction followed by systemic chemotherapy is the preferred initial management for women with stage III or IV EOC. There are three exceptions to an initial surgical approach to management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a complex ovarian cyst in whom an extraovarian primary tumor has not been excluded.",
"     </li>",
"     <li>",
"      Patients with suspected ovarian cancer who are poor candidates for surgery because of significant comorbidities (eg, preexisting medical conditions, severe malnutrition, massive ascites). In such patients, an extensive surgical procedure confers a high risk of perioperative morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients in whom initial cytoreduction is not be feasible because of disease bulk. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Predicting optimal cytoreduction'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with bulky disease or poor performance status, an alternative approach is to establish the diagnosis of presumed ovarian cancer by a confirmatory biopsy or cytologic specimen (eg, from a peritoneal implant or ascitic fluid), followed by the administration of neoadjuvant chemotherapy. One potential advantage of this approach is the avoidance of aggressive surgery in women with chemoresistant disease, who have a poor outcome regardless of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient then has a response to therapy, and becomes a more appropriate surgical candidate, tumor debulking may be considered after chemotherapy. If such an approach is chosen, subsequent surgery should be performed as soon as feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoreductive surgery is the cornerstone of therapy for ovarian cancer. There are several potential benefits of aggressive primary surgical management in women with EOC, particularly those with advanced disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal response to postoperative systemic chemotherapy is achieved in the setting of minimal disease burden. Chemotherapeutic drugs exert their maximum effects on small tumors that are well perfused and therefore mitotically active. Larger tumor size is associated with poorer perfusion and a greater chance of sublethal cellular damage, as well as the emergence of multidrug-resistant clones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/28\">",
"       28",
"      </a>",
"      ]. These pharmacologic principles are supported clinically by the observation that both the relapse-free interval and median survival are inversely related to the size of the largest residual tumor mass at the completion of initial debulking prior to the start of induction chemotherapy.",
"     </li>",
"     <li>",
"      Disease-related symptoms (eg, abdominal pain, increased abdominal girth, dyspnea, early satiety) are related to tumor burden. Removal of bulky disease rapidly improves symptoms and quality of life.",
"     </li>",
"     <li>",
"      Ovarian neoplasms produce multiple cytokines, at least some of which are immunosuppressive (eg, interleukin-10, vascular endothelial growth factor) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. Removal of tumor bulk may improve or restore host immune competence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the survival benefit of cytoreduction, these procedures may be associated with significant morbidity and a potential delay in initiation of chemotherapy. As an example, in one study of women age 65 or older, having one or more radical cytoreductive procedures was associated with a delay in the start of chemotherapy by six or more weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Optimal cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that the volume of residual disease remaining after cytoreductive surgery inversely correlates with survival, as do stage of disease and grade of tumor differentiation (",
"    <a class=\"graphic graphic_table graphicRef63199 \" href=\"mobipreview.htm?11/44/11981\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67007 \" href=\"mobipreview.htm?36/25/37279\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]. Although tumor stage and differentiation cannot be changed, the volume of residual disease is within the surgeon's control.",
"   </p>",
"   <p>",
"    Debulking procedures only improve survival when optimal cytoreduction can be achieved. Women with optimally resected tumor have, on average, a 20-month improvement in median survival compared to those with suboptimal resection. A metaanalysis of over 53 studies with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy found a 5.5 percent increase in median survival for every 10 percent increase in the proportion of patients achieving maximal cytoreduction (defined in this analysis as &le;3 cm maximum tumor diameter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various definitions of optimally resected disease have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/37,41,42\">",
"     37,41,42",
"    </a>",
"    ]. The Gynecologic Oncology Group (GOG) defines optimal cytoreduction as residual disease that is less than 1 cm in maximum tumor diameter. However, this threshold has been challenged. A growing body of literature reports an association between cytoreduction to &lt;1 mm or to no visible disease and improved response to chemotherapy, less platinum resistance, and improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/37,43,44\">",
"     37,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient high quality evidence to support a recommendation to change the GOG definition at this time. These issues are difficult to evaluate in controlled trials since the clinical experience and aggressiveness of the surgeon are key determinants of optimal surgical resection. The intraoperative quantification of residual disease diameter is estimated by the surgeon, and has a subjective component. Prospective clinical trials often require a postoperative CT scan before initiating chemotherapy; however, the accuracy of CT for assessing residual disease has not been validated either. Poor correlation between the surgeon's estimate of residual disease and postoperative CT could be due to the surgeon's underestimation of residual disease, rapid regrowth of the tumor following surgery, or postoperative changes and inflammation following surgery that look like residual disease on CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical cytoreduction should be performed by gynecologic oncologists experienced in this surgery since achieving optimal cytoreduction depends, in part, on the judgment, experience, and aggressiveness of the surgeon. The surgical team should be prepared to undertake potentially extensive surgery, such as splenectomy, bowel resection, partial hepatectomy, and diaphragmatic resection to achieve an optimal procedure. Surgeons performing ovarian cancer surgery should monitor their personal success rates in achieving optimal cytoreduction. Expert surgeons achieve optimal cytoreduction in at least 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/33,46-49\">",
"     33,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors limiting the ability to achieve optimal cytoreduction may be technical or related to poor performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of extraabdominal or retroperitoneal disease, or large tumor bulk",
"     </li>",
"     <li>",
"      Bowel involvement",
"     </li>",
"     <li>",
"      Parenchymal liver involvement",
"     </li>",
"     <li>",
"      Presence of ascites",
"     </li>",
"     <li>",
"      Poor nutritional state",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rectosigmoid colon resection should be attempted in women with bulky abdominal disease if the procedure provides an opportunity for maximal cytoreduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. However, gastrointestinal surgery can add significant morbidity to surgical treatment. A thorough assessment of the intraabdominal findings should be performed prior to attempted resection. Bowel surgery is of little value if there are other areas of grossly unresectable disease, except to relieve gastrointestinal obstruction. Ultraradical surgery, including complex or multiple bowel resection, is associated with substantial morbidity and potential perioperative mortality, particularly in nutritionally depleted patients.",
"   </p>",
"   <p>",
"    Parenchymal hepatic metastases are not necessarily a contraindication to initial cytoreductive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In one series of 84 women with stage IV disease who underwent initial debulking surgery, 37 (44 percent) had parenchymal liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/59\">",
"     59",
"    </a>",
"    ]. Median survival was highest in women in whom optimal debulking of both intrahepatic and extrahepatic disease was achieved (survival 50 months versus less than 20 months in women with suboptimal debulking). Nevertheless, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio for optimal hepatic cytoreduction may be unfavorable if hepatic disease is bulky or involves major vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Predicting optimal cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to predict which patients can be optimally debulked. No set of criteria performs well enough for clinical use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor markers &mdash; The biologic characteristics of ovarian cancer (eg, molecular factors, tumor markers) are being investigated to improve the surgeon's ability to make this assessment and gauge the patient's response to surgical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/62-65\">",
"       62-65",
"      </a>",
"      ]. As an example, strong expression of the p53 tumor suppressor gene correlates with reduced likelihood of achieving complete cytoreduction; however, this information is only available after tissue has been obtained by an invasive procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A high preoperative CA 125 level has been associated with a lower likelihood of optimal cytoreduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/64,66\">",
"       64,66",
"      </a>",
"      ]. A meta-analysis of 14 studies found that a CA 125 of &ge;500",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      has a sensitivity and specificity for predicting optimal cytoreduction of 69 and 63 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Imaging &mdash; Scoring systems based upon the results of imaging studies such as computed tomography (CT) and magnetic resonance imaging (MRI) and combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      have also been investigated. Commonly used selection criteria for neoadjuvant chemotherapy include: stage IV disease, large volume ascites (&gt;1000 mL), bulky (&gt;1 cm to 2 cm) in the upper abdomen, omental extension to the spleen, suprarenal adenopathy, parenchymal liver disease, diaphragmatic disease, and peritoneal carcinomatosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/68\">",
"       68",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, use of preoperative imaging is difficult to apply clinically, and has not been validated in large studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/50,68-70\">",
"       50,68-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diagnostic laparoscopy &mdash; Diagnostic laparoscopy prior to laparotomy is may have role in some patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Use of laparoscopy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other patient characteristics &mdash; In a large case series, the likelihood of optimal cytoreduction was significantly higher in patients who were American Society of Anesthesiologists class 1 or 2, had carcinomatosis (defined as tumor nodules diffusely covering the majority of the surfaces of bowel serosa and the parietal peritoneum of the abdomen and pelvis), or were operated on by a surgeon who performed radical procedures in more than 50 percent of patients operated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"       \"Preoperative medical evaluation of the healthy patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Management after suboptimal cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the optimal initial management of most women with EOC is surgical cytoreduction to no or minimal disease; however, this may not always be possible. Whether the prognosis for women who are suboptimally cytoreduced can be improved if chemotherapy is followed by a second attempt at surgical cytoreduction (interval cytoreduction) is unclear. This issue has been addressed in three randomized trials, two of which failed to show a survival benefit for interval cytoreduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The two largest trials are described in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survival benefit was suggested in the Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC) trial in which 319 women with residual lesions greater than 1 cm in diameter after primary surgery were randomly assigned to receive six cycles of chemotherapy with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"        cisplatin",
"       </a>",
"      </span>",
"      alone or three cycles of chemotherapy followed by interval cytoreduction and then three more cycles of chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/73\">",
"       73",
"      </a>",
"      ]. Compared to the group who received chemotherapy alone, women who underwent a secondary attempt at debulking had significantly longer disease free survival and a significant six-month prolongation in median survival (26 versus 20 months).",
"     </li>",
"     <li>",
"      An attempt to duplicate these results in the United States by the Gynecologic Oncology Group (GOG 152) failed to confirm a survival benefit for interval cytoreduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/74\">",
"       74",
"      </a>",
"      ]. In this trial, 550 women with suboptimally debulked stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      ovarian cancer and performance status &ge;2 received three cycles of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"        paclitaxel",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"        cisplatin",
"       </a>",
"      </span>",
"      and then were randomly assigned to interval cytoreduction or no surgery. Chemotherapy was continued up to a maximum of six cycles. A secondary attempt at cytoreduction was not associated with an improvement in disease-free survival (12.5 versus 12.7 months), overall survival (36.2 versus 35.7 months), or quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/75\">",
"       75",
"      </a>",
"      ]. A much smaller trial was also negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important differences between these two large trials are that in the EORTC trial surgeons other than experienced gynecologic oncologists performed many of the initial procedures, there were more stage IV patients and patients with poor performance status, and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"    </span>",
"    was used instead of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"      paclitaxel",
"     </a>",
"     /cisplatin.",
"    </span>",
"    The most important difference appears to be that patients in the EORTC trial likely underwent less aggressive attempts at primary cytoreduction than those in the GOG trial. The number of patients with less than 5 cm residual tumor after primary surgery in the EORTC trial was fewer than one-third, compared to 55 percent in the GOG trial.",
"   </p>",
"   <p>",
"    Subsequently, a systematic review evaluated these three randomized trials and six nonrandomized studies of chemotherapy and interval cytoreduction following initial suboptimal surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/76\">",
"     76",
"    </a>",
"    ]. Women with suboptimally cytoreduced disease who then underwent chemotherapy and interval cytoreduction had survival rates that were inferior to those of women who underwent successful (optimal) primary surgery followed by chemotherapy. Furthermore, there appeared to be no survival benefit for interval cytoreduction after chemotherapy compared to chemotherapy alone.",
"   </p>",
"   <p>",
"    In summary, the best evidence suggests that aggressive initial surgical debulking is critical to outcome. A second attempt at cytoreduction after chemotherapy for suboptimally debulked disease does not provide an outcome that is equivalent to that achieved by aggressive initial surgical debulking followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and platinum-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/76\">",
"     76",
"    </a>",
"    ]. However, if the initial surgical attempt at cytoreduction was not a maximal surgical effort, then chemotherapy followed by secondary surgical cytoreduction might be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/73\">",
"     73",
"    </a>",
"    ]. An example of this situation is when the initial surgery is not performed by a gynecologic oncologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation should include nutritional assessment and assessment of intercurrent medical diseases, which should be under optimum control (eg, good glycemic control in women with diabetes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link\">",
"     \"Perioperative medication management\"",
"    </a>",
"    .) (See individual topic reviews on preoperative evaluation and management of medical conditions).",
"   </p>",
"   <p>",
"    We obtain the following preoperative laboratory tests: a complete blood count, liver and renal function tests, electrolytes, glucose, coagulation tests, and baseline CA 125. We also obtain a chest radiograph, electrocardiogram, and computed tomography (CT) of the abdomen. Liver imaging helps to determine whether metastatic disease, if present, is confined to surface implants or whether a partial hepatic resection of parenchymal disease may be required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H13733533#H13733533\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A symptomatic plural effusion, if present, can be drained via a chest tube to optimize pulmonary function during surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A central venous catheter may be useful for monitoring patients with ascites who are likely to have large fluid shifts perioperatively, particularly if they have underlying cardiac or renal disease.",
"   </p>",
"   <p>",
"    These patients are at high risk of venous thromboembolism (VTE) and should receive VTE prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. We suggest pharmacologic prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin (in addition to compression devices) as these agents appear to be effective and are not associated with excess intraoperative bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/77\">",
"     77",
"    </a>",
"    ]. Early ambulation in conjunction with intermittent pneumatic compression devices does not appear to be sufficient VTE prophylaxis, although data are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/77,79,80\">",
"     77,79,80",
"    </a>",
"    ]. The increased risk of thrombosis is highest in women with metastatic disease, medical comorbidities, clear cell histology, and in the first three months after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     USE OF LAPAROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic surgery has been used diagnostically to predict resectability of ovarian cancer and therapeutically for cytoreduction. One concern is the potential for tumor seeding of the laparoscopic access sites (port site metastasis), particularly the umbilicus. This usually occurs when there is peritoneal carcinomatosis or positive peritoneal cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7415?source=see_link&amp;anchor=H12#H12\">",
"     \"Complications of gynecologic laparoscopic surgery\", section on 'Port site metastasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carbon dioxide pneumoperitoneum does not appear to adversely affect survival in women with intraabdominal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnostic laparoscopy &mdash; Diagnostic laparoscopy may be useful for distinguishing women who can be optimally debulked at primary surgery. Data from prospective studies are promising [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/86-88\">",
"       86-88",
"      </a>",
"      ]. As an example, in one study, 113 women with a preoperative clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiological diagnosis of stage III or IV ovarian or peritoneal cancer underwent diagnostic laparoscopy followed by laparotomy with staging and cytoreduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/87\">",
"       87",
"      </a>",
"      ]. Use of laparoscopically detected features (omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver superficial metastasis) accurately predicted whether optimal cytoreduction could be achieved.",
"      <br/>",
"      <br/>",
"      However, in our experience, it may not be possible to confirm that a patient can be optimally debulked until the debulking procedure is underway. If diagnostic laparoscopy is performed, it should be done by a gynecologic oncologist experienced in laparoscopic assessment of cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laparoscopic cytoreduction &mdash; Laparoscopic surgical management of ovarian cancer is technically possible, but is not considered prudent by many experts. It is usually undertaken in young women with adnexal disease that is initially believed to be benign, but found to be malignant at exploration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major concern with laparoscopic cancer surgery is that intact removal of the ovarian mass is often not possible; ovarian cyst rupture occurs in 12 to 25 percent of adnexal masses managed laparoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential risk of intraoperative spillage of malignant cells is that it may result in rapid intraabdominal dissemination via the peritoneal circulation, thus worsening the prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. However, the clinical effect of rupturing an ovarian cancer, which can occur even at open procedures, is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. The rarity of this clinical condition makes prospective studies impossible. In the one study that included only patients who were completely staged (via laparotomy) and received platinum-based chemotherapy, 161 women with stage I EOC were followed for 47 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/95\">",
"     95",
"    </a>",
"    ]. There was a significant decrease in disease-free survival in women with stage IC with versus without intraoperative tumor capsule rupture, regardless of the presence of positive peritoneal cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/95\">",
"     95",
"    </a>",
"    ]. No significant disease-free survival difference was found between women with stage IC due solely to intraoperative capsule rupture versus women with stage IA or IB disease, however, the study was underpowered to detect a difference. This suggests rupture of a malignant cyst should be avoided. Many oncologists administer adjuvant chemotherapy to these patients unless the tumor is well differentiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Devices that allow a laparoscopic surgeon to place the ovarian tumor in a leakproof bag are available, but there are no data regarding the effect of these devices on tumor dissemination.",
"   </p>",
"   <p>",
"    Another question regarding laparoscopic initial surgery for EOC is whether the pelvis and abdomen can be inspected as thoroughly as with an open surgical approach. Certainly, surfaces cannot be directly palpated laparoscopically. However, data from small studies suggest that staging via laparoscopy is as accurate as via laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. However, laparoscopic EOC staging is still under investigation, and is not for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the purpose of laparotomy is to determine the site of origin of the cancer, extent of disease spread, presence of coexisting conditions, and feasibility of cytoreductive surgery. This is accomplished through visual assessment, palpation, and biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A vertical midline incision is the best approach for staging and primary cytoreductive surgery: it provides potentially unlimited exposure of the pelvis and abdomen, and access to the peritoneal cavity is gained rapidly and easily.",
"   </p>",
"   <p>",
"    Alternatively, a preexisting paramedian incision can be used to avoid the presence of parallel vertical abdominal incisions and devascularization of tissue between these incisions; however, access is more difficult. The rectus muscle on the side of the incision may be split or reflected to reach the midline. Closure of this paramedian incision is more complex, the appearance is less cosmetic, and patients generally experience more postoperative incisional discomfort.",
"   </p>",
"   <p>",
"    Pfannenstiel incisions should be avoided, but several options exist if this incision was chosen because of erroneous expectations of benign findings. In a slim patient, particularly with a mobile abdominal wall, the incision can be converted to a Maylard or Cherney incision, providing that the resulting exposure does not compromise the extent of surgery performed. It is also possible to flex the middle of the table, which facilitates operating in the upper abdomen. Alternatively, laparoscopic instruments can be introduced through a transverse incision, the abdominal wall manually elevated, and the upper abdomen explored and biopsied. A transverse incision can also be converted into a \"T\". The goal is to minimize technical limitations and maximize the possibility of optimal cytoreductive effort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Staging procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian malignancies are surgically staged according to the 2010 International Federation of Gynecology and Obstetrics (FIGO) system (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/100\">",
"     100",
"    </a>",
"    ]. The components of surgical staging are summarized in Table 3 (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"mobipreview.htm?40/8/41099\">",
"     table 3",
"    </a>",
"    ) and discussed in more detail below. At the completion of the staging operation, the involved organs and the regions most at risk of metastatic disease have been removed or sampled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Collection of fluid for cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any ascites should be collected as soon as the peritoneal cavity is entered and a representative sample sent for cytologic evaluation. The identification of a small volume of ascites, as opposed to normal amounts of peritoneal fluid, is subjective. Washings of the pelvis, paracolic gutters, and both diaphragms are obtained for staging purposes if ascites or extrapelvic tumor nodules are not identified. Washings are obtained by instilling and removing at least 50 to 100 mL of saline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Exploratory laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exploratory laparotomy is then carried out in a systematic manner, assessing the status of the pelvic organs, small and large intestine, mesentery, appendix, stomach, liver, gallbladder, spleen, omentum, both diaphragms, and the entire peritoneum. Retroperitoneal structures, such as the kidneys, pancreas, and lymph nodes, are palpated through the peritoneum and adipose tissue. The umbilicus is carefully palpated, as metastasis to the peritoneal side can occur, and excision is simple.",
"   </p>",
"   <p>",
"    The retroperitoneum may be accessed by dividing the round ligament as lateral as possible, and then developing the pararectal and paravesical spaces. The pararectal space is developed by sharp dissection between the medial leaflet of the broad ligament and the external and internal iliac vessel, taking care to protect the ureter on the medial leaflet and avoiding dissection lateral to the internal iliac artery, which lies inferior and medial to the external iliac vessel.",
"   </p>",
"   <p>",
"    The paravesical space is created by sharp dissection toward the pelvic floor between the superior vesical artery and the external iliac vessels. The pelvis can also be entered from the prevesical space or either paracolic gutter. A retroperitoneal approach is best if the pelvis appears \"frozen.\" This approach allows resection of tumor encroaching on bladder or bowel from a lateral aspect, beneath the bladder and posterior cul de sac reflections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Frozen section",
"    </span>",
"    &nbsp;&mdash;&nbsp;The affected adnexa should be removed intact and a frozen section obtained to confirm the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef64042 \" href=\"mobipreview.htm?4/33/4625\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=see_link\">",
"     \"Oophorectomy and ovarian cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an omental cake is present, the omentum may be removed prior to the adnexa and provides an adequate sample for frozen section (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Omentectomy'",
"    </a>",
"    below). Omentectomy early in the operation results in significant debulking and facilitates packing of the bowel to improve pelvic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of obvious stage IV disease, a full staging procedure is performed. Biopsies are taken from all suspicious areas. If suspicious areas are not apparent, multiple random biopsies are taken from peritoneal surfaces, including the posterior cul-de-sac (pouch of Douglas), bladder peritoneum, paracolic gutters, and bowel mesentery, to help detect micrometastases. Both diaphragms should be biopsied or scraped for cytology. Any adhesions or peritoneal surface irregularities should also be sampled, as tumor may be associated with an inflammatory or desmoplastic reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Omentectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The omentum is resected rather than biopsied. Resection of the omentum, especially when replaced by densely packed metastases (so-called omental cake), is performed even when optimal cytoreduction is not possible in order to decrease tumor bulk and postoperative ascites formation (",
"    <a class=\"graphic graphic_picture graphicRef74312 \" href=\"mobipreview.htm?10/52/11077\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The peritoneal reflection is separated off the transverse colon, after which the mesentery of the colon is identified and preserved. An infracolic or a complete omentectomy is then performed by isolating the gastroepiploic vessels with Kelly (or equivalent) clamps, or by using an automatic stapler, such as the ligate-staple-divide (LDS) device. If necessary, hepatic and splenic flexures can be mobilized to allow for removal of all of the omentum. Care must be taken to not put undo tension on the spleen while mobilizing the omentum.",
"   </p>",
"   <p>",
"    Omental cakes are resected in their entirety by dividing the vascular pedicles close to the transverse colon. The surgeon should not cut across an omental cake, as this leads to troublesome bleeding. When adherent to the abdominal wall, omental cakes can usually be bluntly freed prior to performing omentectomy.",
"   </p>",
"   <p>",
"    Resecting pieces of the omentum for pathology should be discouraged. Total omentectomy is technically easier, associated with less blood loss, and is less morbid than a piecemeal approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Lymph node sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic and paraaortic node sampling is performed to exclude the possibility of microscopic stage III disease, which can occur in up to one-third of patients with apparent stage I disease. There is little or no increase in morbidity attributable to selective node dissection; however, failure to detect nodal disease can have major prognostic implications.",
"   </p>",
"   <p>",
"    Suspicious nodes are removed, random sampling is performed if there are no suspicious nodes. Paraaortic nodes, especially those above the inferior mesenteric artery, are involved more frequently than pelvic nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. The procedure for lymphadenectomy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14730?source=see_link&amp;anchor=H14#H14\">",
"     \"Radical hysterectomy\", section on 'Examination of lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest bilateral lymph node sampling, even in patients with early stage disease. An exception may be patients with stage IA G1-2 disease since lymphatic involvement is rare in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/104\">",
"     104",
"    </a>",
"    ]. Both sides should be sampled because contralateral nodal involvement is unlikely, but not impossible, when ipsilateral nodes are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. One study of 96 patients with disease visibly confined to one ovary noted 14 of 96 patients (15 percent) had microscopically positive lymph nodes on pathologic review; all had grade 3 tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/106\">",
"     106",
"    </a>",
"    ]. Four of 42 patients (10 percent) who were sampled only on the side ipsilateral to the neoplastic ovary had positive nodes; 10 of 54 patients (19 percent) who had bilateral sampling had positive nodes: these were isolated to the ipsilateral lymph nodes in five, isolated to the contralateral nodes in three, and bilateral in two.",
"   </p>",
"   <p>",
"    The role of systematic lymphadenectomy in cytoreduction is discussed below. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Systematic lymphadenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Appendectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendectomy is performed as part of the routine staging procedure, as microscopic metastasis are present in over 10 percent of normal appearing appendixes and may be the only finding necessitating upstaging. However, the need for routine appendectomy is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. Most series have not found isolated microscopic appendiceal metastases in women with apparent early stage disease (stage I or II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The involved appendix is also removed as part of the cytoreduction procedure. Appendectomy is typically performed for women with mucinous ovarian tumors because, in rare cases, these are a primary mucinous appendiceal tumor with metastasis to the ovary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When performed, the mesentery is clamped, cut, and ligated, and the appendix is clamped closed to the cecum. The appendix is then removed and the stump is ligated. The use of absorbable sutures is acceptable if the selected material has delayed absorption to prevent leakage from the stump. Complex procedures involving manipulation of the stump are unnecessary. Stapling devices may be used, but increase the costs of the procedure without any proven benefit. Staplers are useful for resecting Meckel's diverticulum, when found in patients with ovarian carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hysterectomy and salpingo-oophorectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy and bilateral salpingo-oophorectomy are performed in virtually all women with ovarian cancer. The rationale is to remove, if present, occult metastases in the contralateral ovary, adnexa, or uterus, or a synchronous primary endometrial cancer. In addition, removal of the uterus facilitates use of postmenopausal hormone therapy, if desired, and evaluation of the pelvis postoperatively.",
"   </p>",
"   <p>",
"    Supracervical hysterectomy can be considered, especially in women who will receive intraperitoneal chemotherapy or in whom a much more aggressive dissection will be required to remove the cervix. There are limited data comparing oncologic outcomes after supracervical versus total hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/112\">",
"     112",
"    </a>",
"    ]. Potential disadvantages of the procedure include possible bleeding from the retained stump and interference with detecting recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/537?source=see_link\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if the contralateral ovary appears normal, a unilateral salpingo-oophorectomy may be considered for apparent Stage IA EOC in women who strongly desire to preserve fertility. Details of this procedure are described below (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Preservation of fertility'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retroperitoneal approach&nbsp;to hysterectomy &mdash; Pelvic anatomy is frequently distorted in patients with ovarian carcinoma. Resection of confluent, bulky disease by a retroperitoneal technique minimizes the risk of injury to the bladder or ureters and results in excellent access to blood supply.",
"      <br/>",
"      <br/>",
"      Several authors have described an approach called \"radical oophorectomy\" in patients with locally advanced ovarian cancer with extension to or encasement of the reproductive organs, pelvic peritoneum, cul-de-sac, and sigmoid colon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/113\">",
"       113",
"      </a>",
"      ]. The procedure involves retroperitoneal radical hysterectomy with en bloc resection of the adnexae, cul-de-sac tumor, involved peritoneum, and any involved rectosigmoid colon. Since ovarian cancer usually does not extend through the peritoneum, the retroperitoneal approach facilitates resection of bulky, confluent pelvic disease. This procedure is not appropriate for women who have unresectable upper abdominal disease because of the procedure's high morbidity and low potential for cure in such patients.",
"      <br/>",
"      <br/>",
"      The round ligaments are divided as laterally as possible and the lateral broad ligament peritoneum overlying the psoas muscle is incised and the pararectal and perivesical spaces developed. The ureters are exposed and mobilized. Infundibulopelvic ligaments are identified, clamped, cut, and ligated as high as possible out of the pelvis. The uterine artery can be divided laterally, or at its origin. The anterior cul-de-sac peritoneum is incised at the reflection and the bladder is mobilized off the lower uterine segment. If there are implants on the anterior cul-de-sac peritoneum, the space of Retzius can be developed, the bladder elevated, and tumor sharply dissected off. The remainder of the hysterectomy can then be carried out in a routine fashion. If the posterior cul-de-sac is obliterated by cancer, disease-free bowel can usually be identified below the peritoneal reflection, since ovarian cancer implants are generally on the peritoneal surface or bowel serosa, leaving retroperitoneal structures intact. Then the cul de sac disease can be approached laterally. In extreme cases, the peritoneum overlying the paracolic gutters may be incised, the retroperitoneum entered, the ureters and vessels identified, and the pelvis entered from above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Preservation of fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to preserve fertility are most common in young women with ovarian tumors of low malignant potential or nonepithelial ovarian cancers. Fertility preservation is also an option for women with stage IA EOC.",
"   </p>",
"   <p>",
"    If conservative surgery (unilateral salpingo-oophorectomy) is being considered, full surgical staging including washings, omentectomy, appendectomy, and node biopsies should be done and should be negative. A thorough abdominal exploration and biopsy of any abnormal areas is also mandatory and endometrial biopsy should be performed to exclude endometrial cancer. Most surgeons do not routinely biopsy the contralateral ovary if it appears normal. The rationale is that clinically occult bilateral ovarian involvement has been noted in only 2.5 percent of women undergoing staging for ovarian malignancy and ovarian surgery may impair future fertility, which is the purpose of conservative surgery.",
"   </p>",
"   <p>",
"    A review of studies of women with EOC who received conservative treatment included 282 women and 113 deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/114\">",
"     114",
"    </a>",
"    ]. There were 33 relapses and 16 disease-related deaths.",
"   </p>",
"   <p>",
"    Patients who desire fertility preservation should clearly understand that data regarding outcome are limited, in particular, there is little information on the frequency and outcome of recurrent disease or the safety of ovulation induction or hormonal contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. Young women with a well-differentiated lesion of one ovary who have had a full staging operation, but limited organ extirpation to preserve childbearing, are advised to undergo hysterectomy and removal of the remaining ovary upon completion of their families, or by age 35.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cytoreduction procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of bulky disease is distributed in the pelvis, omentum, and right diaphragm. Complete or maximal resection of disease in these locations results in prolonged palliation, and an increase in the likelihood of survival, even in stage IV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/59,117,118\">",
"     59,117,118",
"    </a>",
"    ]. Extensive upper abdominal debulking procedures may be necessary to achieve optimal primary cytoreduction, and are also associated with improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/47,119-121\">",
"     47,119-121",
"    </a>",
"    ]. In a series of 141 patients with advanced ovarian, peritoneal, or fallopian tubal cancer who underwent such procedures, there were two deaths, and major complications occurred in 22 percent of patients; most complications were successfully managed with percutaneous drainage of collections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most difficult areas should be assessed and approached first: if they cannot be resected to a diameter of 1 cm or less, further surgery, other than resecting the ovaries to prove the origin of tumor, is not indicated. If resection of the bulk of disease appears technically feasible, as it should in most patients, an aggressive surgical approach aimed at resection of all or most visible disease is warranted.",
"   </p>",
"   <p>",
"    Sharp dissection and electrocautery, including aggressive peritoneal stripping of the diaphragm and abdominopelvic surfaces, are the traditional methods used to achieve complete cytoreduction. The cavitational ultrasonic surgical aspirator, carbon dioxide laser, and argon beam coagulator have been used as adjuncts to these conventional techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/123-128\">",
"     123-128",
"    </a>",
"    ]. Each surgeon should select equipment and instruments in accordance with availability and his or her skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If tumor nodules extend into the splenic hilum, splenectomy can be justified if optimal cytoreduction is then possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/117,129,130\">",
"     117,129,130",
"    </a>",
"    ]. A series of 112 ovarian cancer patients who underwent splenectomy as part of primary or secondary cytoreductive surgery reported perioperative morbidity and mortality of 15 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/130\">",
"     130",
"    </a>",
"    ]. Median survival was 1.8 years.",
"   </p>",
"   <p>",
"    The spleen is mobilized and the splenic vessels are ligated, taking care to avoid injury to the tail end of the pancreas. Rarely, it may be necessary to resect the tail if involved by contiguous cancer spread.",
"   </p>",
"   <p>",
"    Patients who undergo splenectomy should receive prophylactic vaccines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Partial hepatic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very rarely, hepatic disease is present and affects only a segment of a lobe. In these unusual cases, a partial hepatectomy can be performed to achieve optimal cytoreduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/117\">",
"     117",
"    </a>",
"    ]. Generally, this can be performed with use of intense cautery, which dissects the liver parenchyma. The parenchyma can be finger fractured along cautery dissection, and intact blood vessels ligated as they become accessible. Some surgeons believe the use of an argon beam coagulator is highly effective for obtaining hemostasis after a partial hepatectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Diaphragmatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive cytoreductive surgery includes removal of diaphragmatic disease. Diaphragmatic disease can be approached by stripping or scraping the peritoneal surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/131\">",
"     131",
"    </a>",
"    ]. Alternatively, the liver can be partially retracted, the hepatic ligament divided, and the affected portion of the membranous diaphragm resected using ultrasonic dissection, electrocautery, or argon beam laser. In cases where full-thickness involvement of the diaphragm is present, resection of the diaphragm has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/132-135\">",
"     132-135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of cytoreduction of the diaphragm was illustrated in a series including 181 patients with tumor involving the diaphragm in which patients who underwent diaphragm surgery (stripping of the diaphragmatic peritoneum, full or partial thickness diaphragm resection, excision of nodules or Cavitron Ultrasound Aspiration) had significantly improved five-year overall survival compared to those that did not (53 versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/136\">",
"     136",
"    </a>",
"    ]. The survival advantage for treatment of diaphragm disease was also observed, but to a lesser degree, when only the subset of patients who were optimally cytoreduced was considered (55 versus 28 percent).",
"   </p>",
"   <p>",
"    Most complications are due to breaching the pleural cavity and can be managed by chest tube or thoracentesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Bowel resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectosigmoid implants constitute the bulk of intestinal involvement in women undergoing primary cytoreductive surgery for EOC. Small-volume disease can be simply shaved off, taking advantage of the fact that these implants are often only superficially invasive. Bulkier implants may require bowel resection and reanastomosis (",
"    <a class=\"graphic graphic_figure graphicRef68932 \" href=\"mobipreview.htm?21/20/21826\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/55,117\">",
"     55,117",
"    </a>",
"    ]. These procedures are indicated only if optimal cytoreduction is possible or if obstruction is present.",
"   </p>",
"   <p>",
"    In an unstable patient, if bowel resection is contraindicated, or if optimal cytoreduction is not achievable at other sites, an intestinal bypass procedure can be done instead. Proximal and distal bowel is simply approximated without resection of the involved segment, thus bypassing the area of resistance to permit flow of gastrointestinal contents. The procedure is well tolerated and results in palliation, but may be associated with blind loop syndrome with bacterial overgrowth or potential risk of perforation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative to surgery is placement of a stent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal resections can be performed most rapidly with the aid of stapling devices such as the gastrointestinal anastomosis and transverse anastomosis stapling devices. The continuity of the bowel can be reestablished by aligning the proximal and distal ends of the bowel and stapling the antimesenteric sides to each other in a so-called side-to-side, functional end-to-end anastomosis, using the gastrointestinal anastomosis stapler (",
"    <a class=\"graphic graphic_figure graphicRef67120 \" href=\"mobipreview.htm?27/60/28614\">",
"     figure 3",
"    </a>",
"    ). The enterostomies necessary for placement of gastrointestinal anastomosis are then closed using the transverse anastomosis gun (",
"    <a class=\"graphic graphic_figure graphicRef77471 \" href=\"mobipreview.htm?13/29/13781\">",
"     figure 4",
"    </a>",
"    ). The advantage of stapled anastomoses over traditional hand-sewing (",
"    <a class=\"graphic graphic_figure graphicRef52269 graphicRef61001 graphicRef73759 \" href=\"mobipreview.htm?26/40/27274\">",
"     figure 5A-C",
"    </a>",
"    ) includes speed, improved blood supply at the site, and ease of technique. The procedure can be applied to any segment of the bowel, except when low rectal anastomosis is performed. The end-to-end anastomosis stapler avoids the need for a colostomy in this situation.",
"   </p>",
"   <p>",
"    An alternative technique employs biofragmentable rings (Valtrac), which allows direct end-to-end anastomosis by simply snapping the rings together (",
"    <a class=\"graphic graphic_figure graphicRef77898 \" href=\"mobipreview.htm?39/58/40869\">",
"     figure 6",
"    </a>",
"    ). This procedure can also be performed more rapidly than hand-sewn anastomoses, which are usually done as a double-layer closure. The issue of speed arises in patients having cytoreductive surgery because multiple procedures are often required to achieve optimal cytoreduction and the entire operation can be lengthy.",
"   </p>",
"   <p>",
"    Regardless of the choice of technique, the surgeon must check that the anastomotic site is patent, hemostatic, and does not leak. The mesentery must be approximated after the completion of the anastomosis to prevent formation of an internal hernia or entrapment of the bowel. It is desirable to close only one side, as through-and-through mesenteric sutures can interfere with the blood supply to the respective segments of the anastomosis.",
"   </p>",
"   <p>",
"    An adequate amount of uninvolved intestine for reapproximation is usually available at the time of primary cytoreduction, although a stoma may be required. In some instances, a protective colostomy may be advisable in a woman at high risk for poor healing, or an anastomotic leak. If necessary, an effort should be made to place it in the lower abdominal quadrants as upper abdominal sites limit the type of clothing that can be worn. The best location is in the left lower abdomen, approximately in the middle of a triangle drawn between the public symphysis, umbilicus, and anterior superior iliac spine. Care should be taken to avoid placing the stoma near incisions or skin creases. The site should be selected before surgery, if possible, with the patient placed in different positions to minimize the chance of poor adherence of the stoma bag. Many surgeons believe the bowel should be secured to the fascia and the peritoneum to minimize the risk of hernia or prolapse (",
"    <a class=\"graphic graphic_figure graphicRef78065 \" href=\"mobipreview.htm?3/59/4018\">",
"     figure 7",
"    </a>",
"    ). Liquid output, such as would be expected from transverse colon or proximally, would require a creation of a spout-like stoma. Stomas with solid output can be flush with the skin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Bladder or ureteral resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of the bladder or ureters is rarely necessary to achieve optimal debulking, unless the tumor has invaded the bladder or obstructed the ureter, or the ureter is entrapped by pelvic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/117\">",
"     117",
"    </a>",
"    ]. Resection of these structures may require complete mobilization of the bladder by dividing lateral peritoneal attachments to accommodate the decreased length of the remaining ureter. Ureteral neocystostomy with psoas hitch provides an excellent result. Initially, these anastomoses are not watertight, and drainage of the pelvis by closed suction is prudent. Placement of ureteral stents is based upon the surgeon's preference, since there is no evidence for or against their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Systematic lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic lymphadenectomy of the pelvic and paraaortic nodes, rather than selective resection of bulky nodes, has been proposed as a component of optimal debulking of women with advanced disease. Two large randomized trials have evaluated this issue and neither showed a statistically significant survival advantage with systematic lymphadenectomy (see below). However, both trials showed a trend toward a longer progression free interval with more extensive surgery, suggesting that a modest survival advantage might be demonstrated if a larger number of patients were evaluated.",
"   </p>",
"   <p>",
"    We resect all grossly suspicious lymph nodes to achieve maximal resection of disease. We do not routinely perform systematic lymphadenectomy to resect potential sites of microscopic disease, given the lack of proven survival advantage and the morbidity of the procedure. Potential sites of microscopic disease are treated since most women with EOC receive systemic chemotherapy to treat occult disease.",
"   </p>",
"   <p>",
"    The two trials supporting this approach are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 427 women with stage IIIB-C and IV EOC to undergo either systematic pelvic and paraaortic lymphadenectomy or resection of bulky nodes only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/137\">",
"       137",
"      </a>",
"      ]. All of the patients also underwent aggressive surgical debulking (96 percent had residual disease &le;1 cm) and 88 percent received adjuvant platinum-based chemotherapy. The median length of follow-up was 68.4 months. Positive nodes were detected in 70 percent of patients who underwent systematic lymphadenectomy and 42 percent of those who underwent selective sampling.",
"      <br/>",
"      <br/>",
"      Five-year survival rates were not significantly different for the two groups (48.4 versus 47 percent); however, systematic lymphadenectomy was associated with a five to seven month increase in progression-free survival (PFS). Longer PFS was achieved at a cost of longer median operating times (300 versus 210 minutes), greater blood loss (1000 versus 650 mLs), and a higher proportion of patients requiring transfusion (71.7 versus 59.2 percent). Quality of life measures were not assessed.",
"     </li>",
"     <li>",
"      The other trial randomly assigned 268 women with stage I or II EOC to undergo either systematic pelvic and paraaortic lymphadenectomy or random sampling of these nodes (controls) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/138\">",
"       138",
"      </a>",
"      ]. All of the patients also underwent aggressive surgical debulking (96 percent had residual disease &le;1 cm) and 61 percent received adjuvant platinum-based chemotherapy. The median length of follow-up was 87.8 months. Positive nodes were detected in 22 percent of patients who underwent systematic lymphadenectomy compared to only 9 percent of controls.",
"      <br/>",
"      <br/>",
"      There was no significant difference between groups in five-year survival (84.2 versus 81.3 percent in controls) or five-year PFS (78.3 versus 71.3 percent in controls). Systematic lymphadenectomy was associated with longer median operating times (240 versus 150 minutes), greater blood loss (600 versus 300 mLs), and a higher proportion of patients requiring transfusion (35.5 versus 21.9 percent). Quality of life measures were not assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Placement of a port for chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing body of evidence showing a survival advantage in women with optimally cytoreduced stage III epithelial ovarian cancer who are treated with intraperitoneal chemotherapy. The procedure for port placement and this therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/537?source=see_link\">",
"     \"Intraperitoneal chemotherapy for treatment of ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pseudomyxoma peritonei",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term pseudomyxoma peritonei is used to describe either free mucin deposits or mucin extravasating into tissues in the peritoneal cavity and implants of mucinous epithelium. Pseudomyxoma peritonei has been reported associated with benign, malignant and borderline tumors of the ovary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognosis depends upon the success of removing all visible mucin and mucin producing epithelium. Surgical management consists of removal of the appendix, both ovaries, omentum, and as much of the mucin as is possible. Resection of bowel, diaphragm, peritoneum and mesentery may be required and irrigation may help to remove the tenacious mucin. Repeated surgical debulking is common and performed for symptomatic disease. This treatment is not curative, but aims to resect gross disease to limit the buildup of mucus and its pressure effect. Disease recurrence requires repeated and progressively more difficult surgery due to adhesions and fibrosis. Death results from the mass effect of the mucin and mucin producing tissues on the bowel; however, long-term survival is possible.",
"   </p>",
"   <p>",
"    The addition of external beam radiotherapy, intraperitoneal radioisotopes, intraperitoneal chemotherapy, and systemic chemotherapy has been attempted to improve outcomes. Whether any of these additional treatments prolongs survival is unclear because randomized clinical trials have not been performed, and agreement on definitions of clinical subsets is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Fluid balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to fluid status is a critical component in the postoperative management of these patients. Women with advanced ovarian carcinoma undergoing primary or extensive secondary cytoreduction experience significant fluid shifts and blood loss. The use of volume expanders, including blood products or colloids, may be necessary, with fluid resuscitation being an integral part of the management in the first 24 to 48 hours postoperatively.",
"   </p>",
"   <p>",
"    Invasive monitoring in an intensive care unit is sometimes necessary to administer fluid safely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/48/36618/abstract/139\">",
"     139",
"    </a>",
"    ]. Fluid shifts, including reaccumulation of ascites, continue to occur for several days. Close monitoring of intake and output is important until the patient has established competent gastrointestinal function. Danger of fluid overload is greatest 48 to 72 hours postoperatively, when mobilization of third-spaced fluid results in increased intravascular volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Postoperative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of women with resected EOC benefit from postoperative chemotherapy. Chemotherapy for women with advanced (stage",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    disease, and issues that are specific to treatment of women with earlier stage (I and II) disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26231?source=see_link\">",
"     \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Other postoperative issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy and sexual health issues following ovarian cancer treatment are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link&amp;anchor=H6099467#H6099467\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Postmenopausal estrogen therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link&amp;anchor=H6099475#H6099475\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Sexual health'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one-, two-, and five-year survival rates by stage for ovarian and fallopian tubal cancer are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef64569 \" href=\"mobipreview.htm?27/5/27740\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55344 \" href=\"mobipreview.htm?11/2/11307\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prognosis of ovarian cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link&amp;anchor=H6099435#H6099435\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link&amp;anchor=H6099443#H6099443\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is performed in women with suspected ovarian cancer to obtain tissue to confirm the diagnosis, assess the extent of disease (staging), and attempt to remove as much of the gross tumor as possible, which is crucial for successful treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Gynecologic Oncology Group defines optimal cytoreduction as leaving residual disease less than 1 cm in maximum tumor diameter. The volume of residual disease remaining after cytoreductive surgery inversely correlates with survival; therefore, if it is technically feasible, all visible tumor should be resected at the initial surgical procedure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Optimal cytoreduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Cytoreduction procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that cytoreduction be performed by gynecologic oncologists experienced in this surgery since achieving optimal cytoreduction depends, in part, on the judgment, experience, and aggressiveness of the surgeon (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Cytoreduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the initial surgical attempt at cytoreduction was not optimal and was not a maximal surgical effort, then chemotherapy and secondary surgical cytoreduction may be beneficial, but survival is not as high as with optimal cytoreduction at primary surgery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management after suboptimal cytoreduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend venous thromboembolism prophylaxis in women undergoing surgery for ovarian cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Preoperative issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The steps for surgical staging are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef75194 \" href=\"mobipreview.htm?40/8/41099\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Staging procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/1\">",
"      Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007; 109:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/2\">",
"      Goff BA, Matthews BJ, Wynn M, et al. Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 2006; 103:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/3\">",
"      Petignat P, Vajda D, Joris F, Obrist R. Surgical management of epithelial ovarian cancer at community hospitals: A population-based study. J Surg Oncol 2000; 75:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/4\">",
"      M&uuml;nstedt K, von Georgi R, Misselwitz B, et al. Centralizing surgery for gynecologic oncology--a strategy assuring better quality treatment? Gynecol Oncol 2003; 89:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/5\">",
"      Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005; 99:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/6\">",
"      Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol 2000; 78:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/7\">",
"      Schrag D, Earle C, Xu F, et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 2006; 98:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/8\">",
"      Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/9\">",
"      Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006; 106:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/10\">",
"      NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/11\">",
"      Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet 2006; 367:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/12\">",
"      Paulsen T, Kjaerheim K, Kaern J, et al. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006; 16 Suppl 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/13\">",
"      Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007; 105:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/14\">",
"      Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007; 109:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/15\">",
"      SWERDLOW M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959; 77:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/16\">",
"      Gooneratne S, Sassone M, Blaustein A, Talerman A. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982; 1:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/17\">",
"      Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/18\">",
"      Lele SB, Piver MS, Matharu J, Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol 1988; 31:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/19\">",
"      Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/20\">",
"      Barda G, Menczer J, Chetrit A, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004; 190:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/21\">",
"      Eltabbakh GH, Mount SL. Lymphatic spread among women with primary peritoneal carcinoma. J Surg Oncol 2002; 81:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/22\">",
"      Dubernard G, Morice P, Rey A, et al. Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma. Gynecol Oncol 2005; 97:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/23\">",
"      Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/24\">",
"      Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/25\">",
"      Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998; 25:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/26\">",
"      Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/27\">",
"      Geisler JP, Linnemeier GC, Thomas AJ, Manahan KJ. Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 2007; 106:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/28\">",
"      Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000; 78:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/29\">",
"      Merogi AJ, Marrogi AJ, Ramesh R, et al. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/30\">",
"      Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/31\">",
"      Santin AD, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999; 20:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/32\">",
"      Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 2012; 120:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/33\">",
"      Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/34\">",
"      Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/35\">",
"      Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/36\">",
"      Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995; 16:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/37\">",
"      Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006; 103:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/38\">",
"      Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/39\">",
"      Wimberger P, Lehmann N, Kimmig R, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007; 106:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/40\">",
"      Teramukai S, Ochiai K, Tada H, et al. PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01. J Clin Oncol 2007; 25:3302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/41\">",
"      Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994; 55:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/42\">",
"      Eisenkop SM, Spirtos NM, Lin WC. \"Optimal\" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 2006; 103:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/43\">",
"      Winter WE 3rd, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008; 26:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/44\">",
"      Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008; 108:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/45\">",
"      Chi DS, Ramirez PT, Teitcher JB, et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 2007; 25:4946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/46\">",
"      Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 1986; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/47\">",
"      Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004; 94:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/48\">",
"      Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/49\">",
"      Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/50\">",
"      Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007; 25:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/51\">",
"      Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large-volume malignant ascites. J Surg Oncol 1996; 62:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/52\">",
"      Vergote I, de Wever I, Tjalma W, et al. Interval debulking surgery: an alternative for primary surgical debulking? Semin Surg Oncol 2000; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/53\">",
"      Tamussino KF, Lim PC, Webb MJ, et al. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol 2001; 80:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/54\">",
"      Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000; 88:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/55\">",
"      O'Hanlan KA, Kargas S, Schreiber M, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol 1995; 59:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/56\">",
"      Weber AM, Kennedy AW. The role of bowel resection in the primary surgical debulking of carcinoma of the ovary. J Am Coll Surg 1994; 179:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/57\">",
"      Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 2005; 99:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/58\">",
"      Tebes SJ, Cardosi R, Hoffman MS. Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol 2006; 195:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/59\">",
"      Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/60\">",
"      Liu PC, Benjamin I, Morgan MA, et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997; 64:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/61\">",
"      Chi DS, Temkin SM, Abu-Rustum NR, et al. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol 2002; 87:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/62\">",
"      Berchuck A, Iversen ES, Lancaster JM, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004; 190:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/63\">",
"      Ferrandina G, Fagotti A, Salerno MG, et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999; 81:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/64\">",
"      Eltabbakh GH, Mount SL, Beatty B, et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 2004; 95:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/65\">",
"      Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/66\">",
"      Gilani MM, Karimi Zarchi M, Ghaemmaghami F, et al. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 2007; 105:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/67\">",
"      Kang S, Kim TJ, Nam BH, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 2010; 101:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/68\">",
"      Salani R, Axtell A, Gerardi M, et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008; 108:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/69\">",
"      Qayyum A, Coakley FV, Westphalen AC, et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005; 96:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/70\">",
"      Risum S, H&oslash;gdall C, Loft A, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study. Gynecol Oncol 2008; 108:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/71\">",
"      Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/72\">",
"      Redman CW, Warwick J, Luesley DM, et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/73\">",
"      van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/74\">",
"      Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/75\">",
"      Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23:5605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/76\">",
"      Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/77\">",
"      Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 2007; 105:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/78\">",
"      Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 2007; 97:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/79\">",
"      Martino MA, Borges E, Williamson E, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006; 107:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/80\">",
"      Clarke-Pearson DL, Synan IS, Hinshaw WM, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/81\">",
"      Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007; 105:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/82\">",
"      Matsuura Y, Robertson G, Marsden DE, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007; 104:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/83\">",
"      Morice P, Viala J, Pautier P, et al. Port-site metastasis after laparoscopic surgery for gynecologic cancer. A report of six cases. J Reprod Med 2000; 45:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/84\">",
"      Hopkins MP, von Gruenigen V, Gaich S. Laparoscopic port site implantation with ovarian cancer. Am J Obstet Gynecol 2000; 182:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/85\">",
"      Abu-Rustum NR, Sonoda Y, Chi DS, et al. The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecol Oncol 2003; 90:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/86\">",
"      Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 2006; 100:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/87\">",
"      Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008; 199:642.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/88\">",
"      Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005; 96:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/89\">",
"      Havrilesky LJ, Peterson BL, Dryden DK, et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003; 102:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/90\">",
"      Canis M, Botchorishvili R, Manhes H, et al. Management of adnexal masses: role and risk of laparoscopy. Semin Surg Oncol 2000; 19:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/91\">",
"      Canis M, Rabischong B, Botchorishvili R, et al. Risk of spread of ovarian cancer after laparoscopic surgery. Curr Opin Obstet Gynecol 2001; 13:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/92\">",
"      Leminen A, Lehtovirta P. Spread of ovarian cancer after laparoscopic surgery: report of eight cases. Gynecol Oncol 1999; 75:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/93\">",
"      Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/94\">",
"      Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/95\">",
"      Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol 2009; 113:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/96\">",
"      Ghezzi F, Cromi A, Uccella S, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol 2007; 105:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/97\">",
"      Chi DS, Abu-Rustum NR, Sonoda Y, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005; 192:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/98\">",
"      Park JY, Kim DY, Suh DS, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol 2008; 15:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/99\">",
"      Nezhat FR, Ezzati M, Chuang L, et al. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. Am J Obstet Gynecol 2009; 200:83.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/100\">",
"      Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/101\">",
"      Onda T, Yoshikawa H, Yokota H, et al. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer 1996; 78:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/102\">",
"      Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003; 197:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/103\">",
"      Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/104\">",
"      Ayhan A, Gultekin M, Taskiran C, et al. Lymphatic metastasis in epithelial ovarian carcinoma with respect to clinicopathological variables. Gynecol Oncol 2005; 97:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/105\">",
"      Pereira A, Magrina JF, Rey V, et al. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 2007; 105:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/106\">",
"      Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001; 80:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/107\">",
"      Westermann C, Mann WJ, Chumas J, et al. Routine appendectomy in extensive gynecologic operations. Surg Gynecol Obstet 1986; 162:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/108\">",
"      Ayhan A, Gultekin M, Taskiran C, et al. Routine appendectomy in epithelial ovarian carcinoma: is it necessary? Obstet Gynecol 2005; 105:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/109\">",
"      Ramirez PT, Slomovitz BM, McQuinn L, et al. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol 2006; 103:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/110\">",
"      Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol 2013; 208:46.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/111\">",
"      Patsner B, Chalas E, Orr JW Jr, Mann WJ Jr. Stapler resection of Meckel's diverticulum during gynecologic cancer surgery. Gynecol Oncol 1990; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/112\">",
"      Milam MR, Sood AK, King S, et al. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 2007; 109:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/113\">",
"      Bristow RE, del Carmen MG, Kaufman HS, Montz FJ. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003; 197:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/114\">",
"      Maltaris T, Boehm D, Dittrich R, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006; 103:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/115\">",
"      Marpeau O, Schilder J, Zafrani Y, et al. Prognosis of patients who relapse after fertility-sparing surgery in epithelial ovarian cancer. Ann Surg Oncol 2008; 15:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/116\">",
"      Zapata LB, Whiteman MK, Marchbanks PA, Curtis KM. Intrauterine device use among women with ovarian cancer: a systematic review. Contraception 2010; 82:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/117\">",
"      Scholz HS, Tasdemir H, Hunlich T, et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 2007; 106:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/118\">",
"      Salani R, Zahurak ML, Santillan A, et al. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol 2007; 107:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/119\">",
"      Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006; 107:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/120\">",
"      Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006; 103:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/121\">",
"      Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009; 114:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/122\">",
"      Chi DS, Zivanovic O, Levinson KL, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 2010; 119:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/123\">",
"      Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001; 83:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/124\">",
"      Eisenkop SM, Nalick RH, Wang HJ, Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993; 51:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/125\">",
"      van Dam PA, Tjalma W, Weyler J, et al. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol 1996; 174:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/126\">",
"      Rose PG. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992; 166:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/127\">",
"      Fanning J, Hilgers RD, Richards PK, Hunt KD. Carbon dioxide laser vaporization of intestinal metastases of epithelial ovarian cancer. Int J Gynecol Cancer 1994; 4:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/128\">",
"      Patsner B. Carbon dioxide laser vaporization of diaphragmatic metastases for cytoreduction of ovarian epithelial cancer. Obstet Gynecol 1990; 76:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/129\">",
"      Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 2006; 100:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/130\">",
"      Magtibay PM, Adams PB, Silverman MB, et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 2006; 102:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/131\">",
"      Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 2004; 94:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/132\">",
"      Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol 1990; 39:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/133\">",
"      Montz FJ, Schlaerth JB, Berek JS. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol 1989; 35:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/134\">",
"      Tsolakidis D, Amant F, Van Gorp T, et al. Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. Gynecol Oncol 2010; 116:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/135\">",
"      Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol 2010; 116:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/136\">",
"      Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006; 100:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/137\">",
"      Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/138\">",
"      Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/48/36618/abstract/139\">",
"      Amir M, Shabot MM, Karlan BY. Surgical intensive care unit care after ovarian cancer surgery: an analysis of indications. Am J Obstet Gynecol 1997; 176:1389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3193 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36618=[""].join("\n");
var outline_f35_48_36618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Confirmation of clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Exceptions to initial surgical staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Optimal cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Predicting optimal cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Management after suboptimal cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      USE OF LAPAROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGICAL PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Staging procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Collection of fluid for cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Exploratory laparotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Frozen section",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Biopsies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Omentectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Lymph node sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Appendectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hysterectomy and salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Preservation of fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cytoreduction procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Partial hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Diaphragmatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Bowel resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Bladder or ureteral resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Systematic lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Placement of a port for chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      POSTOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Fluid balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Postoperative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Other postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3193|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/25/37279\" title=\"figure 1\">",
"      Survival by residual tumor vol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/20/21826\" title=\"figure 2\">",
"      Enterotomy for metastatic CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/60/28614\" title=\"figure 3\">",
"      Side by side closure enterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/29/13781\" title=\"figure 4\">",
"      Staple closure of enterotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/49/4884\" title=\"figure 5A\">",
"      Bowel resection and reapprox A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/35/33333\" title=\"figure 5B\">",
"      Bowel resection and reapprox B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/58/43938\" title=\"figure 5C\">",
"      Bowel resection and reapprox C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/58/40869\" title=\"figure 6\">",
"      Valtrac device anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/59/4018\" title=\"figure 7\">",
"      Attachment of stoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3193|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/33/4625\" title=\"picture 1\">",
"      Bilateral ovarian cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/52/11077\" title=\"picture 2\">",
"      Omental cake ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/44/11981\" title=\"table 2\">",
"      Survival residual dz ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/8/41099\" title=\"table 3\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/5/27740\" title=\"table 4\">",
"      Ovarian cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/2/11307\" title=\"table 5\">",
"      Fallop tube cancer FIGO surv",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7415?source=related_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25847?source=related_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/537?source=related_link\">",
"      Intraperitoneal chemotherapy for treatment of ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14730?source=related_link\">",
"      Radical hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_48_36619="Known Gla-containing proteins";
var content_f35_48_36619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Known gamma-Carboxyglutamic acid-containing proteins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Blood clotting and regulatory proteins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prothrombin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Factor VII",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Factor IX",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Factor X",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Protein C",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Protein S",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Protein Z",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Other proteins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gas6",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          PRGP1",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          PRGP2",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Bone proteins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Osteocalcin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Matrix Gla protein",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Conopeptides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Conantokin G",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Conantokin T",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from Furie, B, et al. Blood 1999; 93:1798.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36619=[""].join("\n");
var outline_f35_48_36619=null;
var title_f35_48_36620="Chronic liver failure";
var content_f35_48_36620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Allogeneic hepatocyte transplantation for patients with chronic liver failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis, [reference]",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Cryptogenic cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [1]",
"       </td>",
"       <td>",
"        3 weeks",
"       </td>",
"       <td>",
"        Intraportal (7x10",
"        <sup>",
"         8",
"        </sup>",
"        cells). NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr;. OLT after 1 week with full recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        TPN + sepsis (Child C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [2]",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        Splenic artery infusion (5x10",
"        <sup>",
"         7",
"        </sup>",
"        cells). NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr;; encephalopathy improved. Intracranial hemorrhage on d7.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Alpha-1 antitrypsin disease (PiZZ), cirrhosis; pulmonary insufficiency, encephalopathy grade 4; Child C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [2]",
"       </td>",
"       <td>",
"        52 years",
"       </td>",
"       <td>",
"        NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr;, PiMM alpha-1 present in plasma. OLT on d2 with full recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        HCV, cirrhosis, Child C encephalopathy grade 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [2]",
"       </td>",
"       <td>",
"        40 years",
"       </td>",
"       <td>",
"        Intracranial hemorrhage on d2 (hepatocytes in spleen at autopsy).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        EtoH cirrhosis. Male, Child C; encephalopathy grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [3]",
"       </td>",
"       <td>",
"        62 years",
"       </td>",
"       <td>",
"        Splenic artery infusion (6x10",
"        <sup>",
"         8",
"        </sup>",
"        ). Encephalopathy improved, and NH",
"        <sub>",
"         3",
"        </sub>",
"        &darr;, full recovery. Hyperkalemic cardiac arrest at day 33.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        EtoH cirrhosis. Male, encephalopathy grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        [4]",
"       </td>",
"       <td>",
"        46 years",
"       </td>",
"       <td>",
"        No improvement, death on day 50.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Soriano HE, Wood RP, Kang DC, et al. Hepatocellular transplantation HCT) in children with fulminant liver failure. Hepatology 1997; 30:239A.",
"     <br>",
"      2. Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63:559.",
"      <br>",
"       3. Sterling RK, Fisher RA. Liver Transplantation: Living Donor, Hepatocyte, and Xenotransplantation. In: Current Future Treatment Therapies for Liver Disease. Clinics in Liver Disease. Gish, R, ed. Philadelphia: WB Saunders, 2001.",
"       <br>",
"        4. Strom SC, Roy-Chowdhury J, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999; 19:39.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36620=[""].join("\n");
var outline_f35_48_36620=null;
var title_f35_48_36621="Motivational interviewing technique - Planning";
var content_f35_48_36621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F87245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F87245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motivational interviewing technique - Planning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So Susan, it sounds like you're really ready to stop smoking weed every day. You've noticed that your concentration and memory are not as good as they were, and you're tired of feeling too zoned out to shop for groceries, help with your kids' homework, and keep up with your job schedule. You've always liked the feeling of being high, but now you're wanting to set a good example for your kids, and \"being high through life\", as you put it, doesn't really fit with that. (Summary of previous conversation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Exactly. That's exactly how I feel. I'm ready to do it, but I know I have to think it through - it would be hard to just go cold turkey.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        We talked before about how you used to use other drugs, but you quit. (Reflection) You were successful in stopping your cocaine use, and it's been over 5 years since you used, and you're glad about that. (Affirmation) Tell me more about how you were able to do that, and what parts of that change might be relevant now, as you consider quitting smoking weed? (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Crack is different than weed; it takes over your life, and makes you act different. I could tell that if I didn't stop, it would not take me anywhere I wanted to go.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So with crack, you looked ahead, and didn't like what you saw if you kept using. Maybe looking ahead with weed would be helpful. If you do the same thing, look ahead, imagine that you keep smoking weed daily like you are now, what do you see?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Probably nothing much. I'd continue to make mistakes, small stuff, but every day, like missing my shifts at work. I might even get fired, because they're starting a drug testing program. I might not be the best mom, because I'm too zoned out to really pay attention like my children need me to. Most of all, I'd feel like I'd wasted years, literally. I don't like that future much.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So looking ahead with smoking weed, you see a future that looks a lot like having more of the same kinds of problems as you have now, and worse, you'd feel bad about yourself, like you'd been less than you could have been. (Complex reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yeah, but I don't seem to be able to smoke just a little. I think what I'm getting to realize is that I probably need to quit smoking altogether, to have the kind of life I want.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So while part of you would like to find a way to smoke weed sometimes, another part thinks you need to give it up entirely. (Complex reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes. I want to quit completely. I want to clean it out of my system. It's next month that work starts drug testing, and I've heard it takes a month to clean it out of you.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        That's about right, depending on your weight, body composition, and a few other things. (Affirmation, providing information) So you'd like to start right away, and clean the marijuana out of your system. (Reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes, and that should work because I'm down to about one joint's worth left. I need to tell my friend that I'm not ordering any more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        So a first step is to not replace it when you run out, which will be soon. (Reflection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yeah, like tomorrow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        Tell me more about how you'll quit and stay quit. (Open question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Well, I already told my husband I'm going to do this. Also, I talked about it with some of my close friends who usually smoke it with me. They all understand, and they're planning not to offer it to me. But even if they do, I will say, no thanks. But at first, I probably need to hang out with them in other ways, like going out to movies or out to eat, rather than just hang at each other's houses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You've given this a lot of thought, and you've already taken important steps - letting people know what you're doing it, asking for their help, and planning what you'll do if it's offered. (Affirmation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Yes I have. I think I'm ready.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        How confident are you, on a scale of 0 to 10, that you can quit smoking weed now? (Open question using scaling ruler strategy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        I'm a 9. I think I'm ready, and I have a plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        What makes it a 9 and not a 0?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Like we talked about, I was able to quit using crack cocaine. I saw how it was going to ruin my life, and I said no way. It's the same with weed. I can see a bad path there, and I am ready to start a new phase of my life. I think I have enough support, and now it's time to start.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doctor:",
"        </strong>",
"        You're committed. You're ready. I'm here to help in any way you need. I'm looking forward to hearing how it goes, next time you come in. Good luck!",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patient:",
"        </strong>",
"        Thanks - I'll call you if I need anything.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36621=[""].join("\n");
var outline_f35_48_36621=null;
var title_f35_48_36622="Contents: Adult toxicology";
var content_f35_48_36622=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult toxicology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult toxicology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/10/32937\">",
"           Acetaminophen (paracetamol) poisoning in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/51/20281\">",
"           Acute amphetamine and synthetic cathinone (���������bath salt���������) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/39/31351\">",
"           Acute ingestion of illicit drugs (body stuffing)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43319\">",
"           Anticholinergic poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/33/8730\">",
"           Arsenic exposure and poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/52/11080\">",
"           Benzodiazepine poisoning and withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/19/33081\">",
"           Beta blocker poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/63/31736\">",
"           Calcium channel blocker poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/19/11577\">",
"           Carbamazepine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10345\">",
"           Carbon monoxide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41096\">",
"           Ciguatera fish poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1786\">",
"           Clinical manifestations and evaluation of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22313\">",
"           Clonidine and related imidazoline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/18/7466\">",
"           Cyanide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/60/17353\">",
"           Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2615\">",
"           Dextromethorphan poisoning: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/13/25817\">",
"           Digitalis (cardiac glycoside) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/32/23043\">",
"           Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/13/20694\">",
"           Ethanol intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/31/4600\">",
"           First generation (Typical) antipsychotic medication poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/27/3514\">",
"           Gamma hydroxybutyrate (GHB) dependence and withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/25/31130\">",
"           Gamma hydroxybutyrate (GHB) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/58/16297\">",
"           Gastrointestinal decontamination of poisoned adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/6/1129\">",
"           General approach to drug poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/5/27736\">",
"           Hydrocarbon poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/20/5448\">",
"           Hyperbaric oxygen therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/2/43047\">",
"           Initial management of the critically ill adult with an unknown overdose",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/28/12744\">",
"           Internal concealment of drugs of abuse (body packing)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/34/44584\">",
"           Intoxication from LSD and other common hallucinogens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7191\">",
"           Isoniazid (INH) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/62/40935\">",
"           Ketamine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/0/9225\">",
"           Lithium poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/61/20441\">",
"           Management of moderate and severe alcohol withdrawal syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21560\">",
"           MDMA (ecstasy) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/43/4792\">",
"           Meprobamate poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/18/21799\">",
"           Metformin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/29/474\">",
"           Methamphetamine intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/2/47\">",
"           Nonsteroidal antiinflammatory drug (NSAID) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/51/3897\">",
"           Opioid intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/5/28758\">",
"           Opioid withdrawal in the emergency setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/25/33176\">",
"           Organophosphate and carbamate poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/17/6425\">",
"           Phencyclidine (PCP) intoxication in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41863\">",
"           Phenytoin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/28/19913\">",
"           Salicylate (aspirin) poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/22/32104\">",
"           Scorpion stings in the United States and Mexico",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43320\">",
"           Second generation (atypical) antipsychotic medication poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/26/11690\">",
"           Selective serotonin reuptake inhibitor poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/63/16376\">",
"           Serotonin syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/5/40022\">",
"           Strychnine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/23/13687\">",
"           Sulfonylurea agent poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/24/36231\">",
"           Tricyclic antidepressant poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/38/28264\">",
"           Valproic acid poisoning",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F1296C3199-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_48_36622=[""].join("\n");
var outline_f35_48_36622=null;
var title_f35_48_36623="Hayman stitch";
var content_f35_48_36623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Hayman stitch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hayman described a modification of the B-Lynch suture that is performed without a hysterectomy. Two to four vertical compression sutures are placed, as needed, but in contrast to the B-Lynch technique, these sutures pass directly from the anterior uterine wall to the posterior uterine wall. A transverse cervicoisthmic suture can also be placed if needed to control bleeding from the lower uterine segment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Hayman, RG, Arulkumaran, S, Steer, PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet Gynecol 2002; 99:502.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_48_36623=[""].join("\n");
var outline_f35_48_36623=null;
